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Abstract 
Parkinson's disease (PD) is the most common neurodegenerative movement disorder 
characterized by the progressive loss of dopamine (DA)-producing neurons in the substantia 
nigra pars compacta (SNc). A neuropathological hallmark of PD is the gradual appearance of 
neuronal protein aggregates termed Lewy bodies (LBs). The main component of these 
aggregates is the protein α-Synuclein (α-Syn). Although the exact mechanism of α-Syn-
mediated cell death remains elusive, recent research suggests that α-Syn-induced alterations in 
neuronal excitability precede cell death in PD. The fragile X mental retardation protein (FMRP) 
controls the expression and function of numerous neuronal genes related to neuronal excitability 
and synaptic function. Therefore, we investigated the role of FMRP in α-Syn-associated 
pathological changes in cell culture and animal models of PD as well as in post-mortem human 
brain tissue from PD patients. We found the abundance of FMRP to be decreased in cultured 
human DA neurons and in SNc DA neurons of mice over-expressing α-Syn. Reminiscent of 
fragile X syndrome (FXS) neurons, DA neurons overexpressing α-Syn exhibited an increased 
membrane abundance of the N-type calcium channel α1 subunit CaV2.2 and a large increase in 
N-type calcium currents as measured by patch-clamp electrophysiology. Similar to FXS, α-Syn 
overexpression increased the phosphorylation of extracellular signal-regulated kinase 1/2 
(ERK1/2), eukaryotic translation initiation factor 4E (eIF4E) and S6, the expression of Matrix 
Metalloproteinase 9 (MMP9) and the overall cellular protein synthesis. Similar to cultured 
neurons and to mouse brain, FMRP expression was lost in SNc DA neurons of PD patients 
where it disappeared early in the disease course and prior to the appearance of LBs. Different 
from FXS, fragile X mental retardation 1 (FMR1) did not exhibit a hyper-methylation-induced 
transcriptional silencing in cultured neurons over-expressing α-Syn but appeared to be 
regulated through a mechanism involving protein kinase C (PKC) and cyclic adenosine 
monophosphate (cAMP) response element-binding protein (CREB)-driven transcription. Fmr1 
knockout (FMR1 KO) mice were protected from reduced striatal DA release when injected with 
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α-Syn-expressing adeno-associated viruses (AAV) into the SN, suggesting a protective effect of 
FMRP loss in PD. In summary, our results reveal a new role of FMRP in PD and will support the 
examination of FMRP-regulated genes in PD disease progression.   
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1 Introduction 
1.1 Parkinson’s disease 
Parkinson’s disease (PD), initially named “the shaking palsy” by James Parkinson two 
hundred years ago (Parkinson, 1817), is one of the most prevalent neurodegenerative diseases 
with an incidence of 2–3% among the population above 65 years of age (Kalia & Lang, 2015). In 
PD, dopaminergic neurons in the substantia nigra pars compacta (SNc) undergo a progressive 
cell death (Del Rey et al., 2018; Fyfe, 2017; Postuma & Berg, 2016). This results in a reduced 
striatal dopamine (DA) release and, as a consequence, in an inhibition of cortical motor 
programs, causing the typical parkinsonian motor features, including muscular rigidity, tremor, 
freezing gait and impaired movement execution (Calabresi, Picconi, Tozzi, Ghiglieri, & Di Filippo, 
2014; Kones, 2010; Rodriguez-Sabate et al., 2017). Beyond the evident motor deficiency, PD 
patients exhibit multiple non-motor symptoms, such as hyposmia, constipation, and cognitive 
decline (Phillipson, 2017; Tibar et al., 2018), thus demonstrating the additional affection of other 
brain regions. Moreover, the associated non-motor symptoms frequently appear years ahead of 
the motor dysfunction and characterize the early stages of the disease (Berg et al., 2014; 
Postuma & Berg, 2016; Ray Chaudhuri et al., 2016; Tibar et al., 2018). Although tremendous 
efforts have been made so far, the definitive diagnosis remains challenging during the early 
stages (De Pablo-Fernandez, Lees, Holton, & Warner, 2019). Until today, the ultimate cause of 
PD remains elusive (Phillipson, 2017). Existing research supports the theory that environmental 
and genetic risk factors both contribute to the development of the disease (Del Tredici & Braak, 
2016; Pan-Montojo et al., 2012). The diagnostic criterion for PD is the appearance of Lewy 
pathology and the degeneration of SNpc neurons (Goedert, Spillantini, Del Tredici, & Braak, 
2013; Hawkes, Del Tredici, & Braak, 2010). Previous studies have identified misfolded α-
Synuclein (α-Syn) and lipids as the main component of Lewy bodies (Auluck, Caraveo, & 
Lindquist, 2010; Doria, Maugest, Moreau, Lizard, & Vejux, 2016; Marin et al., 2017; Tan et al., 
2019), in conjunction with Lewy neurites termed Lewy pathology (Prymaczok, Riek, & Gerez, 
 15 
2016; Volpicelli-Daley, Luk, & Lee, 2014). Due to the neuroanatomical spreading pattern of 
Lewy pathology in many cases from the brainstem to the cortex, Braak et al. developed a 
staging with six different disease stages (Braak et al., 2003; Del Tredici & Braak, 2016). 
Although there is currently no cure for PD, disease-modifying drugs likely require an early 
diagnosis and treatment intervention (Ray Chaudhuri et al., 2016; Tibar et al., 2018). Therefore, 
studying the early molecular events and looking for potential targets during such an early 
prodromal stage will make a noteworthy contribution to the diagnosis and cure of the disease. 
1.1.1 Clinical characterization and genetic risks 
In general, the clinical features of PD can be divided into two main sub-groups: classical 
motor features and non-motor features (Brys, Nunes, & Fuentes, 2017; Stacy, 2011). This 
system of classification offers a unique perspective on the pathogenic progression of PD, as it 
was able to indicate a prolonged prodromal stage, sometimes up to a decade, before the 
appearance of gradually worsening motor features (Figure 1). 
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Figure 1 Progression of PD and clinical features during different stages (from Poewe et al., 
2017). PD usually begins with a prodromal stage in which patients only develop non-motor 
features like depression. The appearance of motor features during the early stage assists in the 
PD diagnosis. However, the accurate diagnosis is often made years later than the onset of non-
motor features and more additional non-motor features appear during the early stage. The 
disability is getting worse over time and during the mid-stage, patients will develop dyskinesias 
accompanied by psychotic features. In the late stage, frequent falls and other postural instability 
are prevalent. Meanwhile, patients also suffer from severe cognitive deficiency. REM= rapid eye 
movement. 
 
Classical motor features of PD include rigidity, tremor, bradykinesia, and postural instability 
(Berg et al., 2014; Del Rey et al., 2018). In fact, there might be only one or two features present 
in a given patient, especially during the early disease stages. Tremor sometimes is not obvious 
or even absent in PD, people thereby further categorize motor features into three subtypes: 
tremor-dominant, non-tremor-dominant, and mixed. Clinical statistics reveal that the non-tremor-
dominant disease variant is usually developing more rapidly than tremor-dominant patients do, 
and also has a higher tendency to associate with a severe movement disability later on (Fyfe, 
2017; G. M. Halliday et al., 1996). 
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Non-motor features are miscellaneous, including enteric nervous system symptoms like 
constipation or hypotension; brainstem symptoms, including REM sleep disorder (RBD), 
depression, or anxiety; basal ganglia symptom like rigidity or bradykinesia; and cortical 
symptom including cognitive decline and dementia (Kurtis, Rajah, Delgado, & Dafsari, 2017; 
Tibar et al., 2018). 
Up to 90% of all PD cases are sporadic. Current theories suggest that the interplay 
between environment and genetic risk factors contributes to the progression of the disease 
(Kones, 2010; Pan-Montojo et al., 2012; M. Zhang et al., 2017). For instance, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to induce parkinsonism (Dauer & 
Przedborski, 2003; Patil, Jain, Ghumatkar, Tambe, & Sathaye, 2014). From post-mortem brain 
examination of MPTP-intoxicated patients; however, no Lewy bodies were identified as well as 
in the MPTP-induced mouse and primate models (Gibb & Lees, 1988; G. Halliday et al., 2009; 
Jiang & Dickson, 2018). Therefore, more attention was focused on the genetic risk factors when 
A53T synuclein alpha (SNCA) was identified as an autosomal-dominant mutation for PD at the 
end of the last century (Puschmann et al., 2009). Subsequent research, in succession, 
discovered more and more pathogenic SNCA genetic variants including A30P, E46K, H50Q, 
G51N, as well as gene duplications and triplications (Campelo & Silva, 2017). Other than SNCA, 
there are 21 additional genetic loci that have been identified to be associated with PD (Table 1). 
Glucosylceramidase beta (GBA) and microtubule-associated protein tau gene (MAPT) have 
been recently demonstrated as candidates through large genome-wide association studies 
(GWAS) (Lill, 2016). Different from PD-causative mutants, genetic variants in GBA only 
contribute to higher susceptibility in PD, whereas the strongest relative mutations at GWAS level, 
like MAPT, usually correlate with an earlier age-at-onset. Meanwhile, there are still several PD-
associated loci under debate due to a limited amount of original research, like TMEM230 (Giri et 
al., 2017). 
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Table 1 Causative gene for PD (from Del Rey et al., 2018). 
 
1.1.2 Lewy body pathology, synucleinopathies and the Braak staging hypothesis 
Existing research recognized Lewy body pathology (LBP), including the appearance of 
Lewy bodies and Lewy neurites, as a specific neuropathological hallmark in PD (Berg et al., 
2014; Braak et al., 2003). Lewy bodies are intracellular inclusions containing insoluble, 
misfolded and unbranched α-Syn aggregates (DelleDonne et al., 2008). Aggregated α-Syn has 
a β-sheet structure with highly packed repetitive and hyperphosphorylated α-Syn molecules at 
Ser129 (Delic et al., 2018; Karampetsou et al., 2017). The hyperphosphorylation is mainly 
regulated by G-protein-coupled receptor kinases (Arawaka et al., 2006). Interestingly, based on 
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hematoxylin-eosin (H&E) staining, two distinct forms of LBs can be distinguished (Covell et al., 
2017; Kuusisto, Parkkinen, & Alafuzoff, 2003); one was found in the brainstem with an 
eosinophilic, argyrophilic core and strong peripheral pale halo, the other one was discovered in 
both the limbic system and cortex with irregular formation, weak halo, and robust α-Syn 
immunoreactivity. Lewy neurites can be generally divided into spheriform and linear patterns 
(Kuusisto et al., 2003). When vestigial Lewy neurites wrap extracellular amyloid-β (Aβ) 
aggregates in some Alzheimer’s disease (AD) cases, it forms a specific deposit termed Lewy 
plaque (Adamowicz et al., 2017; Orr, Wordehoff, Hoyer, & Tamamis, 2016). Thus far, LBs have 
been broadly demonstrated as a pathogenic indicator for PD; however, whether the presence of 
LBs induces cell death still remains unclear. According to some studies, it is certain that cells 
can survive for many years despite the presence of intracellular Lewy bodies (Beyer, Domingo-
Sabat, & Ariza, 2009). On the other hand, LBs can be found anywhere in the whole neuraxis 
and developing numbers of LBs (Sorrentino et al., 2017), in most cases, reflect the progression 
and severity of the disease. 
Abnormal α-Syn not only accumulates in neurons but also in oligodendrocytes termed 
Papp-Lantos bodies which are the typical hallmark of multiple system atrophy (MSA) (Jellinger 
& Lantos, 2010; Peng et al., 2018), another synucleinopathy with distinct clinical traits. Together 
with LBP, the α-Syn aggregation-induced pathological lesion was named synucleinopathies 
(Alegre-Abarrategui et al., 2019; Candelise et al., 2019; El-Agnaf et al., 2017). From previous 
research, the Papp-Lantos body was shown to contain ubiquitin, tau, leucine-rich repeat kinase 
2 (LRRK2), and many other proteins, but with α-Syn remaining the main component. Besides, it 
was also infrequently identified in progressive supranuclear palsy (PSP) cases and other 
neurodegenerative diseases (Jellinger, 2009). With different clinical presentations, MSA patients 
can be classified into parkinsonism- (over 80%) and cerebellar-predominant (Peelaerts, Bousset, 
Baekelandt, & Melki, 2018). The former sometimes was initially misdiagnosed with PD, but MSA 
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patients later will develop additional symptoms and exhibit a weak response to levodopa 
treatment, which in a way could help to distinguish it from PD (Schrag et al., 2010) 
As described earlier, PD is a progressive neurodegenerative disorder with constantly 
worsening motor symptoms. By examining post mortem brain tissue from PD patients at 
different disease stages, Braak et al. (Braak et al., 2003) found LBs to appear in a predictable 
pattern. In the first stage, LBs mainly accumulated in the olfactory bulb or lower brainstem. In 
accord, Braak stage 1 is characterized by non-motor symptoms like loss of olfaction. In stage 2, 
LBs were observed in the raphe nuclei, medulla oblongata, and locus coeruleus, whereas 
patients exhibited more non-motor symptoms. Once Lewy bodies can be identified in the SN or 
nucleus basalis Meynert, this indicates the disease moving to stage 3 or higher. Usually, the 
motor dysfunction remains unnoticeable during stage 3 and starts to be evident from stage 4 
when LBs reach the temporal cortex. In stage 5, LBs appear in the neocortex and significant 
dopaminergic neurodegeneration can be observed. The patients also display obvious cognitive 
dysfunction in this stage. Finally, the LBs will “spread” to the whole neocortex and reach the 
primary sensory area in stage 6. The symptoms also become the most serious during the last 
stage (Figure 2). As has been noted, the pathology exhibits a strong spreading pattern following 
the disease progression which was well supported by presenting of LBs in the grafted tissue 
(Kordower, Chu, Hauser, Freeman, & Olanow, 2008; J. Y. Li et al., 2008). 
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Figure 2 Braak staging hypothesis (from Doty, 2012). 
 
1.1.3 The role of α-Syn in PD and incidental Lewy body disease 
Spillantini (Spillantini et al., 1997) demonstrated α-Syn as the main component of LBs. α-
Syn was initially identified by Maroteaux (Maroteaux, Campanelli, & Scheller, 1988) and isolated 
from synaptic vesicles and the nuclear envelope in cholinergic neurons of Torpedo californica. It 
has three homologues: β -synuclein, γ -synuclein, and synoretnin, all of them with frequent 
KTKEGV repeat sequences (Lashuel, Overk, Oueslati, & Masliah, 2013; Rodriguez et al., 2015). 
Interestingly, although all the family members are highly homologous, only α-Syn has the 
propensity for aggregation (Auluck et al., 2010). Data from several sources suggested a 12 
amino acid region in the hydrophobic domain of α-Syn, which was absent in other homologues, 
to be responsible for α-Syn's ability to oligomerize and aggregate (Giasson, Murray, 
Trojanowski, & Lee, 2001). On the other hand, there was research that demonstrated the 
existence of SDS-non-resistant α-Syn oligomers of ~ 60 kDa in size in both control and LBD 
patients (Bartels, Choi, & Selkoe, 2011). Different from monomers, native tetramers do not 
puncture the lipid membrane and display a limited tendency to form aggregates (Nuber et al., 
2018; W. Wang et al., 2011). Debate continues about whether α-Syn oligomers exist under 
physiological conditions or whether different conformations exist in different cellular 
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compartments. Independent from these experiments, SDS-resistant α-Syn oligomers, in 
particular dimers, have been frequently detected from different models under oxidative stress 
condition or after treatment with cytochrome c/hydrogen peroxide (Grassi et al., 2018; 
Hashimoto, Hsu, et al., 1999; Hashimoto, Takeda, Hsu, Takenouchi, & Masliah, 1999). 
Therefore, studying the function and distribution of α-Syn oligomers may contribute to a better 
understanding of PD pathology. 
So far, the actual function of α-Syn is still under the mask. Current research indicates α-
Syn monomer to be involved in synaptic function, lipid metabolism, and epigenetic modification 
(Adamczyk & Strosznajder, 2006; Auluck et al., 2010; Soldner et al., 2016). The α-Syn 
oligomers, fibrils, and aggregates have been reported to harm neurons by inducing 
mitochondrial dysfunction, impairing vesicle trafficking, and protein degradation (Phillipson, 
2017). Meanwhile, α-Syn fibrils were shown to exhibit prion-like features, in accord with Braak's 
staged progression (Hasegawa, Nonaka, & Masuda-Suzukake, 2016).  
Although LBs contain a large amount of α-Syn fibrils, the accumulation mechanism under 
physiological condition has not yet been comprehensively investigated due to the limitation of 
appropriate model systems. LBs seem to be restricted to humans and are not even present in 
our primate relatives (Visanji et al., 2016). However, a consistent mechanism of α-Syn 
accumulation and aggregation in different models still can be recapitulated. First, increased 
production of α-Syn, caused by SNCA gene triplication or single nucleotide polymorphisms 
(SNPs) of the SNCA gene, leads to an accumulation of α-Syn (Oliveira et al., 2015). Current 
knowledge based on in vitro protein kinetic assays can well explain the formation of oligomers 
and fibrils in a long run from sufficient monomer α-Syn (Narkiewicz, Giachin, & Legname, 2014; 
Ponzini et al., 2019). Second, factors such as mutations and oxidative stress can induce α-Syn 
accumulation through seeding from a small seed concentration (Lazaro et al., 2016; W. Wang et 
al., 2016). Of note, different mutations under distinct conditions exhibit identical patterns of 
 23 
aggregation. For example, A30P α-Syn expedites the process of α-Syn oligomerization in vitro 
but induces fibrillation in vivo (Lemkau et al., 2012; J. Li, Uversky, & Fink, 2001). Third, impaired 
protein degradation, autophagy dysfunction for instance, is also able to accelerate protein 
aggregation (Melo, Copray, & Ferrari, 2018; Moors et al., 2017). Reduced protein degradation 
leads to an increased level of α-Syn or misfolded α-Syn (Cuervo, Stefanis, Fredenburg, 
Lansbury, & Sulzer, 2004). Meanwhile, previous studies suggest that misfolded protein 
elimination deficiency is associated with sporadic PD and DLB (Candelise et al., 2019). 
Although different forms of α-Syn were monitored in vitro and in vivo, it remained unclear 
whether they are toxic or not. A systematic study that examined the effect of α-Syn conformation 
on toxicity in vivo was reported by Peelaerts et al. (Peelaerts et al., 2015). They demonstrated 
that fibrils are more toxic than oligomers and ribbons, also distinct strains resulted in a different 
pathology pattern. The incidental Lewy body disease (iLBD) refers to cases without clinical 
symptoms of PD, but with the appearance of LBs and LNs in the brain (DelleDonne et al., 2008). 
Nearly one-third of people above 65 have iLBD. The iLBD has hitherto received scant attention 
by scholars’ due to vague clinical symptoms. Current preliminary researches suggest iLBD is 
likely the preclinical phage of DLB and PD (Bloch, Probst, Bissig, Adams, & Tolnay, 2006).  
 
1.1.4 Voltage-gated calcium channels in PD 
Voltage-gated calcium channels (VGCCs) are membrane resident calcium-conducting ion 
channels that flux calcium in response to membrane depolarization. VGCCs control many 
functions including gene expression, neurotransmitters release, cell excitability, etc. (Buraei & 
Yang, 2013; Dolphin, 2009). According to their electrophysiological and pharmacological 
characterization, VGCCs are generally grouped into CaV1, CaV2 and CaV3 (Table 2). CaV1 and 
CaV3 family are L-type and T-type, respectively. CaV2 contains P/Q-type (CaV2.1), N-type 
(CaV2.2), and T-type (CaV2.3) (Dai, Hall, & Hell, 2009). Perturbed calcium homeostasis due to 
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the activation of different VGCCs has been reported in different PD models (Duda, Potschke, & 
Liss, 2016; Hurley & Dexter, 2012). Chan et al. found that isradipine, which is an L-type calcium 
channel blocker, can rescue the SNc neurons by changing aged pacemaking to the juvenile 
form in the MPTP-induced mouse PD model (Chan et al., 2007). The protective effect of L-type 
calcium channel blockers in different PD models is well supported by other researches (Guzman 
et al., 2018; Liss & Striessnig, 2019) and isradipine was recently a potential drug for early PD 
patients in clinical trial phase III. α-Syn overexpressed in SH-SY5Y cells induced a cobalt-non-
sensitive calcium channel activation (Danzer et al., 2007), indicating that the N-type calcium 
channel is not involved. Conversely, Adamczyk (Adamczyk & Strosznajder, 2006) reported 
omega-conotoxin GVIA, which is also an N-type calcium channel blocker, to block calcium influx 
induced by extracellular α-Syn in rat brain synaptosomes. 
 
 
Table 2 Different voltage-gated calcium channels (from C. Y. Wang, Lai, Phan, Sun, & Lin, 
2015). 
 
Existing research recognizes the critical role of α-Syn in regulating calcium homeostasis. In 
turn, deregulated intracellular calcium can induce α-Syn oligomerization and aggregation which 
further accelerates the disease progression (Nath, Goodwin, Engelborghs, & Pountney, 2011; 
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Zaichick, McGrath, & Caraveo, 2017). A study by Follett et al. showed that pre-incubation with 
BAPTA-AM can significantly reduce α-Syn aggregation in both HEK293T and SHSY-5Y cells 
(Follett, Darlow, Wong, Goodwin, & Pountney, 2013). Likewise, an increased intracellular 
calcium level by applying thapsigargin or the calcium ionophore A23187 resulted in the 
formation of α-Syn plaques (Nath et al., 2011). 
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1.2 Fragile X syndrome 
Fragile X syndrome (FXS) is an inherited mental disease due to the absence of the fragile 
X mental retardation protein (FMRP) (Budimirovic & Kaufmann, 2011). FMRP is coded from the 
fragile X mental retardation 1 (FMR1) gene on the X chromosome (De Rubeis & Bagni, 2011). 
In line, male patients usually have more severe symptoms than female patients (Alisch et al., 
2013). In FXS patients, there are more than 200 CGG repeats (full mutation) in the 5′ 
untranslated region of FMR1. These induce hypermethylation of FMR1 followed by 
transcriptional silencing (Jalnapurkar, Cochran, & Frazier, 2019).  FMRP acts as a 
transcriptional regulator, controls the expression of many synaptic proteins like Arc and STEP 
(H. Y. Lee et al., 2011; Richter, Bassell, & Klann, 2015), and plays a critical role in the synaptic 
maturation (Oostra & Willemsen, 2003). The deficiency of FMRP leads to nervous system 
dysfunction and abnormal synapse formation (Sunamura, Iwashita, Enomoto, Kadoshima, & 
Isono, 2018). Healthy people normally harbor 5-40 times CGG repeats. Individuals with 55 to 
200 CGG repeats, termed FMR1 premutation, have a risk to develop what is called the fragile 
X-associated tremor/ataxia syndrome (FXTAS) (R. J. Hagerman & Hagerman, 2016). Different 
from FXS, FXTAS patients usually retain general intelligence and typical symptoms like tremor 
and/or ataxia only occur in the middle age (D. A. Hall et al., 2005). Instead of silenced gene 
expression of FMR1 in FXS, the transcription of the FMR1 gene in FXTAS is increased and 
therefore produces excess FMR1 mRNA (D. A. Hall, Howard, Hagerman, & Leehey, 2009). 
However, the FMRP level is either normal or moderately decreased in FXTAS (P. J. Hagerman 
& Hagerman, 2015). Thus, the cause of FXTAS is rather due to elevated RNA gain of function 
toxicity. In addition, pathogenic intranuclear inclusions, which are tau and α-Syn negative, are 
frequently observed in both neurons and glial cells throughout FXTAS patients’ brain (Boivin, 
Willemsen, Hukema, & Sellier, 2018). Although there is currently no cure for FXS and FXTAS, 
normalizing the over-activated mGluR5-mediated FXS pathophysiology showing great potential 
in ameliorating FXS behaviors in mouse model. In 2018, a new emerging CRISPR-Gold technic 
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has shown that controlling the numbers of affected striatum mGluR5 neurons can improve 
abnormal behaviors of FMR1 knockout (FMR1 KO) mice (B. Lee et al., 2018). 
1.2.1 Clinical characterization and pathogenesis 
Intellectual disability is the most prominent clinical feature of FXS and includes impaired 
short-term memory, delayed development of speech, and inattention (Bagni, Tassone, Neri, & 
Hagerman, 2012). Apart from intellectual disability, FXS patients also exhibit morphological 
abnormalities after puberty, including a long face with an arched palate, big ears, soft skin, 
unusually hyperextensible fingers, flat feet as well as macroorchidism (Contractor, Klyachko, & 
Portera-Cailliau, 2015).  Associated symptoms include autism-like behavior, social anxiety, and 
hypersensitivity (Tranfaglia, 2011). Unlike FXS, FXTAS patients exhibit predominantly motor 
symptoms and therefore are often misdiagnosed as PD at the beginning (Sellier et al., 2017). 
Individuals with FXTAS usually present with action tremor, rigidity, ataxia, slow movement, and 
diminished sensation (Niu et al., 2014). In addition, some patients suffer from immune system 
problems (R. J. Hagerman & Hagerman, 2016). Similar to FXS, the number of CGG repeats 
correlates with the severity of the disease (Oostra & Willemsen, 2003). 
The “fragile locus” constriction in FXS was identified from the long arm of the X 
chromosome by Lubs in 1969 (Lubs, 1969). Under the healthy condition, FMRP is abundant in 
the human brain and can selectively bind to a large number of mRNAs. Studies have suggested 
that up to 4% of RNA transcripts in the brain interact with FMRP (Bhakar, Dolen, & Bear, 2012; 
Miyashiro et al., 2003). Through physical binding, FMRP is able to cargo newly synthesized 
mRNAs out of the nucleus and suppress their translation (Garber, Smith, Reines, & Warren, 
2006; Stefani, Fraser, Darnell, & Darnell, 2004). Most of these mRNAs exist in dendrites and 
translated proteins are predominantly associated with the synaptic function (Feng et al., 1997; 
Higashimori et al., 2013). As a result, mRNA translation and protein synthesis are increased in 
FXS and accompanied by abnormal dendritic spine morphology in FXS human neurons and 
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neurons from FMR1 KO mice (De Rubeis & Bagni, 2011; Kazdoba, Leach, Silverman, & 
Crawley, 2014). The abnormal development and structure of synapses lead to impaired synaptic 
plasticity, learning and memory (K. Zhang et al., 2017). This is likely the basis of the early 
intellectual disability in FXS children. Moreover, FMRP loss can amplify neuronal long-time 
depression (LTD) through the metabotropic glutamate receptor (mGluR) cascade (Osterweil, 
Krueger, Reinhold, & Bear, 2010). FMRP loss likely impairs DA release, which may contribute to 
typical features in FXS, such as hyperactivity (H. Wang et al., 2008). 
In the case of FXTAS, much uncertainty still remains about the RNA gain of function 
toxicity. In view of published work so far, previous studies support the hypothesis that excess 
FMR1 mRNAs competitively bind to some RNA-binding proteins and derail the actual function of 
those proteins (Sellier et al., 2017). The subsequent protein aggregation forms inclusions 
(Greco et al., 2002), and exerts neuronal toxicity to induce cell death (Jeon et al., 2012). In 
addition, mitochondrial deficiency or inflammation may also have a detrimental effect on disease 
progression (Liu et al., 2018; Shen et al., 2019). 
1.2.2 Regulation of fragile X mental retardation protein and protein-related pathways 
In the mouse brain, neurons start to express FMRP in the early stages of gestation 
(Arsenault et al., 2016; Kazdoba et al., 2014). Later on, FMRP expression is restricted to the 
brain (Zhang et al., 2015). In neuronal cells, FMRP mainly exists in the perikaryon, bound to 
ribosomes or polyribosomes, as well as in neurites (Liu et al., 2018). Others spot at nucleopore 
or in the nucleolus (Lai, Sakkas, & Huang, 2006). Although in situ hybridization and 
immunofluorescent studies have recognized the distribution and localization of FMRP 
(Dictenberg, Swanger, Antar, Singer, & Bassell, 2008; Feng et al., 1997), no systematic studies 
have been performed to investigate the regulation of protein expression and shuttling 
mechanism of FMRP between nucleus and cytoplasm. According to the promoter sequences, 
Hansen et al. (H. Wang et al., 2012) speculated that the phosphorylation of cyclic AMP-
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responsive element-binding protein (CREB), as a transcriptional factor, might be a key 
intermediate step involved in the translation of FMRP. Full-length FMRP contains a nuclear 
localization signal (NLS) domain (Kim, Bellini, & Ceman, 2009), however, the binding sequence 
of classical NLS receptor, importin alpha, is absent in its NLS domain. Therefore, the 
translocation mechanism of FMRP remains unclear. 
Two canonical pathways under mGluRs, mechanistic target of rapamycin complex 1 
(mTORC1) and mitogen-activated protein kinase/extracellular signal-regulated kinase 
(MAPK/ERK), are hyperactivated in both FXS patients and FMR1 KO mice (Figure 3) (Sharma 
et al., 2010; Zhao, Chuang, Bianchi, & Wong, 2011). In FMR1 KO mice, inhibitory 
pharmacologic treatments targeting these pathways, like metformin, exhibit a protective effect 
with rescued abnormal spine morphology and alleviated behavior deficits (Gantois et al., 2017). 
The mTOR is a highly conserved kinase among different species, and involved in almost all the 
aspects of cellular processes, including cell survival, growth, proliferation, protein degradation, 
lipid synthesis, et al. (Niere & Raab-Graham, 2017; Zhu, Chen, Mays, Stoica, & Costa-Mattioli, 
2018). Unlike mTORC2, which is a rapamycin-insensitive mTOR complex, mTORC1 mainly 
regulates phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) binding proteins 
(4E-BPs) and p70 S6 kinase 1 (S6K1) (Marat et al., 2017; Niere & Raab-Graham, 2017). As a 
consequence of mTORC1 activation, eIF4E-eIF4G translation initiation complex is assembled 
and protein synthesis is boosted therewith (Napoli et al., 2008). Additional knockout of S6K1 in 
FMR1 KO mice exhibits recovered social behavior, dendritic morphology, and function 
(Bhattacharya et al., 2012). Moreover, treatment of temsirolimus, a mTORC1 inhibitor, improves 
mice cognitive function which is impaired in FMR1 KO mice (H. Wang, Pati, Pozzo-Miller, & 
Doering, 2015). The MAPK/ERK pathway, as the name suggests, is mainly related to cell 
proliferation in response to extracellular mitogens (Y. Li et al., 2016). Therefore, it has been well 
studied in cancer research. ERK also acts on eIF4E, but through MAP kinase interacting protein 
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kinases (MNKs) (Waskiewicz, Flynn, Proud, & Cooper, 1997; Waskiewicz et al., 1999). 
Normalizing ERK signal by lovastatin has ameliorated movement activity in FXS patients and 
has shown corrected protein synthesis in vivo (Caku, Pellerin, Bouvier, Riou, & Corbin, 2014; 
Osterweil et al., 2013). Once again, genetically deletion of MMP9, which is frequently implicated 
in FXS as excessive production of eIF4E phosphorylation, prevents the formation of immature 
spine morphology (Sidhu, Dansie, Hickmott, Ethell, & Ethell, 2014). 
 
 
Figure 3 FMRP related protein translation initiation pathways (from Richter et al., 2015). 
 
1.2.3 Commonalities with PD 
FXS patients do not exhibit a PD-like movement disorder. Hall et al. reported a 60-year-old 
male FXS patient, with 540 and 447 CGG repeats in two alleles, displaying a prominent 
cognitive decline and parkinsonism (D. Hall, Pickler, Riley, Tassone, & Hagerman, 2010). In 
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FXTAS, which is normally diagnosed at a later age, parkinsonism has been commonly reported 
(Cilia et al., 2009). Interestingly, almost all typical PD symptoms, including both non-motor and 
motor, have been found in FXTAS patients (Fay-Karmon & Hassin-Baer, 2019). FXTAS cases 
sometimes have concomitant LBP in the brain. Meanwhile, nearly one-fifth of the FXTAS 
patients have also shown impaired nigrostriatal projection and related DA deficiency (D. A. Hall, 
Jennings, Seibyl, Tassone, & Marek, 2010).   
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1.3 Aim of the study 
 
1) Neuronal calcium homeostasis contributes to neurodegeneration in PD (Duda et al., 
2016). The effect of α-Syn on neuronal calcium channels has not been well studied. Therefore, 
we aimed to investigate the effect of α-Syn on VGCCs in cultured dopaminergic neurons. 
 
2) Activated N-type calcium channels were recognized in this dissertation to be related to 
α-Syn overexpression in LUHMES cells. Although one publication reported a physical direct 
interaction between FMRP and N-type calcium channel (Ferron, Nieto-Rostro, Cassidy, & 
Dolphin, 2014), much uncertainty still exists about the relationship between N-type calcium 
channels and FMRP. Thus, we attempted to ascertain the role of FMRP in regulating N-type 
calcium channels and other downstream proteins in PD models. 
 
3) FMRP has been reported in a number of FXS studies involving in regulating synaptic 
function and protein synthesis. However, the role of FMRP has hitherto received scant attention 
in PD research. Our third aim of this study was to assess the FMRP expression in different 
pathological stages and regions of PD patients’ brains. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Antibodies 
 
Antibody Cat. No. 
Dilution 
(WB) 
Dilution  
(ICC/IHC) Supplier 
FMRP 4317S 1:1000 1:50 Cell Signaling  
FMRP 5C2 834701 
 
1:100 Biolegend 
FMRP 4G9 NBP1-42567 
 
1:100 Novus Biologicals 
Alpha-synuclein 15G7 ab195561 
 
1:50 Abcam 
Alpha-synuclein 2642S 1:1000 
 
Cell Signaling  
Alpha-synuclein C20 sc-7011-R 1:1000 
 
Santa Cruz  
Beta-actin 4967S 1:10000  Cell Signaling 
CACNA1B PA5-21440 1:1000 1:100 Thermo Fisher  
CACNA1B ACC-002 1:1000 1:100 Alomone Labs 
CACAN1B Sc-377489  1:200 Santa Cruz 
S6 Ribosomal Protein 
5G10 2217S 1:1000 
 
Cell Signaling  
Phospho-S6 Ribosomal 
Protein Ser240/244 2215S 1:1000 
 
Cell Signaling  
Phospho-eIF4E Ser209 9741S 1:1000 
 
Cell Signaling  
eIF4E 9742S 1:1000 
 
Cell Signaling  
MMP-9 PA5-16851 1:1000 
 
Thermo Fisher  
MMP-9 D6O3H 13667S 1:1000 
 
Cell Signaling  
EEA1 610456 1:1000  
BD Transduction 
Laboratories 
HDAC2(3F3) 5113 1:1000  Cell Signaling 
GAPDH(14C10) 3683S 1:1000  Cell Signaling 
CREB 48H2 9197S 1:1000 
 
Cell Signaling  
Phospho-CREB Ser133 
87G3 9198S 1:1000 
 
Cell Signaling  
Phospho-CREB 
Ser133 MA5-11192 1:1000  Thermo Fisher 
Tyrosine Hydroxylase AB152 
 
1:500 Millipore 
Tyrosine Hydroxylase PA1-4679, 
 
1:100 Thermo Fisher  
Na+-K+-ATPase 3010S 1:1000 
 
Cell Signaling  
NMDAR1 48066 1:1000 
 
BD Pharmingen 
Pan-Cadherin 4068 1:1000  Cell Signaling 
Puromycin MABE343 1:1000 
 
Millipore 
Tryptophan Hydroxylase 2 ABN60  1:200 Millipore 
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Choline Acetyltransferase Ab178850  1:500 Abcam 
LC3B (D11) 3868S 1:1000  Cell Signaling 
Goat anti-Mouse IgG H&L 
Alexa Fluor® 488 ab150117 
 
1:500 Abcam 
Peroxidase Labeled Goat 
anti-Rabbit IgG H&L PI-1000 1:10000 
 
Vector 
Peroxidase Labeled Goat 
anti-Mouse IgG H+L PI-2000 1:10000 
 
Vector 
Biotynl Tyramide 6241 
  
Tocris 
Cy®3-Streptavidin 434315 
 
1:300 Invitrogen 
Cy®5-Streptavidin 434316 
 
1:300 Invitrogen 
Donkey anti-Rabbit IgG 
H+L Alexa Fluor® 594 A21207 
 
1:500 Life Technologies 
Goat anti-Rabbit IgG H&L 
Alexa Fluor® 488 A11008 
 
1:500 Invitrogen 
Donkey anti-Rabbit IgG 
H+L Alexa Fluor® 680 A10043 
 
1:500 Life Technologies 
Goat anti-Rat IgG H&L 
Alexa Fluor® 568 A11077 
 
1:500 Invitrogen 
Horse anti-Mouse 
Biotinylated IgG BA-2000 
 
1:2000 Vectastain 
Goat anti-Mouse Biotin-SP-
conjugated IgG H+L 115-065-068 
 
1:2000 
Jackson 
ImmunoResearch 
 
Table 3 Antibodies used for WB, VIP, Co-Immunoprecipitation, and immunofluorescent staining. 
  
 35 
2.1.2 PCR Primers 
 
Gene Primer Name Sequence 5' to 3' 
FMR1 Forward Primer CCAACAAACCTGCCACAAAAG 
 
Reverse Primer GCACACATTTGCCGTAAGTCTT 
POLR2A Forward Primer GCGGAATGGAAGCACGTTAAT 
 
Reverse Primer CCCAGCACAAAACACTCCTC 
RPL22 Forward Primer CACGAAGGAGGAGTGACTGG 
 
Reverse Primer TGTGGCACACCACTGACATT 
TBP Forward Primer AAAGAACGCTGTACTCAGTGTG 
 Reverse Primer CCCCGGTTGAGGGCTTTTA 
 
Table 4 qRT-PCR primer sequences for FMR1 and housekeeping genes. 
 
 
Gene Primer Name Sequence 5' to 3' 
FMR1 Forward Primer ATAGGATCCGGCCACCATGGAGGAGCTGGT 
 
Reverse Primer GACTGCAGAATTCTTAGGGTACTCCATTCACCAGC 
Backbone Forward Primer GTAAGAATTCGATATCAAGCTTATCGAT 
 
Reverse Primer ATACTCGAGGATCCAATTCTTTGCCAAAATGATG 
 
Table 5 Primer sequences for FMR1 plasmid cloning.  
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2.1.3 Human brain samples 
 
 
Table 6 Information on PD and control brain tissue donors. All the brain slices were provided by 
the Munich Brain Bank, Department of Neuropathology, Ludwig Maximilian University Munich. 
The selected 24 cases were staged according to the presence of LBs in the dorsal motor 
nucleus of the vagus nerve (DMV), locus coeruleus, the SN and the cortex. The table shows the 
respective Braak stage, the disease onset age, symptoms, sex, death age, and fixation time for 
each case. PD: Parkinson's disease; D: Dementia; Dep: Depression; Dys: Dystonia; RLS: 
Restless Legs Syndrome, -: no neurological or psychiatric symptoms; n.a. = not applicable. 
 
 
  
Case 
# 
Braak 
Stage 
Age at Disease 
Onset (yrs) 
Clinical 
Symptoms 
Age at 
Death (yrs)  
Sex Tissue 
Fixation 
Time (days) 
1 5 unknown PD, D, Dep 82 f 83 
2 6 51 PD, D 73 m 96 
3 6 unknown PD 86 f 71 
4 3 n.a. - 54 m 83 
5 3 unknown PD 58 m 103 
6 4 80 D  86 f 111 
7 6 65 PD 82 m 42 
8 6 49 PD, D 69 m 68 
9 6 65 (D), 73 (PD) PD, D 77 m 112 
10 6 54 (PD), 69 (D) PD, D 74 m 100 
11 6 73 PD 82 f 113 
12 2 n.a. - 60 m 14 
13 1 unknown Dys 66 m 41 
22  1 unknown RLS 90 f 377 
23  1 unknown RLS 95 f 352 
24  1 n.a. - 65 f 14 
14 0 n.a. - 70 m 68 
15 0 n.a. - 60 f 47 
16 0 n.a. - 59 f 110 
18 0 n.a. - 60 m 30 
19 0 n.a. - 82 m 63 
20 0 n.a. - 73 f 111 
21 0 n.a. - 66 f 90 
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Case # Age at 
Death 
Sex  Neuropathological 
Diagnosis 
Tissue Fixation Time 
 (days) 
30 73 f PSP 4 
31 62 f PSP <89 
32 67 m PSP <30 
33 81 m PSP <112 
34 71 m PSP 6 
35 62 m PSP <66 
36 62 f PSP <56 
37 76 m PSP <106 
38 74 m PSP 9 
39  71 m PSP <59 
40 68 f MSA 60 
41 64 m MSA 59 
42 71 m MSA 56 
43 76 f MSA 55 
44 64 f MSA 62 
45 63 m MSA 67 
46 62 m MSA 62 
47 77 f MSA 103 
48 37 m MSA 18 
 
Table 7 Information on PSP and MSA brain tissue donors. All the brain slices were provided by 
the Munich Brain Bank, Department of Neuropathology, Ludwig Maximilian University Munich. 
The selected 24 cases were staged according to the presence of LBs in the dorsal motor 
nucleus of the vagus nerve (DMV), locus coeruleus, the SN and the cortex. The table shows the 
age, sex fixation time of all brain tissues. PSP: Progressive supranuclear palsy; MSA: Multiple 
System Atrophy.  
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2.2 Molecular biology 
2.2.1 Plasmid cloning  
AAV5-α-Syn and AAV5-GFP (both from BioFocus DPI, Saffron Walden, England) were 
described elsewhere (Hollerhage et al., 2014). The AAV5-FMRP vector plasmid was generated 
by cloning the mouse Fmr1 gene from the plasmid pCMV-EGFP-FMR1 (a gift from D. Edbauer, 
German Center for Neurodegenerative Research, https://benchling.com/s/seq-
gP4TDhOSjnm4IdV0NSkf) into the open reading frame of the AAV expression plasmid pAAV-
CAG-GFP (Addgene # 37825, https://benchling.com/s/seq-LGOlDvNxKaeEecH6vPzA) by using 
BamH1 and EcoR1 restriction sites. The primer sequences used for cloning and amplification 
are specified in Table 5. The resulting plasmid was packed into an AAV5 at the viral vector core 
facility at the Technical University Munich (https://benchling.com/s/seq-
UmUs71yDNZ8jb9SUuy4P). 
2.2.2 Nucleic acids and polymerase chain reaction 
RNA was extracted from cultured neurons by using the NucleoSpinTM RNA Kit (Macherey‐
Nagel, Düren, Germany). For quantitative real-time polymerase chain reaction (qRT-PCR), 1 μg 
RNA was converted into cDNA using the iScriptTM single cDNA Synthesis Reaction Kit (Bio‐Rad, 
Hercules, USA). The qRT-PCRs reactions were performed using SYBR GreenTM Select qPCR 
Supermix (Life Technologies, Carlsbad, USA). All primers used for qRT-PCR were designed 
using OLIGOTM Primer analysis software (Vers. 6.41; Molecular Biology Insights) and are listed 
in Table 4. The qRT-PCR analysis was performed on a Step One Plus instrument (Thermo 
Fisher Scientific, Waltham, USA). Initial incubation at 10 min at 95 °C was followed by 40 cycles 
of 15 sec at 95 °C and 60 sec at 60 °C. The threshold cycle (CT) values were set within the 
exponential phase of the PCR. Data were normalized to three housekeeping genes: POLR2A, 
RPL22 and TBP and the comparative normalized relative quantity (CNRQ) was used to 
calculate fold expression (qBase, Biogazelle, Zwijnaarde, Belgium). Gene regulation was 
statistically evaluated by two-tailed Student’s t-test on the assumption of equal variances. 
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2.2.3 Small interfering RNA transfection 
Small interfering RNAs (siRNAs) (Silencer Select siRNAsTM, Thermo Fisher Scientific) 
targeting FMR1 (# 4392420) or control siRNAs (# 4390843) were mixed with Lipofectamine 
RNAiMaxTM in Optimum medium (Thermo Fisher Scientific) according to the manufacturer 
recommendations. The siRNAs were applied 24 h post-transduction with the AAVs at a final 
concentration of 10 nM and the cells were incubated with the siRNAs for the following 3 days 
until day 6 in vitro, which is when the cells were harvested for Western blot or used for 
electrophysiology.   
2.2.4 Methylation sequencing 
To detect the methylation status of FMRP in cultured neurons, the cells were differentiated 
and transduced with α-Syn- or GFP-expressing viruses as described above. On day 4 post-
transduction, the cells were washed once and detached in PBS. After spinning down (300 x g 
for 5 min at 4°C), the pellet was collected and stored at -80°C.  For DNA extraction, the 
QiaAmpTM DNA Mini Kit was used according to the manufacturer`s protocol (Qiagen, Hilden, 
Germany). The Infinium Human Methylation EPIC BeadChipTM (Illumina Inc., San Diego, USA) 
was used for methylation analysis. 200 ng of bisulfite-converted DNA was hybridized to the 
arrays according to the manufacturer´s instructions. Array data were evaluated, preprocessed 
and normalized using the ChAMP pipeline (V.2.8.1) (Morris et al., 2014; Tian et al., 2017) with 
minor modifications. Specifically, raw array data were uploaded to the ChAMP pipeline using the 
minfi option (Aryee et al., 2014). Probes with less than three measured beads or a detection P-
value > 0.01, as well as probes interrogating CpGs that fall on or near to a SNP, were removed 
based on recommendations by Zhou et al. (Zhou, Laird, & Shen, 2017). Similarly, probes 
aligning to multiple locations as defined by Nordlund et al. were removed from the analysis 
(Nordlund et al., 2013). All samples had more than 99.3 % of valid probes; therefore no samples 
were removed from the analysis based on the quality of the data. Differences between probes 
due to InfI and InfII probe usage as well as between samples were normalized using BMIQ 
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(Teschendorff et al., 2013). Differential methylation was determined using the champ.dmp 
function using linear regression analysis based on the limma package (Smyth, 2004) adjusting 
P-values for multiple testing with Benjamini-Hochberg correction. Differentially methylated CpGs 
were considered significant at adjusted P-values < 0.05.   
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2.3 Cell biology 
2.3.1 Cell culture 
Proliferating LUHMES (Lund human mesencephalic) cells were maintained on Nunc™ 
Delta Surface tissue culture flasks (Thermo Fisher Scientific) coated with 100 μg/ml poly-L-
lysine (Sigma-Aldrich, St. Louis, USA). The proliferation medium consisted of DMEM/F-12 
(Sigma-Aldrich) with 1% N2 supplement (Life Technologies) and 0.04 μg/ml basic fibroblast 
growth factor (Peprotech). In order to differentiate the cells, they were cultured on Nunc™ Delta 
Surface multi-well tissue culture vessels (Thermo Fisher Scientific) in differentiation medium 
consisting of DMEM/F-12 supplemented with 1% N2, 1 μg/ml tetracycline, 0.5 μg/ml dibutyryl 
cyclic AMP (all Sigma-Aldrich), and 2 ng/mL glial cell-derived neurotrophic factor (R&D Systems, 
Minneapolis, USA). Unless stated otherwise, the cells were seeded at a density of 125,000 
cells/cm2 to achieve a final confluence of ~ 50%. Before plating the cells for differentiation, the 
tissue culture vessels were coated with 0.1 mg/mL poly-L-lysine (Sigma-Aldrich) at 4 °C 
overnight, washed three times with phosphate-buffered saline and coated again with 5 μg/ml 
bovine fibronectin (Sigma-Aldrich) at 37°C overnight. Proliferating and differentiated LUHMES 
cells were cultured at 37 °C with 5% CO2 and water-saturated air. Unless otherwise stated, cells 
were differentiated for 6 days in differentiation medium into post‐mitotic neurons with a 
dopaminergic phenotype (Bruch et al., 2017; Scholz et al., 2011). In order to achieve viral 
overexpression of α-Syn, GFP or FMRP, AAV5-α-Syn, AAV5-GFP or AAV5-FMRP were added 
24 h after plating the cells in differentiation medium at an MOI (multiplicity of infection) of 2.15 
as described previously (Hollerhage et al., 2014). After the virus application, the cells were 
incubated for another 24 h and rinsed thereafter three times with PBS before the fresh 
differentiation medium was added and the cells incubated for another 4 days before being used 
for experimentation. Rotenone (Sigma) was dissolved in DMSO; the cells were treated for 24 h 
with increasing concentrations of rotenone as described elsewhere (Bruch, Xu, De Andrade, & 
Hoglinger, 2014) and cell death was measured against DMSO by quantifying medium LDH. For 
 42 
C1 (20μM) and Go6983 (5μM) treatment (both from Tocris, Wiesbaden-Nordenstadt, Germany), 
both compounds were dissolved in DMSO and the cells were incubated after virus washing. 
2.3.2 Quantification of cell death by LDH release 
Cell death in cultured dopaminergic neurons was quantified as described before 
(Hollerhage et al., 2014). In brief, lactate dehydrogenase (LDH) released into the culture 
medium was measured using the CytotoxOne Membrane Integrity Assay (Promega, Madison, 
USA) according to the manufacturer's instructions with a Fluostar Omega fluorescence reader 
(BMG Labtech, Ortenberg, Germany). 
2.3.3 Subcellular fractionation 
The protocol to separate distinct cellular compartments has been applied as described 
(Alisch et al., 2013) with minor modifications (Figure 4). In brief, differentiated LUHMES cells (at 
day 6 post-transduction) were trypsinized for 5 min., centrifuged at 1,200 x g for 7 min. and the 
cell pellet homogenized by using a pre-chilled Dounce homogenizer in a detergent-free lysis 
buffer containing the following: 10 mM Tris/HCl (pH 7.4), 10 mM NaCl, 0.5 mM MgCl2, and 
EDTA-free protease inhibitor cocktail (Roche, Rotkreuz, Switzerland). The homogenates were 
centrifuged at 1,200 x g for 5 min. The pellets (P1) were re-suspended in 250 mM sucrose 
solution containing 10 mM MgCl2 and centrifuged through an 880 mM sucrose cushion 
containing 0.5 mM MgCl2 at 1,200 x g for 10 min in order to obtain the crude nuclear fraction. 
The supernatants (S1) were centrifuged at 1,200 x g for 5 min to obtain the crude cytosolic 
fraction (S2). This fraction was further subjected to a 16,000 x g centrifugation step for 10 min to 
isolate the heavy membrane pellet (S3) and the post-nuclear supernatants. The post-nuclear 
supernatants were then centrifuged for 90 min at 130,000 x g. The resulting supernatants 
contained the cytosolic fraction (S4); the pellets contained the light membrane fraction and 
polysomes (P4). The nuclei (P5) were resuspended and homogenized in the detergent-free lysis 
buffer by pipetting up and down and centrifuged through a cushion of 880 mM sucrose 
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containing 0.5 mM MgCl2 at 2000 x g for 20 min to isolate the nucleolar pellets (P6) and post-
nucleolar supernatant (S6). The post-nucleolar supernatants were finally centrifuged for 90 min 
at 130,000 x g. The resulting pellets contained the nuclear membranes and the supernatants of 
the nucleoplasmic fractions. All fractionation steps were carried out at 4 °C. The protein 
concentration of all fractions was determined by bicinchoninic acid (BCA) assay. The samples 
were mixed with loading buffer containing 10% beta-mercaptoethanol and 4x Laemmli sample 
buffer (Bio-Rad). In total, 14 µg of protein of each fraction was subjected to WB. 
 
Figure 4 Schematic for subcellular fractionation of cultured human DA neurons. 
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2.3.4 Cell surface protein biotinylation 
In order to label cell surface proteins, cultured neurons were rinsed twice with PBS and 
incubated with PBS containing 1 mg/ml Sulfo-NHS-SS-BiotinTM (Thermo Fisher Scientific) for 30 
min. at room temperature. Excess biotin was quenched by washing with PBS containing 200 
mM glycine. Cells were lysed in RIPA buffer (Sigma) including protease inhibitors for 30 min on 
ice and the lysates clarified by centrifugation (14,000 x g, 30 min, and 4 °C). Biotinylated 
proteins were precipitated by adding streptavidin-agarose beads (Thermo Fisher Scientific) and 
incubated 1 h at 4 °C. The streptavidin-agarose beads were washed three times and incubated 
for 1 h at 37 °C with 100 mM dithiothreitol and 4 x Laemmli sample buffer. Eluted proteins were 
separated by SDS–PAGE and subjected to Western blot. 
2.3.5 Calcium imaging 
Cells were plated onto 25 mm coverslips instead. Absolute cytosolic Ca2+ levels in cells 
were determined using the Ca2+-sensitive fluorescent indicator Fura-2 AM (Molecular Probes / 
Invitrogen, Waltham, USA) and a Leica Live-Cell fluorescence microscope equipped with Fura-2 
filters. Cells were loaded with Fura-2 in sterile-filtered Hepes-buffered saline (HBS: 20 mM 
Hepes, 150 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, pH 7.4) containing 
2.5 μM Fura-2 AM for 30 min at 37°C, 5% CO2. The Fura-2-containing medium was replaced 
with fresh HBS without Fura-2 and incubated additionally for 30 min. The fluorescence was 
measured on the microscope using excitation wavelengths at 340 and 380 nm and emission at 
510 nm. The ratio of the fluorescence signal at 510 nm upon excitation at 340 nm and excitation 
at 380 nm (FL_ex340/ FL_ex380) gives a relative Ca2+ estimate independent of cell morphology. 
The cytosolic Ca2+ levels in single cells were measured by placing a region of interest (ROI) 
outside the nucleus. 
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2.4 Protein biochemistry 
2.4.1 Immunochemistry 
2.4.1.1 Immunocytochemistry (ICC) 
For immunocytochemistry (ICC), cultured neurons were fixed for 15 min. at room 
temperature in 4% paraformaldehyde, washed once for 10 min. in PBS and permeabilized for 1 
min. with 0.125 % Triton X-100 in PBS. Unspecific antibody binding was blocked by 1% bovine 
serum albumin in PBS for 1 h followed by incubation with the respective primary antibody at 
4 °C overnight. Unbound antibodies were removed by washing with PBS and the cells were 
incubated with Alexa Fluor-conjugated secondary antibodies for 1 h at room temperature. 
Unbound secondary antibodies were removed by washing in PBS and the cells were air-dried, 
covered with fluorescence mounting medium (Dako, Jena, Germany) and sealed under the 
cover glass. 
2.4.1.2 Immunohistochemistry (IHC) 
For immunohistochemistry (IHC) of mouse brain slices, the animals were anesthetized with 
a combination of midazolam, medetomidine, and fentanyl, and perfused transcardially with PBS 
for 2.5 min. and 4% paraformaldehyde for 10 min. The brains were quickly removed, immersed 
in 4% paraformaldehyde for 24 h at 4°C and in 30 % sucrose for another 24 h at 4°C. The post‐
fixed brains were frozen over liquid nitrogen, cut into 60 μm thick coronal sections with a 
cryotome (Leica, Wetzlar, Germany) and the free-floating sections were transferred into PBS. 
The tissue sections were blocked with 1% bovine serum albumin in PBS for 1 h and incubated 
with the respective primary antibody overnight at 4 °C. The brain slices were then washed 3 x 5 
min. with PBS and incubated with fluorescent secondary antibodies for 1 h at room temperature 
and mounted in fluorescence mounting medium (Dako). 
Human brain samples were obtained at autopsy with approval from Ludwig Maximilian 
University ethics commission from the Munich Brain Bank (Department of Neuropathology, 
Ludwig Maximilian University, Munich, Germany) and in accordance with the anatomical tissue 
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procurement guidelines. Human SNc sections were deparaffinized in xylene and rehydrated in 
graded alcohol series. The slices were incubated in 10 μg/ml proteinase K (Qiagen) in TE buffer 
(pH = 7.5) for 10 min at 37 °C in a humidified chamber. The sections were subsequently 
permeabilized by 0.125% Triton X-100 for 10 min. at room temperature and blocked in 5% 
normal serum (Vector Laboratories, Burlingame, USA) for 1 h at room temperature. Tissue 
sections were rinsed multiple times in PBS and incubated with anti-FMRP primary antibody 
(Novus Biologicals, Centennial, USA) overnight at 4 °C. Tissue sections were washed with PBS 
and incubated with anti-mouse biotinylated secondary antibodies (Vector Laboratories) for 2 h at 
room temperature. Sections were then washed with PBS and incubated with AB solution (ABC 
kit, Vector) for 1 h Biotinylated tyramide (10 µM), containing 0.005 % H2O2 was used for 20 min 
for signal amplification as described (G. Wang, Achim, Hamilton, Wiley, & Soontornniyomkij, 
1999). FMRP immunoreactivity was visualized by Cy3-conjugated streptavidin (Invitrogen). After 
washing, sections were air-dried and mounted with a quick-hardening mounting medium (Fluka, 
Buchs, Switzerland). All mages were captured using a Leica SP5 confocal microscope and 
analyzed using Fiji software (http://fiji.sc/Fiji). Two pictures per case were used for analysis. One 
set of macros was created for semi-automated fluorescence analysis. In brief, the grey channel 
was selected manually for identifying the region of interest (ROI) of neuromelanin-positive cells, 
and then the red channel was selected manually to quantify the mean fluorescent intensity of 
FMRP from the same ROI. Meanwhile, the background fluorescent intensity of FMRP was 
acquired manually and subtract from cell fluorescent intensity for normalization. All antibodies 
used for ICC and IHC are listed in Table 3. 
2.4.2 Western blot 
For total protein lysates, cultured neurons were lysed in RIPA buffer incl. a protease and 
phosphatase inhibitor cocktail (Complete™ Protease Inhibitor Cocktail, PhosStop™ 
Phosphatase Inhibitor Cocktail, both Roche). The lysates were incubated for 30 min. on ice and 
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centrifuged at 5,000 x g for 15 min. at 4 °C, and the supernatant retrieved. The membrane 
protein fraction from cultured cells was isolated by using the Mem-PERTM Plus Membrane 
Protein Extraction Kit (Pierce Protein Biology, Waltham, USA) according to the manufacturer’s 
instructions. Protein concentrations were determined using the BCA method (Thermo Fisher 
Scientific) and a spectrophotometer (NanoDrop™, Thermo Fisher Scientific). After adjusting 
protein concentrations, total and membrane protein lysates were heated to 75 °C for 15 min. in 
Laemmli sample buffer containing 10 % beta-mercaptoethanol. SDS-PAGE was performed by 
using Mini‐Protean TGX™ Gels (Bio‐Rad Laboratories) and a Tris-glycine-based running buffer. 
The protein was blotted onto polyvinylidene difluoride (PVDF) membranes (Bio‐Rad) at 150 mA 
for 60 - 120 min on ice. The membranes were blocked with 5 % dry milk in TBST wash buffer 
(Tris-buffered saline containing 0.05 % Tween) for 1 h and incubated at 4 °C overnight under 
gentle shaking with the primary antibody in TBST / 5 % BSA (Cell Signaling Technology, 
Danvers, USA). The membranes were washed and incubated with the respective HRP‐
conjugated secondary antibody (Vector Labs) in TBST / 5 % milk for 1 h, followed by further 
washing and exposure to Clarity™ Western blot ECL Substrate (Bio‐Rad) or ECL Prime™ (GE 
Healthcare, Chicago, USA). Chemiluminescence was detected with the LI-COR Odyssey Fc 
Imaging system and analyzed by Image Studio software (Licor, Lincoln, USA). Western blot 
images were further processed by ImageJ and the optical densities of target proteins were 
scaled to the respective loading controls for statistical analysis. Therefore, a normalized 
experimental signal (measured experimental signal/lane normalization factor) was used, where 
the lane normalization factor was calculated from the ratio between the measured signals of a 
housekeeping protein for each lane divided by the highest measured signal of housekeeping 
protein on the blot. All antibodies used for Western blot are listed in Table 3. 
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2.4.3 Puromycin incorporation 
Overall protein synthesis was quantified as described previously (Schmidt, Clavarino, 
Ceppi, & Pierre, 2009). In brief, puromycin (10 μg/ml) was added to the medium 30 min. prior to 
cell harvesting. Standard western-blot was then developed with the puromycin antibody. 
2.4.4 Co-Immunoprecipitation 
The FMRP antibody was immobilized on beads as recommended by the manufacturer 
(Pierce). Immobilized antibody beads were incubated in modified high salt cell lysates 
containing the following: 10 mM Hepes (pH = 7.4), 200 mM NaCl, 30 mM EDTA, 0.5% Triton X-
100, 1 x Protease Inhibitor (Roche), and 1 x PhosStop Phosphatase Inhibitor Cocktail Tablets 
(Roche) at 4 °C overnight. Washing and elution steps were carried out as described in the 
protocol from the kit. The eluted sample was resolved by SDS-PAGE and analyzed by Western 
blotting. 
2.4.5 Generation of α-Syn preformed fibrils and Silver Staining  
Preformed fibrils (PFFs) were generated from monomeric α-Syn. Therefore, 50 µM α-Syn 
was dissolved in 50 mM Tris-HCl (pH = 7.0), 100 mM NaCl and 0.02% NaN3. The solution was 
agitated on a shaker (500 rpm) for 6 days at 37 °C, aliquoted, snap-frozen and stored at -80°C 
until used. For silver staining, PFFs were diluted in Tris buffer and centrifuged at 100,000 x g for 
1 h at 4°C and the Tris soluble fraction obtained from the supernatant. The pellet was 
resuspended in 5% SDS buffer and centrifuged again at 100,000 x g for 30 min at 25°C and the 
SDS soluble fraction obtained from the supernatant. The pellet was again resuspended in 8 M 
Urea in 5% SDS buffer to obtain the Urea soluble fraction. 5 µg of protein of each fraction was 
loaded on a Bis-Tris 4- 12% gradient gel and stained with silver according to the manufacturer’s 
instructions (Pierce).  
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2.4.6 Thioflavin T Assay 
Aggregation reaction samples were taken at DIV 0 and DIV 6, and mixed with a ThT 
solution with a final concentration of 25 µM thioflavine T (ThT; Sigma-Aldrich). Fluorescence 
was measured with a FLUOstar Omega plate reader. 
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2.5 Electrophysiology 
2.5.1 Patch-clamp 
Whole-cell patch-clamp electrophysiology in differentiated LUHMES cells was performed 
on a BX51 upright microscope (Olympus, Shinjuku, Japan). Experiments were performed at 
room temperature. Cells were grown in differentiation medium for 6-8 days on coverslips at a 
density of 75,000/cm2. The coverslips were transferred to the recording chamber and immersed 
with extracellular solution (ECS) containing the following (in mM): 140 NaCl, 2.4 KCl, 10 Hepes, 
10 glucose, 4 CaCl2 and 4 MgCl2, 320 mOsmol/L, pH 7.4); Patch electrodes were fabricated 
from filamented, thin-wall borosilicate glass (Sutter Instruments, Novato, USA) pulled on a 
P1000 pipette puller (Sutter). Pipette resistance was typically 3 - 6 MΩ when filled with the 
recording solution. The recording internal solution (pipette solution) consisted of (in mM): 40 KCl, 
10 Hepes, 10 EGTA, 1 MgCl2, 5 NaCl, 90 K-Gluconate, 15 creatine phosphate, and 5 U/ml 
phosphocreatine kinase, 315–320 mOsmol/L, pH 7.3. Somatic whole-cell patch-clamp 
recordings were obtained via an EPC-10 USB amplifier (Heka, Lambrecht/Pfalz, Germany) 
interfaced to a PC running PatchMaster (Heka). The signal was filtered at 1-4 kHz and digitized 
at 5–20 kHz and the data analyzed by Igor Pro (WaveMetrics, Lake Oswego, USA). For current-
clamp recordings, the amplifier bridge circuit was adjusted to compensate for electrode 
resistance and monitored continuously throughout the experiment.  
The following compounds were used in conjunction with electrophysiological 
measurements: isradipin, SNX-428, ω-agatoxin (ATX), ML-218, ω-conotoxin GIVA (OCTX), 
tetrodotoxin (TTX), tetraethyl ammonium (TEA) (all from Tocris) and diluted in ECS. NS309 
(Sigma) was diluted in DMSO, cobalt (II) chloride (Sigma) was diluted in ECS.   
2.5.2 Fast-scan cyclic voltammetry 
Following isoflurane anesthesia, brains from mice were removed and coronal brain slices 
(400 μm) including the dorsal striatum were prepared in carbogen-bubbled, cold high-sucrose 
solution (in mM: Sucrose 194, NaCl 30, KCl 4.5, MgCl2 1, NaHCO3 26, NaH2PO4 1.2, Glucose 
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10), as described previously (Sgobio et al., 2014). Slices from the left hemisphere were stored 
separately from the right hemisphere and kept at 32 ˚C for 30 min and then at room temperature 
before the recording session in oxygenated ECS containing the following (in mM): NaCl 126, 
KCl 2.5, NaH2PO4 1.2, CaCl2 2.4, MgCl2 1.2, NaHCO3 25, glucose 11, Hepes 20, L-ascorbic 
acid 0.4.  For voltammetry recordings, the slices were transferred into a recording chamber and 
perfused at a rate of 1.5 ml/min with ECS at 32 °C. Cylindrical carbon-fiber microelectrodes (75 
– 125 μm exposed fiber) were prepared with T650 fibers (Goodfellow, Huntingdon, UK) and 
inserted into a glass pipette containing a 2 M KCl solution. The sensitivity of carbon-fiber 
electrodes was calculated exposing them to different standard concentrations of DA (1, 5 and 
10 µM) before and after the recording sessions. The carbon-fiber electrode was held at - 0.4 V. 
Every 100 ms, the potential was ramped to + 1.2 V and back at 400 V / s. DA release was 
evoked every 3 min. by a rectangular stimulus (400 μA, 1.2 ms, monophasic) generated by a 
DS3 Constant Current Stimulator (Digitimer, Welwyn Garden, UK) and delivered by a bipolar 
electrode placed in the corpus callosum. Data were collected using the DEMON software 
(Yorgason, Espana, & Jones, 2011). Ten cyclic voltammograms of charging currents were 
recorded as background before stimulation, and the average was subtracted from data collected 
during and after stimulation. DA peak amplitude responses were obtained from nine to twelve 
recordings across the rostro caudal extent of the dorsolateral striatum in each hemisphere and 
averaged for every single mouse. Input / output function (I/O) curves were generated by plotting 
the peak amplitude of DA release as a function of the stimulus current over a range of 
increasing stimulus intensities. 
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2.6 Animal related methods 
2.6.1 Animal surgery 
All animal procedures were performed according to the EU Council Directive 2010/63/EU, 
the Guide for the Care and Use of Laboratory Animals (National Research Council 2011), and 
the guidelines of the local institutional committee. The experiments were approved by the local 
authority. Overexpression of α-Syn and LUC was achieved by stereotaxic injection of α-Syn- or 
LUC-expressing adeno-associated viruses (AAVs). Premade AAV5-α-Syn and AAV5-LUC 
viruses, which express α-Syn or LUC under the CBA promoter, were obtained from the viral 
vector core facility at the University of North Carolina, USA through the Michael J. Fox 
Foundation (Perez-Villalba et al., 2018; Volpicelli-Daley, Kirik, Stoyka, Standaert, & Harms, 
2016). Either C57BL/6J or Fmr1 KO mice (B6.129P2-Fmr1tm1Cgr/J, Stock No.: 003025) were 
purchased from The Jackson Laboratory and housed under standard conditions with access to 
food and water ad libitum. 8-10 wks. old female animals were anesthetized with midazolam, 
medetomidine and fentanyl, and given eye ointment. Thereafter, the mice were placed in a 
stereotaxic head frame (Stoelting) and the dorsal scull was disinfected with a povidone iodine 
scrub. Analgesics consisting of buprenorphine (0.1 mg/kg) and carprofen (4 mg/kg) were 
injected. The skin was opened by a 1 cm long midline incision and a 2-mm wide borehole was 
drilled on either side. Subsequently, 2 x 1012 viral particles of AAV5-α-Syn, AAV5-LUC or AAV5-
FMPR in 2 μl PBS were injected at a rate of 0.2 μl/min with a 33-gauge needle on a Hamilton 
syringe at the following coordinates relative to bregma: anterior -3.16 mm, lateral +1.50 mm, 
ventral -4.50 mm. The needle was left in place for an additional 5 min before being retracted. 
Subsequent to surgery, the mice were returned to their home cages, housed singly, allowed 
unrestricted movement and access to food and water ad libitum, and put on an analgesic 
regimen of buprenorphine (0.1 mg/kg) and carprofen (4 mg/kg) for 3 days. Thereafter, the 
animals were housed under standard housing conditions with 1 mice/cage until sacrifice. 
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2.6.2 Stereological cell counting 
A series of 60 μm thick, coronal midbrain sections were stained with tyrosine hydroxylase 
(TH) as described above. Every fourth section between - 2.92 mm and - 3.88 mm relative to 
bregma was used for stereological analysis. The slices were examined and pictures taken under 
a 10 x objective of an inverted microscope (Leica). The number of TH-positive neurons in each 
SNc was quantified using the optical fractionator function of Stereo InvestigatorTM 8, an 
unbiased stereological procedure (MicroBrightField Inc., Williston, USA). The sampling scheme 
was designed to maintain a coefficient of error (CE) of less than 10 %. 
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2.7 Statistical analysis 
Prism 7 (GraphPad Software) was used for statistical analysis and for creating line and bar 
graphs. Two datasets were compared by t‐tests. When there were more than two datasets with 
two variables, data were generally compared by two‐way ANOVAs with Tukey’s or Dunnett’s 
post hoc test, unless indicated otherwise. Assays with one variable were compared by oneway 
ANOVAs with Tukey’s or LSD post hoc test. Data are shown as mean ± standard error of the 
mean (SEM). P < 0.05 was considered to be significant.  
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3 Results 
Most of the following results have been published recently in Acta Neuropathologica (Tan 
et al., 2019). The authorization letter for using the published figures and tables is attached 
below in the authorization section. The first author of the manuscript mentioned above (Yi Tan) 
participated in almost all the following work individually or together with collaborators under the 
supervision of Dr. Thomas Köglsperger and Prof. Günter U. Höglinger. Dr. Thomas Köglsperger 
contributed the cell electrophysiology characterization data as the preliminary driving force of 
the project.  
3.1 α-Syn Overexpression activates N-type calcium channel in transduced Lund 
Human Mesencephalic (LUHMES) cells 
α-Syn-mediated neurodegeneration is associated with a deregulated calcium homeostasis. 
(Rcom-H'cheo-Gauthier, Goodwin, & Pountney, 2014). In order to investigate the effect of α-Syn 
on neuronal calcium channels, we began by characterizing suitable cell culture model systems 
to study DA neuron physiology in vitro. The immortalized LUHMES cell line exhibits a neuronal 
phenotype upon differentiation (Scholz et al., 2011). Moreover, differentiated LUHMES cells 
exhibit a dose-dependent neuronal death in response to viral α-Syn overexpression (Fussi et al., 
2018; Hollerhage et al., 2014). Collectively, these studies suggested them as a potential model 
for electrophysiological examination of DA neurons.  
3.1.1 Electrophysiological characteristics of LUHMES cells 
The first step in this section was to measure the action potential (AP) after 6 days of 
differentiation. Figure 5 and 6 indicate typical spontaneous and induced APs in differentiated 
LUHMES cells.  
 
 56 
  
Figure 5 Spontaneous APs in differentiated LUHMES cells. After differentiation, LUHMES cells 
displayed spontaneous APs under current clamp. 
 
 
 
Figure 6 Induced APs in differentiated LUHMES cells. GFP-transduced LUHMES cells exhibited 
typical induced APs after current injection (left). The half-maximal AP amplitude duration time 
(APt1/2) related to different current injection (right) (n=15). Data are shown as means ± SEM. 
 
The second major electrophysiological feature was a prominent hyperpolarization-
activated inward current presented in Figure 7. 
 
 
Figure 7 Differentiated LUHMES cells display a prominent hyperpolarization-activated inward 
current. After 100 ms-hyperpolarizing current injection, the membrane potential was becoming 
significantly positive at 90 ms than at 10 ms, indicating a hyperpolarization-activated inward 
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current in LUHMES cells upon differentiation (n=10). For comparison of the means, two-tailed 
unpaired t-test was used. ***P < 0.001. Data are shown as means ± SEM. 
 
Additionally, we observed an SK-type potassium channel induced outward current in 
Figure 8 and SK-type channel-mediated after hyperpolarization (AHP) which can be blocked by 
apamin and enhanced by the SK channel activator NS309 in Figure 9. 
 
 
Figure 8 Differentiated LUHMES cells exhibit SK-type channel induced outward current. 
Differentiated LUHMES cells exhibited SK-channel-mediated outward currents in response to a 
tail current protocol. 
 
 
Figure 9 After-hyperpolarization (AHP) induced by SK-type channel was blocked by apamin or 
elevated by SK-channel activator NS309. (a) After current injection, cells exhibited an AHP 
which can be elevated by the SK-channel activator NS309 (10 µM) and blocked by SK-channel 
blocker apamin (1 µM) (n = 15). (b) Under voltage clamp, cells showed an enhanced outward 
current by NS309 and a reduced current in response to apamin (n=15). 
 
Together, the evidence above suggests that LUHMES cells exhibit typical 
electrophysiological features of A9 SNpc neurons, making them a suitable model for further 
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investigation. Prior to commencing the study of neuronal excitability and calcium influx, we 
inspected the ion channel activity under voltage clamp. As shown in Figure 10, rectangular 
voltage steps in LUHMES cells led to fast-inactivating Na+ inward currents and sustained K+ 
outward currents which can be respectively blocked by TTX, and TEA with Cesium internal 
solution. 
 
 
Figure 10 Fast-inactivating Na+ inward currents and sustained K+ outward currents in 
differentiated LUHMES cells which can be blocked, respectively, by tetrodotoxin (TTX) and 
tetraethyl ammonium (TEA). (a) Traces indicating LUHMES cells to have voltage-activated fast-
inactivating inward Na+ and sustained K+ channels (left) which can be blocked by TTX (1 µM) 
(middle) and TEA (10 mM) with cesium-based internal pipette solution(right). (b) I-V graphs 
illustrating voltage-activated inward currents in LUHMES cells that can be modulated by the 
extracellular calcium concentration, thus indicating that the inward currents are driven by Na+ 
channels. (c) I-V graphs illustrating voltage-activated K+ outward currents which are efficiently 
blocked by TEA (n=25). Data are shown as means ± SEM. (Ca2+)ex = extracellular calcium 
concentration. 
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3.1.2 α-Syn transduced LUHMES cells exhibit activated calcium channel currents  
After these initial electrophysiological experiments, cells were transduced with α-Syn 
adenovirus or GFP adenovirus at the same multiplicity of infection (MOI = 2.15). By comparing 
cells under these two different conditions, we found that APs in α-Syn transduced cells were 
followed by a prominent afterdepolarization (ADP) that was absent in GFP transduced neurons 
(Figure 11). 
 
  
 
Figure 11 Induced APs in GFP or α-Syn transduced LUHMES cells. (a) Induced APs in α-Syn 
transduced LUHMES cells displayed a brief ADP which was missing in GFP transduced cells. 
(b) Quantification of APt1/2 in GFP and α-Syn transduced LUHMES (left) and the corresponding 
voltage when the APt1/2 was calculated (right) (n=15). For comparison of the means, two-tailed 
unpaired t-test was used in (b). ***P < 0.001. Data are shown as means ± SEM. 
 
Moreover, unlike the GFP transduced cells, Figure 12 indicates an additional slow-
inactivating inward current after the fast Na+ inward current in α-Syn transduced cells. 
 
 
 
Figure 12 α-Syn transduced cells show additional slow-inactivating Na+ inward current. (a) 
Rectangular voltage steps led to a brief membrane depolarization with an additional non-sodium 
inward current in α-Syn transduced LUHMES cells. (b) Averaged current traces (n = 10) of both 
α-Syn and GFP transduced LUHMES under rectangular voltage step, and corresponding I-V 
graph. Data are shown as means ± SEM. 
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To better understand the regulations of these conductances, cultured cells were treated 
with 1 µM TTX and 10 mM TEA for blocking Na+ and K+ channels. In addition, potassium 
chloride has been replaced with cesium chloride in the pipette solution. As can be seen from 
Figure 13, it is apparent that APs in α-Syn transduced cells showed a long plateau phase which 
is otherwise missing in GFP transduced cells. 
 
 
Figure 13 α-Syn transduced LUHMES cells present sustained induced Aps. (a) Rectangular 
current puls injection led to a capacitive membrane potential deflection in LUHMES cells treated 
with TTX, TEA and cesium-based internal solution. (b) Different from GFP transduced cells, α-
Syn transduced cells exhibited sustained APs with a long plateau phase after current injection 
under the same condition as in (a). (c) Quantification of APt1/2 (left), VAP (middle) and the 
duration of the APs (right) (n = 20). For comparison of the means, a two-tailed unpaired t-test 
was used. ***P < 0.001. Data are shown as means ± SEM. 
 
When using voltage-clamp, α-Syn transduced cells, in particular, displayed high-voltage 
activated inward currents as displayed in Figure 14, which were consistent with previous 
current-clamp studies. 
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Figure 14 α-Syn transduced cells display activated inward currents. When blocking both Na+ 
and K+ channels, α-Syn transduced cells exhibited an additional voltage activated inward 
currents. Corresponding I/V graph with leak current compensation (n = 15). α-Syn transduced 
cells also exhibited increased leak current. Data are shown as means ± SEM. 
 
3.1.3 α-Syn overexpression enhances N-type calcium channel-mediated calcium 
currents 
Finally, we aimed to identify the specific type of calcium channels activated in the α-Syn 
transduced cells. By applying different VGCC-specific antagonists, our data revealed that 
activated inward currents were efficiently blocked by N-type calcium channel specific 
antagonists, including cobalt-II-chloride and ω -conotoxin GIVA, at 500 µM and 100 nM, 
respectively. No significant reduction in currents was found when applying other VGCC-specific 
antagonists (Figure 15).  
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Figure 15 α-Syn transduced LUHMES cells show elevated N-type calcium currents. (a-f) I/V 
graphs of α-Syn transduced LUHMES cells and cells after the treatment with different calcium 
channel antagonists (in brackets, the blocked channel type is specified) (n=15/condition), 
including isradipine (L-type), SNX 428 (R-type), ω-agatoxin (P-type), ML-218 (T-type), cobalt-II-
chloride (VGCCs), conotoxin GIVA (N-type). (g) Quantification of APt1/2 for different conditions 
suggesting cobalt-II-chloride, ω-conotoxin GIVA and MVIIA can inhibit activated inward currents 
in α-Syn transduced LUHMES cells. Data were analyzed by one-way ANOVA followed by 
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Tukey’s post hoc test in (g). ***P < 0.001, **P < 0.01. Box and whiskers representing min to max 
values ± SEM.  
 
To confirm the electrophysiology results, Fura-2-based calcium imaging was applied. 
Compared to the GFP transduced cells, α-Syn overexpression aggravated the calcium influx in 
response to 30 mM potassium chloride (KCl) excitation (Figure 16). Pre-incubation with ω-
conotoxin in α-Syn transduced cells normalized the calcium influx to the GFP control level. 
 
  
Figure 16 Inhibition of calcium influx by ω-conotoxin GIVA (OCTX) demonstrate the activation of 
N-type calcium channel in α-Syn transduced LUHMES cells. GFP transduced cells exhibited a 
small amount of calcium influx after depolarization with 30 mM KCl. The average traces 
returned to base level at 50 s. An elevated calcium influx was observed in α-Syn transduced 
cells under the same condition. Treatment with ω-conotoxin abolished the activated N-type 
calcium channel-mediated calcium influx (n=6). Data are shown as means ± SEM. OCTX: ω-
conotoxin GIVA. 
 
Overall, the results in this chapter indicate that α-Syn overexpression in LUHMES cells 
leads to enhanced N-type calcium channel-mediated inward calcium currents. 
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3.2 Overexpression of α-Syn leads to a decrease expression of FMRP in 
transduced LUHMES cells 
As described in the previous chapter, it is clear that α-Syn overexpression activates the N-
type calcium channel, but what remains unclear is how α-Syn regulates N-type calcium channel 
activity. N-type calcium channels localize predominantly in the presynaptic membrane where 
neurotransmission and synaptogenesis are extraordinarily active. Results from earlier research 
suggest a consistent and solid association between synaptogenesis and synaptic protein 
synthesis (Dictenberg et al., 2008). The regulation of synaptic protein synthesis has been shown 
to be related to several signaling pathways (Hafner, Donlin-Asp, Leitch, Herzog, & Schuman, 
2019; Niere & Raab-Graham, 2017; Zhang et al., 2015). Among these pathways, the 
postsynaptic FMRP-controlled pathway appears to be closely linked with calcium channels 
(Castagnola et al., 2018; Danesi et al., 2018). In particular, previous data has demonstrated that 
the N-type calcium channels have a direct interaction with FMRP and that FMRP acts as a 
negative regulator of N-type calcium channels. Therefore, it is intriguing to examine whether 
FMRP is affected by α-Syn overexpression. 
3.2.1 WB result displays reduced FMRP intensity in α-Syn transduced LUHMES cells 
In order to test the conceivable hypothesis that α-Syn regulates N-type calcium channels 
through FMRP, we investigated FMRP abundance in α-Syn transduced LUHMES cells 6 days 
post transduction (DPT). As demonstrated in Figure 17 and Figure 18, FMRP shows a clear 
trend of reduction in response to the overexpression of wildtype, mutant A53T and A30P α-Syn 
as compared to GFP transduced neurons. Conversely, treatment of α-Syn preformed fibrils 
(PFFs) did not result in an additional effect on FMRP (Figure 19 and Figure 20). 
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Figure 17 α-Syn transduced LUHMES cells show downregulated FMRP. WB result and 
quantification (n = 9) demonstrating a significant reduction of FMRP in α-Syn transduced 
LUHMES cells, as compared to GFP transduced cells. For comparison of the means, two-tailed 
unpaired t-test was used. **P < 0.01. Data are shown as means ± SEM. 
 
 
Figure 18 Overexpression of mutant α-Syn (A53T, A30P) decrease FMRP expression. WB 
result and quantification (n = 4) demonstrating a significant reduction of FMRP in A53T and 
A30P α-Syn transduced LUHMES cells, as compared to GFP transduced cells. For comparison 
of the means, two-tailed unpaired t-test was used. **P < 0.01, *P < 0.05. Data are shown as 
means ± SEM. 
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Figure 19 Characterization of α-Syn preformed fibrils. (a) Representative silver staining shows 
different α-Syn molecular fractions in PFF-treated neurons after elution by Tris, sodium 
dodecylsulfate (SDS) and urea. By using different solvents, different α-Syn fractions at different 
molecular weight emerged; the insoluble fraction is indicated as arrow. (b) WB result shows the 
existence of α-Syn at different molecular weights after the treatment of α-Syn PFFs (150 nM, 4 
days). (c) Increased Thioflavin T fluorescence indicates the generation of beta sheet-rich 
fibrillary material after the treatment with α-Syn PFFs (n = 12). (d) α-Syn overexpression leads 
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to the generation of a well-defined 37 kDa oligomeric α-Syn fractions (middle lane). Treatment 
of PFFs additionally increased the amount of all α-Syn species in LUHMES cells. For 
comparison of the means, one-way ANOVA with Tukey’s post hoc test was used in (c). ****P < 
0.0001. Data are shown as means ± SEM. 
 
 
 
Figure 20 α-Syn PFFs co-application doesn't further decrease FMRP expression. WB and bar 
graph showing the FMRP expression after α-Syn PFFs co-application in LUHMES cells. α-Syn 
overexpression leads to the downregulation of FMRP in a dose-dependent manner (MOI: 
multiplicity of infection). High MOI (2.15) had a stronger effect on FMRP expression than low 
MOI (0.538). α-Syn PFFs so-application (150 nM) had no additional effect on FMRP expression 
(n = 3). For comparison of the means, one-way ANOVA with Tukey’s post hoc test was used. *P 
< 0.05. Data are shown as means ± SEM. 
 
3.2.2 Immunofluorescent result shows decreased FMRP abundance in α-Syn 
transduced LUHMES cells 
Further immunofluorescent staining confirmed the reduced fluorescent FMRP intensity in 
α-Syn transduced cells (Figure 21). Among the α-Syn positive neurons, cells with a weak α-Syn 
 68 
signal (arrowhead) also exhibited a higher FMRP intensity than cells with strong α-Syn intensity 
(arrow), thus demonstrating a negative correlation between FMRP and α-Syn. 
 
Figure 21 FMRP signal is significantly decreased in α-Syn transduced cells. Immunostaining 
results demonstrating a reduced FMRP intensity in α-Syn transduced neurons as compared to 
GFP transduced cells. In α-Syn transduced neurons, cells expressing a higher amount of α-Syn 
(arrow) also exhibited a lower FMRP intensity than cells expressing less α-Syn (arrowheads). 
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3.2.3 FMRP decreases in both cytoplasmatic and nuclear compartments in response to 
α-Syn transduction in LUHMES cells. 
When we investigated the distribution of FMRP in LUHMES cells, we found that FMRP 
localizes to the perinuclear region, which is consistent with its role as a mRNA binding protein 
(Figure 22)(Richter et al., 2015), while punctate FMRP-positive structures in the nucleus 
potentially indicates its presence in Cajal bodies (Dury et al., 2013). In α-Syn transduced cells, 
we found FMRP to be diminished in both compartments. 
 
 
 
Figure 22 High magnification of FMRP signal in α-Syn or GFP transduced cells. High resolution 
FMRP immunostaining images of GFP and α-Syn transduced cells at 6 DPT showing the 
absence of perinuclear (arrow) FMRP-positive structures and an overall reduction of FMRP 
intensity in α-Syn transduced LUHMES cells. 
 
To further characterize the distribution of FMRP in LUHMES cells, we separated different 
compartments of LUHMES cells through biochemical fractionation (Figure 4, method section 
2.3.3). Our WB results (Figure 23) suggest that α-Syn transduced cells exhibit a reduced FMRP 
signal in the light and heavy membrane fraction, and the nuclear lysate, thus confirming the 
downregulation of FMRP in both compartments after α-Syn overexpression. 
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Figure 23 FMRP in the light membrane, heavy membrane, and nuclear lysate were less in α-
Syn transduced cells. WB results of separated cellular compartments indicating that FMRP 
mainly located in light plasma membranes (LM), heavy intracellular membranes (HM), and the 
nuclear lysate (NL). Meanwhile, the α-Syn transduced cells showed a decreased intensity in all 
the existing fractions. CYT=cytosol, NP=nuclear pellet, NM=nuclear membrane. 
 
3.2.4 FMRP shows persistent downregulation after α-Syn transduction in LUHMES cells 
We next set out to investigate the effect of α-Syn overexpression on FMRP over time; 
therefore, we tested the abundance of FMRP in α-Syn-transduced neurons after different 
periods of time. It is apparent from Figure 24 that GFP did not change the expression of FMRP, 
whereas a constant downregulation of FMRP was observed in α-Syn transduced cells as early 
as day 2 after transduction. 
 
Figure 24 α-Syn overexpression leads to constant downregulation of FMRP. WB of FMRP in 
LUHMES cells from 1-6 DPT with α-Syn showing that FMRP started to decrease at 2 DPT. 
 
3.2.5 The effect of different neurotoxins on the expression of FMRP 
Another unanswered question concerns the effect of cell death on FMRP since the results 
from Figure 25 illustrates an increased cell death on day 6 after α-Syn transduction. We, 
therefore, assessed the FMRP level in response to treatment with the mitochondrial complex-I 
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inhibitor rotenone. Treatment with the complex-I inhibitor rotenone is a widely used model in PD 
research (Ebrahimi, Oryan, Izadpanah, & Hassanzadeh, 2017; Pacelli et al., 2015). By treating 
cultured neurons with rotenone for 48 hours (0-1µM), FMRP remained unchanged (Figure 26), 
even though measuring LDH release (Figure 27) confirmed the increase in cell death in 
response to rotenone treatment.  
 
Figure 25 α-Syn induces cell apoptosis after 6 DPT. Bar graph of LDH result showing that α-
Syn-induced neuronal cell death is absence before 4 DPT and significantly increases at 6 DPT 
(n=4). For comparison of the means, one-way ANOVA with Tukey’s post hoc test was used. 
****P < 0.0001. Data are shown as means ± SEM. 
 
 
Figure 26 Expression of FMRP remains steady in response to rotenone-induced cell apoptosis. 
WB result demonstrating that treatment with rotenone from 0-1µM for 24 h doesn't affect FMRP 
expression.  
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Figure 27 Rotenone-induced cell apoptosis. Bar graph of LDH results demonstrating that 
rotenone induces a dose-dependent cell apoptosis (n=4). For comparison of the means, one-
way ANOVA with Tukey’s post hoc test was used. ****P < 0.0001, ***P < 0.001, **P < 0.01. 
Data are shown as means ± SEM. 
 
In addition, application of the 10 µM PD-associated toxins 1-Methyl-4-phenylpyridinium 
(MPP+) for 24 h (Figure 28) or substrate starvation (Figure 29) did not decrease the expression 
of FMRP. Interestingly, treatment with 20 µM 6-hydroxydopamine (6-OHDA) for 24 h decreased 
FMRP by ~30% (Figure 28). Further research is required to explore the relation between FMRP 
and DA. As α-Syn overexpression-induced cell death is associated with the 
ubiquitin/proteasome system (UPS) pathway and autophagy (Winslow et al., 2010), we also 
investigate the influence of the treatment with 100 nM of the autophagy inhibitors bafilomycin A1 
(6 h), 1µM UPS-inhibitor MG132 (6 h) and 50 µM chloroquine (24 h) on FMRP. WB results 
indicate that these three compounds did not have a further effect on the expression of FMRP in 
LUHMES cells (Figure 30).  
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Figure 28 6-Hydroxydopamine (6-OHDA), but not MPP+, decreases the FMRP expression. WB 
and bar graph show the application of 10 µM 6-OHDA (24 h) significantly decreased FMRP 
expression, while application of 50 µM MPP+ (24 h) did not statistical significantly affect FMRP 
expression (n = 3). For comparison of the means, one-way ANOVA with Tukey’s post hoc test 
was used. **P < 0.01. Data are shown as means ± SEM. 
 
 
Figure 29 Starvation has no effect on FMRP expression. WB and bar graph demonstrating that 
substrate starvation does not affect FMRP expression. LUHMES cells were cultured in pure 
DMEM without glucose and other additives (N2 Supplement, cAMP or GDNF) (n = 3). For 
comparison of the means, one-way ANOVA with Tukey’s post hoc test was used. ****P < 
0.0001, ***P < 0.001. Data are shown as means ± SEM. 
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Figure 30 FMRP expression is independent of ubiquitin/proteasome system (UPS) and 
autophagy. Western blot and bar graph demonstrating that treatment with 1 µM MG132 (6 h), 
100 nM bafilomycin A1 (6 h) and 50 µM chloroquine (24 h) did not produce any further effect on 
FMRP. Increased LC3-II after application of Bafilomycin A1 and chloroquine demonstrating the 
inhibition of autophagy (n = 3). For comparison of the means, one-way ANOVA with Tukey’s 
post hoc test was used. ***P < 0.001, **P < 0.01, *P < 0.05. Data are shown as means ± SEM. 
 
Taken together, the results in this chapter suggest that wildtype, A53T and A30P 
mutations α-Syn overexpression induces FMRP downregulation in dopaminergic LUHMES 
neurons independent from α-Syn-induced cell apoptosis. Moreover, FMRP expression was 
independent from starvation, UPS, autophagy and MPP+-induced neurotoxin, whereas 
treatment of 6-OHDA resulted in a decreased abundance of FMRP in LUHMES cells. 
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3.3 α-Syn regulates N-type calcium channel activity by modulating FMRP 
The results of the previous chapter demonstrate that α-Syn overexpression induces a 
downregulation of FMRP. We therefore further tested, if α-Syn activates N-type calcium 
channels through decreasing the FMRP protein abundance. 
3.3.1 α-Syn overexpression enhances the membrane proportion of N-type calcium 
channels  
First, we investigated the membrane abundance of the N-type calcium channel pore-
forming subunit alpha 1B in response to α-Syn overexpression via two different approaches, 
namely by using a detergent-based membrane protein extraction and by surface protein 
biotinylation. Figure 31 illustrates that the proportion of membrane-resident CaV2.2 was 
increased with both approaches in response to α-Syn overexpression. In accord with a role for 
FMRP, we found that co-expression of FMRP normalized the increase CaV2.2 membrane 
abundance. Given the unchanged total amount, our results thus support a regulation of 
membrane N-type calcium channels by FMRP (Ferron et al., 2014). 
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Figure 31 α-Syn transduced cells exhibit increased membrane N-type calcium channel. (a) WB 
and quantification of separated membrane proteins by the membrane protein extraction kit 
(Thermo fisher) illustrating that α-Syn transduced cells have a higher membrane N-type calcium 
channel density as compared with GFP transduced cells at 6 DPT. Na+/K+ - ATPase was used 
as control for membrane protein. Total cell lysate WB and quantification illustrating that α-Syn 
overexpression doesn't affect the total N-type calcium abundnace (n=6). (b) Alternative 
biotinylated membrane protein extraction confirmed that membrane biotinylated N-type calcium 
channels were increased in the α-Syn transduced cells. NMDAR1 and Pan-Cadherin was used 
as control for normalization and quantification. Co-overexpression FMRP in α-Syn transduced 
cells normalized the increased surface membrane N-type calcium channel (n=5). For 
comparison of the means, two-tailed unpaired t-test was used (a) and one-way ANOVA with 
Tukey’s post hoc test was used in (b). **P < 0.01, *P < 0.05. Data are shown as means ± SEM. 
 
3.3.2 α-Syn overexpression does not raise the mRNA level of N-type calcium channels 
To systematically assess the regulation of N-type calcium channels under α-Syn 
overexpression, we examined the mRNA of CACNA1B, which is the coding gene for subunit 
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alpha 1B. The results suggested a slight decrease of CACNA1B after α-Syn overexpression 
(Figure 32). 
 
  
Figure 32 Gene array and qRT-PCR indicate a moderate downregulation of CACNA1B mRNA 
in α-Syn transduced cells. (a) Heat map of voltage- and ligand-activated calcium channel mRNA 
level measured through Chip-based transcriptome analysis showed that α-Syn overexpression 
doesn't affect the expression of N-type calcium channel subunits in LUHMES cells. (b) qRT-
PCR illustrating a mild reduction in the mRNA level of N-type calcium channels in α-Syn 
overexpressing cells. For comparison of the means, two-tailed unpaired t-test was used. *P < 
0.05. Data are shown as means ± SEM. 
 
3.3.3 IHC demonstrates that α-Syn transduction in LUHMES cells does not affect the 
total N-type calcium channel abundance 
In addition to the WB result, we also performed an immunofluorescent experiment to 
investigate the overall distribution of N-type calcium channels in response to α-Syn 
overexpression. There was no difference in both mean intensity and the number of puncta 
between GFP or α-Syn transduced cells (Figure 33). 
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Figure 33 GFP or α-Syn transduced cells exhibited no difference in N-type calcium channel 
intensity. (a) Immunofluorescent staining showing that the total N-type calcium channel intensity 
in α-Syn transduced cells is similar to cells transduced with GFP. (b) The average number of N-
type calcium channel punctate in each Triton X 100-permeabilized α-Syn or GFP transduced 
LUHMES cells was also similar (n = 72). Data are shown as means ± SEM. 
 
3.3.4 FMRP knockdown increases membrane N-type calcium channel and induces 
inward calcium currents in LUHMES cells 
To demonstrate the regulation of N-type calcium channels by FMRP in LUHMES cells, we 
measured the membrane proportion and calcium channel activity under the condition of FMRP 
silencing. FMRP silencing did not additionally affect cell viability (Figure 34). From Figure 35, it 
can be seen that cells treated with FMR1 siRNAs exhibited a dramatic increase in the level of 
membrane N-type calcium channels as well as an increased inward currents under voltage 
clamp. 
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Figure 34 Co-application of FMRP siRNA does not induce further cell death in LUHMES cells. 
FMRP silencing did not further affect the LDH release (n = 6). For comparison of the means, 
one-way ANOVA with Tukey’s post hoc test was used. ****P < 0.0001, **P < 0.01. Data are 
shown as means ± SEM. 
 
 
Figure 35 FMRP silencing activated calcium channel and increased membrane abundance of N-
type calcium channel. (a) WB and quantification of the membrane N-type calcium channel 
intensity in response to FMR1 silencing in both GFP and α-Syn transduced LUHMES, 
suggesting that both FMR1 silencing and α-Syn overexpression led to an increased membrane 
N-type calcium channel intensity. Co-transfection of FMR1 siRNA in α-Syn transduced cells 
didn't further increase the membrane N-type calcium channel (n=3). (b) I-V graph illustrating that 
FMR1 siRNA treatment could induce inward currents in LUHMES cells (n=12). For comparison 
of the means, one-way ANOVA with Tukey’s post hoc test was used in (a), and two-way 
ANOVA with Bonferroni post hoc test was used in (b). *P < 0.05. Data are shown as means ± 
SEM. 
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Drawing upon all the data from this chapter, these studies provided reasonably evidence 
that α-Syn regulates N-type calcium channel by manipulating FMRP. 
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3.4 Co-expression of FMRP in α-Syn overexpressing LUHMES cells normalizes 
deregulation of protein synthesis 
FMRP is associated with intrinsic synaptic neuronal excitability by regulating the translation 
of synapse-related proteins (Davis & Broadie, 2017; Ferron, 2016). In FXS, the translation of 
FMRP-controlled synaptic proteins is greatly elevated due to the absence of direct FMRP-
mRNA binding (Ferder et al., 2013; Liu et al., 2018; Tsang et al., 2019). Normally, FMRP 
interacts with it's target mRNA and thereby inhibits eIF4E initiation complex-mediated translation 
(Gantois et al., 2017; Napoli et al., 2008). Since our present data support the downregulation of 
FMRP in α-Syn transduced cells, we further investigated the protein synthesis rate as well as 
dysregulated translation-related proteins in FXS. 
3.4.1 α-Syn overexpression increases the protein synthesis rate in LUHMES 
Much of the available literature on FMRP reveal an exaggerated overall protein synthesis 
rate in FMR1 KO mice (Richter et al., 2015; Zeng, Adamson, Curry, & Tarbell, 2014). In 
accordance with previous results, our study also demonstrated an elevated puromycin content, 
incorporated during peptide elongation, in α-Syn transduced cells (Figure 36 and Figure 37). 
Cycloheximide treatment served as positive control (Figure 37). 
 
Figure 36 α-Syn overexpression LUHMES cells display elevated protein synthesis rate. As 
assessed by puromycin incorporation, α-Syn transduced LUHMES cells exhibited an increased 
overall protein synthesis compared to vehicle (VEH) and GFP transduced cells (n = 6). For 
comparison of the means, one-way ANOVA with Tukey’s post hoc test was used. *P < 0.05. 
Data are shown as means ± SEM. 
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Figure 37 Application of cycloheximide entirely blocks the incorporation of puromycin. WB result 
demonstrating that α-Syn overexpression lead to an increased puromycin incorporation, 
whereas cycloheximide (10 uM) blocked the incorporation of puromycin (right lane).  
3.4.2 Co-expression of FMRP normalizes the increased phosphorylation of eIF4E, S6 
and Erk.  
Results from previous studies demonstrate that FMRP is associated with the mTORC1 
and Erk-mediated translation pathway (Gross et al., 2018; Osterweil et al., 2010). Hence, it’s 
conceivable to examine the key proteins involved in both pathways. In line with previous FXS 
studies, the phosphorylation of eIF4E, Erk and S6 was significantly raised in α-Syn transduced 
cells (Figure 38). MMP9, another protein regulated by FMRP, was also dramatically increased in 
response to α-Syn overexpression. In summary, co-expression of FMRP in α-Syn transduced 
cells reversed the dysregulated proteins, thus indicated an important role of FMRP in α-Syn 
related disease. 
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Figure 38 α-Syn overexpression induces upregulation of FXS related proteins expression, which 
can be also reversed by FMRP co-expression. WB and quantification demonstrating α-Syn 
transduction to increase the phosphorylation of S6, eIF4E, Erk and the MMP9 expression in 
LUHMES cells. The upregulation of these proteins was normalized by co-overexpression of 
FMRP in α-Syn transduced cells (n = 6). For comparison of the means, one-way ANOVA with 
Tukey’s post hoc test was used. ***P < 0.001, **P < 0.01, *P < 0.05. Data are shown as means 
± SEM. 
 
These studies evaluated for the first time the role of observed downregulated FMRP as a 
vital protein in regulating disordered proteins, in agreement with FXS, in α-Syn transduced cells, 
further support the idea that FMRP may play an important role in pathological events during the 
progression of PD. 
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3.5 α-Syn regulates FMRP, not through hypermethylation, but rather potentially 
through PKC -CREB pathway 
Causal factors leading to FMRP loss remain speculative in α-Syn transduced cells. A 
search of the literature revealed few studies on FMRP protein regulation. Hypermethylation of 
the FMRP promoter, the pathogenic mechanism involved in FXS, is reported as one of the 
factors that could induce FMRP loss (Kazdoba et al., 2014; Salat, Bardoni, Wohrle, & 
Steinbach, 2000). In addition, Wang et al. analyzed the promoter region of FMRP and assumed 
a regulation of FMRP by phosphorylation of cAMP response element-binding protein (CREB) 
due to the existence of the CRE sequence in the promoter (H. Wang et al., 2012). Data from 
different sources have conclusively shown that the phosphorylation of CREB can be regulated 
by protein kinase C (PKC) (Mao, Tang, & Wang, 2007). Moreover, a direct interaction exists 
between different isoforms of PKC and α-Syn as identified by Ostrerova et al. (Ostrerova et al., 
1999). In view of these results, we speculated that α-Syn might regulate FMRP through either 
direct binding, hypermethylation of the FMRP promoter or alternatively through the PKC-CREB 
pathway. 
3.5.1 Co-Immunoprecipitation indicates no direct binding between α-Syn and FMRP 
A previous proteomic analysis reported a weak interaction between α-Syn and Fragile X 
mental retardation syndrome-related protein 1/2, which are autosomal homologs of FMRP (Hein 
et al., 2015). Even though the proteomic analysis implies a potential interaction between FMRP 
and α-Syn, our co-Immunoprecipitation data, however, rules out the possibility that α-Syn has a 
direct physical interaction with FMRP (Figure 39). 
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Figure 39 Co-Immunoprecipitation detect no physical interaction between α-Syn and FMRP. As 
compared to the antibody control (Ab control, left panel), FMRP protein in the cell lysate of 
LUHMES cells was precipitated in the IP. Right panels illustrating that the pulled-down FMRP 
band wasn't able to blot the α-Syn antibody, thus indicating the absence of a physical interaction 
between FMRP and α-Syn. Input and output in the figure was the cell lysate samples before and 
after FMRP precipitation, respectively. 
 
3.5.2 α-Syn overexpression decreases the mRNA level of FMRP 
After excluding a direct interaction, we next aimed to investigate whether the mRNA level 
of FMRP has a consistent phenotype with FMRP the protein level. Figure 40 illustrates that 
FMR1 mRNA, after normalizing with the housekeeping gene, indeed decreased in α-Syn 
transduced cells as assessed by using qRT-PCR. 
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Figure 40 α-Syn overexpression lead to decreased FMR1 mRNA in LUHMES cells. The qRT-
PCR result showing that the mRNA level of FMR1 in α-Syn transduced LUHMES cells was 
decreased as compared to GFP transduced cells (n = 6). For comparison of the means, one-
way ANOVA with Tukey’s post hoc test was used. **P < 0.01, *P < 0.05. Data are shown as 
means ± SEM. 
 
3.5.3 α-Syn overexpression doesn't affect methylation status of FMR1 promotor 
α-Syn has been found to interact with histones and therefore to induce methylation of 
promoter regions (Burre et al., 2010), like SNAP25. The methylation status of FMR1 promoter, 
in general, determines the transcription of FMR1. Hence, current literature provides strong 
incentive to investigate whether α-Syn overexpression has an effect on the methylation status of 
the FMR1 promoter to induce FMRP loss. A comparison of the methylation status of the FMR1 
promoter in GFP or α-Syn transduced cells, however, revealed no difference in the number of 
CpG islands (Table 8, Figure 41).  
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Table 8 α-Syn overexpression doesn’t affect FMR1 promotor methylation. FMR1 mean 
methylation at individual CpG sites of both α-Syn and GFP transduced LUHMES cells. 
 
Position on X 
Chromosome 
Mean 
Methylation 
GFP 
Mean 
Methylation α-
Syn △ GFP-α-Syn p-Value 
146992908 0.692654837 0.723143076 -0.030488239 0.162 
146993010 0.336611029 0.335952806 0.000658222 0.556 
146993092 0.082477587 0.097698101 -0.015220515 0.999 
146993125 0.450827358 0.448164193 0.002663165 0.2855 
146993175 0.516109728 0.563232918 -0.04712319 0.0818 
146993420 0.942363374 0.947145719 -0.004782345 0.2382 
146993433 0.462917019 0.448689399 0.01422762 0.5845 
146993447 0.820288404 0.821642625 -0.001354221 0.6526 
146993485 0.931255804 0.94600782 -0.014752016 0.4242 
146993722 0.440806175 0.46723549 -0.026429315 0.1311 
146993778 0.158826463 0.158217166 0.000609297 0.9151 
146994128 0.457139053 0.502463983 -0.04532493 0.002 
146994166 0.447973669 0.437237579 0.010736091 0.9021 
146994369 0.214187838 0.23952351 -0.025335672 0.5058 
146996911 0.407077213 0.414794256 -0.007717043 0.8719 
146999718 0.506541132 0.542851083 -0.03630995 0.1759 
147004697 0.984888615 0.978570061 0.006318554 0.0953 
147011671 0.640345118 0.650572584 -0.010227466 0.6298 
147011710 0.587193457 0.626438143 -0.039244685 0.0113 
147021905 0.527907972 0.536883186 -0.008975214 0.6199 
147023809 0.266867406 0.2545677 0.012299706 0.4443 
147024735 0.929010587 0.930883618 -0.001873031 0.8034 
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Figure 41 Methylation status of FMR1 promoter doesn't show any significant differences 
between GFP and α-Syn transduced cells. No significant difference was observed in the relative 
FMR1 methylation status at all CpG loci between α-Syn and GFP transfected LUHMES cells. 
 
3.5.4 α-Syn overexpression leads to inhibition of CREB phosphorylation 
We next sought to investigate whether α-Syn regulates FMRP through the PKC-CREB 
pathway. We first examined the phosphorylation status of CREB in response to α-Syn 
overexpression. As shown in Figure 42, α-Syn transduced cells indeed exhibited a significantly 
suppressed CREB phosphorylation at Ser133. 
 
 
Figure 42 α-Syn overexpression suppresses phosphorylation of CREB. WB and quantification 
illustrating a reduced phosphorylation of CREB in α-Syn transduced LUHMES cells (n = 6). For 
comparison of the means, two-tailed unpaired t-test was used. **P < 0.01. Data are shown as 
means ± SEM. 
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3.5.5 PKC inhibitor treatment downregulates FMRP in LUHMES 
As was pointed out in the introduction of this chapter, phosphorylation of CREB can be 
modulated by PKC. Since the inhibition of phosphorylation of CREB was identified in α-Syn 
transduced cells, it went on to suggest that PKC inhibition, similar to an effect of α-Syn 
overexpression, could induce FMRP loss through regulating CREB phosphorylation. With this 
intention, we investigated FMRP levels after treatment with PKC inhibitor. The result below 
(Figure 43) demonstrates that PKC inhibition by the PKC inhibitor C1 downregulated FMRP 
protein and therefore further supports the novel idea that α-Syn regulates FMRP through the 
PKC-CREB pathway in dopaminergic neurons. 
 
 
Figure 43 Inhibition of PKC induces FMRP loss. WB and quantification showing that incubation 
of PKC-inhibitor C1 in LUHMES cells decreased the FMRP expression (n=3). For comparison of 
the means, two-tailed unpaired t-test was used. *P < 0.05. Data are shown as means ± SEM. 
 
3.5.6 PKC inhibitors treatment increases membrane abundance of N-type calcium 
channel and induce inward calcium currents in LUHMES 
As demonstrated above, PKC appears to regulate FMRP, raising the question whether 
FMRP-related functions, like N-type calcium channel activity, is equally modulated by PKC 
activity. Corroborating evidence below in two aspects, both membrane protein concentration, 
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and electrophysiology demonstrate that N-type calcium channel activity can be truly activated by 
inhibiting PKC with PKC inhibitors C1 or Go6983 (Figure 44). 
 
Figure 44 PKC inhibition induce activated N-type calcium channel. (a) WB and quantification 
illustrating that both PKC inhibitors, C1 and Go6983, significantly enhanced the membrane N-
type calcium channel intensity in LUHMES cells (n=6). (b) I-V graph illustrating that blocking 
PKC by Go6983 induced an inward current in LUHMES cells (n=16). For comparison of the 
means, one-way ANOVA with Tukey’s post hoc test was used in (a), and two-way ANOVA with 
Bonferroni post hoc test was used in (b). **P < 0.01, *P < 0.05. Data are shown as means ± 
SEM. 
 
In brief, our results in this chapter consolidated the hypothesis that the regulation of FMRP 
by α-Syn is independent from direct protein-protein interaction or the methylation of FMR1, but 
occurs rather through a PKC-CREB pathway in dopaminergic cells.  
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3.6 Loss of FMRP in α-Syn overexpression tyrosine hydroxylase-positive cells in 
a PD mouse model preserves DA release in the striatum 
Studies on our immortalized cell model were limited by the absence of a physiological CNS 
environment, where a variety of cells may interact with each other (Scholz et al., 2011). 
Therefore, we attempted to evaluate the response of mouse dopaminergic neurons under the 
condition of viral-induced α-Syn overexpression. It has been demonstrated that the α-Syn 
overexpression mouse model displays a PD-like progressive dopaminergic neuronal 
degeneration and an impaired nigrostriatal DA system (Oliveras-Salva et al., 2013; Tonges et 
al., 2014). In PD patients, reduced dopaminergic neurons lead to a significant reduction of DA 
release, thus causing typical PD symptoms (Elkouzi, Vedam-Mai, Eisinger, & Okun, 2019; Veys 
et al., 2019). Since our observations suggest a link between α-Syn and FMRP and because the 
loss of FMRP precedes cell death, it would be interesting to investigate whether FMRP has an 
effect on TH+ cell death, striatal TH fiber density and DA release. 
3.6.1 α-Syn overexpression induces FMRP immunofluorescent intensity reduction in 
tyrosine hydroxylase-positive in the mouse model 
In an attempt to study the FMRP intensity in response to α-Syn overexpression in the 
above-mentioned mouse model, C57BL/6N mice were stereotactically injected with AAV5-α-Syn 
or AAV5-Luciferase respectively into the SNc. Three weeks after surgery, mice were sacrificed 
and brains were coronally sliced for FMRP staining. In line with our in vitro studies, SNc neurons 
overexpressing α-Syn also exhibited significant FMRP loss in vivo (Figure 45). 
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Figure 45 Overexpression of α-Syn decreases FMRP intensity in SNc neurons in mice. (a, b) 
Immunofluorescent result showing a reduced FMRP intensity in mouse SNc TH+ neurons 
overexpressing α-Syn, as compared to Luciferase (LUC) overexpression neurons. Scale bars 
150 µm in (a) and 5 µm in (b). (c) Quantification of FMRP mean intensity in both LUC and α-Syn 
overexpression neurons (n=360, 6 animals per condition). For comparison of the means, two-
tailed unpaired t-test was used. **P < 0.01. Data are shown as means ± SEM. 
 
3.6.2 Regression analysis between FMRP and α-Syn 
Regression analysis was used to determine the relationship between FMRP and α-Syn. 
The FMRP and α-Syn mean intensity of each cell was unbiasedly acquired by an ImageJ macro 
(Section 2.4.1.2). The result of the regression analysis in Figure 46 indicates a negative non-
linear correlation between these two proteins in α-Syn overexpressing mouse SNc neurons. 
 
Figure 46 Regression analysis shows negative non-linear correlations between FMRP and α-
Syn in mouse model. Increased α-Syn expression induced a reduction of FMRP mean intensity 
in SNc dopaminergic neurons (n = 360). Non-linear regression was analyzed via Prism 7. 
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3.6.3 Stereological cell counting of tyrosine hydroxylase-positive cells of FMR1 KO mice 
or wildtype control in response to α-Syn overexpression. 
To assess the role of FMRP in PD pathology, we first examined the TH+ cell number in 
both FMR1 KO and wildtype (WT) littermate control mice in response to α-Syn overexpression. 
No significant differences were detected 3 weeks after surgery (Figure 47).  
 
Figure 47 There are no observed differences of TH+ cells number between WT or FMR1 KO 
mice after viral α-Syn overexpression for three weeks. The number of α-Syn overexpressed 
SNc TH+ neurons from both WT and FMR1 KO mice was similar. Data are shown as means ± 
SEM. 
 
3.6.4 Striatal Tyrosine hydroxylase fibres intensity displays no difference between of 
FMR1 KO mice and wildtype control mice in response to α-Syn overexpression 
We next investigated striatum TH fiber intensity under the same condition. TH DAB 
staining suggested the similar mean intensity of TH fiber in both mice three weeks after α-Syn 
virus injection (Figure 48). 
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Figure 48 No observed differences of mean tyrosine hydroxylase fibrils intensity are found 
between wildtype and FMR1 KO mice after viral α-Syn overexpression for three weeks. DAB 
staining of TH and quantification demonstrating a similar striatal fiber density between FMR1 
KO and WT animals after α-Syn virus injection for 3 weeks. Data are shown as means ± SEM. 
 
3.6.5 Fast-cycling voltammetry reveals preserved DA release in α-Syn virus injected 
FMR1 KO mice 
Finally, we examined the effect of FMRP on DA release. By cooperating with Dr. Carmelo 
Sgobio from Prof. Jochen Herms’ lab, we were able to measure striatal DA release ex vivo by 
using fast-cycling voltammetry (Sgobio et al., 2014) in slices from luciferase or α-Syn virus 
injected mice. As expected, t-tests revealed a significant reduction of striatal DA release in WT 
mice after α-Syn virus injection (Figure 49). We next injected the FMR1 KO mice with the same 
viral conditions. Surprisingly, there was no statistical significant difference between luciferase 
and α-Syn virus injected mice in regard to the striatal DA release. 
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Figure 49 DA release in FMR1 KO mice is more resistant after α-Syn virus injection. (a) Fast-
cycling voltammetry demonstrating that, after α-Syn virus injection, WT mice hemispheres 
exhibit a reduced DA release in the dorsolateral striatum as compared to luciferase (LUC) 
injected hemispheres (left) (ANOVA Genotype Main Effect: F(1,40) = 14.02,  P < 0.001, n = 6). 
Input/output curve and representative DA traces demonstrate a decreased release of DA in α-
Syn injected hemispheres independently from the applied stimulus intensities (right) (n = 6). (b) 
DA release in FMR1 KO mice showed no difference between α-Syn injected hemisphere and 
luciferase injected hemisphere (ANOVA Genotype Main Effect: F(1,24) = 1.55,  P > 0.05, n = 4). 
For comparison of the means, two-way ANOVA with Bonferroni post hoc test was used in (a), 
(b). ***P < 0.001; N.S., not significant. Data are shown as means ± SEM. 
 
Together these results provide further support for our previous hypothesis in vivo. Although 
FMRP had no effect on the numbers of TH+ cells, fast-cycling voltammetry results indicated a 
protective role of FMRP loss in preserving DA release after α-Syn overexpression. 
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3.7 Loss of FMRP occurs in all Braak stages of human SN samples 
Last of all, we investigated the role of FMRP under α-Syn related pathological conditions. 
In the human brain, misfolded α-Syn mainly exists in LBs. Therefore, we evaluated the FMRP 
intensity of SN dopaminergic neurons from non-LBP cases and LBP cases from Braak stage 1 
to 6 (Table 6). 
3.7.1 H&E staining demonstrating a reduced number of DA neurons in the SNc of PD 
cases 
Previous studies demonstrated a reduced number of DA neurons in PD (Rietdijk, Perez-
Pardo, Garssen, van Wezel, & Kraneveld, 2017). In accord, Figure 50 consistently indicates a 
significant reduction of neuromelanin-positive, pigmented neurons in the SNc of PD cases at 
Braak stage 6. 
 
 
Figure 50 Reduced SN dopaminergic neurons are observed in Braak stage 6 samples. 
Representative H&E staining of post-mortem SNc sections demonstrating a significant 
decreased number of neuromelanin-positive DA neurons in PD, as compared to a control case. 
Scale bars 150 µm for lower magnification and 40 µm for higher magnification.  
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3.7.2 Immunofluorescence and VIP staining results reveal a reduced FMRP intensity in 
neuromelanin-positive cells of human SN samples with LBP. 
In the follow-up phase of the study, we compared the abundance of FMRP in all the cases, 
including control cases without LBP as well as other neurological diseases, iLBD cases at Braak 
stages 1 and 2,, where LBs were constrained to the medulla oblongata and locus coeruleus 
(Castellani, Smith, Richey, & Perry, 1996; Ulusoy et al., 2016), and PD cases from Braak stage 
3 to 6. Interestingly, a clearly reduced FMRP immunofluorescent intensity was observed in all 
the cases with LBP, whereas all the control cases displayed a clear and strong cytoplasmic 
FMRP signal (Figure 51, 52, and 53). An enzymatic VIP staining also exhibited the same trend 
(Figure 54). 
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Figure 51 Cases with LBP display reduced FMRP intensity. (a-c) Immunofluorescent staining of 
FMRP combined with bright field photomicrographs of neuromelanin-containing neurons in SNc 
demonstrating a dramatic reduction of FMRP intensity in iLBD cases at different Braak stages, 
as compared to the control cases. 
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Figure 52 Zoomed in pictures of FMRP in both control cases and cases with LBP. High 
magnification (63x) micrographs demonstrating a reduced FMRP immunostaining intensity in 
LBD cases, as compared to control cases. 
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Figure 53 Significant reduced FMRP intensity are identified in LBP cases, and quantification of 
FMRP signal for all cases. (a) Quantification of FMRP mean intensity of all cells from both LBP 
cases (cases/neurons = 16/1169) and non-LBP control cases (cases/neurons = 7/670) 
demonstrating a loss of FMRP in LBP cases. (b) Bar graph shows the abundance of FMRP 
mean intensity in each non-LBD cases and iLBD cases at different Braak stages. All the iLBD 
cases show a reduced FMRP abundance irrespective of the Braak stage. For comparison of the 
means, two-tailed unpaired t-test was used in (a, b). ****P < 0.0001. Data are shown as means 
± SEM. 
 
 
Figure 54 VIP staining of FMRP for control case and Braak stage 1 case. Representative 
chromogenic VIP staining shows a reduced cytoplasmatic FMRP signal in iLBD as compared to 
a non-PD control case. 
 104 
3.7.3 FMRP is decreased in neuromelanin-positive cells with LBP, but retained in 
neurons in locus coeruleus, raphe nuclei and nucleus basalis of Meynert 
To investigate the expression of FMRP in SNc neurons, we stained FMRP in conjugation 
with a TH antibody in human SNc sections (Figure 55). Besides the SNc DA neurons, TH-
positive noradrenergic cells in the locus coeruleus (lc), tryptophan hydroxylase 2 (TH2) -positive 
serotonergic cells in the raphe nuclei (rn) and choline acetyltransferase (ChAT)-positive 
cholinergic neurons in the nucleus basalis of Meynert (nbM) have been reported to exhibit LBP 
(Bohnen & Albin, 2011; Braak et al., 2003; Giguere, Burke Nanni, & Trudeau, 2018; G. M. 
Halliday, Blumbergs, Cotton, Blessing, & Geffen, 1990; Schulz, Pagano, Fernandez Bonfante, 
Wilson, & Politis, 2018). Therefore, we also investigated the expression of FMRP in these cells 
in conjunction with corresponding marker proteins (Figure 56). Immunostaining data confirmed a 
consistent downregulation of FMRP in TH-positive SNc DA cells in PD cases. However, the 
expression of FMRP was found to be retained in neurons from lc, rn and nbM in PD cases.  
 
Figure 55 Loss of FMRP present in the TH-positive cells of LBP cases. FMRP is decreased in 
neuromelanin- and TH double-positive neurons. (a) Schematic and corresponding H&E staining 
depict the anatomical and histological presence of neurons in the SN. (b-c) TH and FMRP 
double Immunohistochemically staining and quantification of FMRP intensity in both PD (n 
cases/neurons = 11/78) and Non-PD cases (n cases/neurons = 4/46). For comparison of the 
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means, the two-tailed unpaired t-test was used in (c). ****P < 0.0001. Data are shown as means 
± SEM. Aq: aquaeduct; SNc: substantia nigra pars compacta; Rn: red nucleus. 
 
 
Figure 56 FMRP is retained in neurons in the region of locus coeruleus (lc), raphe nuclei (rn) 
and nucleus basalis of Meynert (nbM) in PD cases. (a-c) Schematic and corresponding H&E 
staining depict the anatomical and histological presence of neurons in the locus coeruleus (lc) 
(a), the dorsal raphe nuclei (rn) (b) and the nucleus basalis of Meynert (nbM) (c). (d-f) Double 
immunohistochemically staining for both PD and control cases from the corresponding regions 
as shown in (a-c). The sections were double-stained with FMRP in conjunction with either TH 
(d), tryptophan hydroxylase 2 (TH2) (e) or choline acetyltransferase (ChAT) (f). (g-i) Bar graphs 
demonstrate the FMRP expression to be retained in neurons from lc (PD: n cases/neurons = 
4/93 vs. control: n cases/neurons = 5/119), rn (PD: n cases/neurons = 5/60 vs. control: n 
cases/neurons = 4/123), and nbM (PD: n cases/neurons = 9/65 vs. control: n cases/neurons = 
5/105). For comparison of the means, the two-tailed unpaired t-test was used in (g-i). Data are 
 106 
shown as means ± SEM. 4V: fourth ventricle; rn: raphe nuclei; lc: locus coeruleus; Igp: internal 
globus pallidus; Egp: external globus pallidus; Pu: putamen (Pu); nbM: nucleus basalis of 
Meynert. 
 
3.7.4 Immunofluorescent staining results reveal FMRP to be decreased in DA SNc 
neurons in PSP and MSA cases 
To further investigate the expression of FMRP in other neurodegenerative conditions, we 
also stained FMRP in SNc DA neurons from Progressive Supranuclear Palsy (PSP) cases 
(Table 7, Figure 57) and Multiple System Atrophy (MSA) cases (Table 7, Figure 58). Likewise, 
FMRP also decreased in SNc neurons in both conditions thus indicating an important role of 
FMRP during neurodegenerative process in different neurodegenerative conditions.   
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Figure 57 loss of FMRP also present in dopaminergic SNc neurons of PSP. (a,b) 
Photomicrographs and bar graphs demonstrating FMRP to be decreased in SNc neurons in 
Progressive Supranuclear Palsy (PSP) cases (n cases/neurons = 10/88), as compared to 
control cases (n cases/neurons = 4/54). For comparison of the means, two-tailed unpaired t-test 
was used ****P < 0.0001. Data are shown as means ± SEM. 
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Figure 58 loss of FMRP also present in dopaminergic SNc neurons of MSA. (a,b) 
Photomicrographs and bar graphs demonstrating FMRP to be decreased in SNc neurons in 
Multiple System Atrophy (MSA) cases (n cases/neurons = 9/77), as compared to control cases 
(n cases/neurons = 4/54). For comparison of the means, two-tailed unpaired t-test was used 
****P < 0.0001. Data are shown as means ± SEM. 
 
In summary, our study on human samples suggests an overall reduction of FMRP among 
all the tested LBP cases. It is, therefore, demonstrated that FMRP has a strong connection with 
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α-Syn related pathology. In general, the whole study indicates an important role of FMRP during 
PD progression, the early stage in particular. 
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4 Discussion 
4.1 α-Syn overexpression results in a loss of FMRP in vitro 
The present research was designed to study the effect of α-Syn overexpression on human 
DA neurons. The most compelling finding in our study is a decreased abundance of FMRP in 
these cells in response to α-Syn (Figure 21) as well as in the SNc of mice injected with α-Syn 
overexpressing virus (Figure 45).  
FMRP contains a nuclear localization and export sequence (Bhattacharya et al., 2012), 
and although its expression is largely cytoplasmic, FMRP can be found shuttling in and out of 
the nucleus (Carbone, Costa, Provensi, Mannaioni, & Masi, 2017; Ceman et al., 2003; Ferron et 
al., 2014). In the nucleus, FMRP binds to newly synthesized pre-mRNAs while being transcribed 
(Contractor et al., 2015) and transporting them from the soma to the dendrites and axons while 
inhibiting the translation of the encased mRNA (Aryee et al., 2014; Ashley, Wilkinson, Reines, & 
Warren, 1993; Berg et al., 2014; V. Brown et al., 2001). Once arrived at the synapse, mRNAs 
are released from these RNA granules and subsequently translated in response to stimuli 
(Damier, Hirsch, Agid, & Graybiel, 1999). FMRP thus presumably also acts as an mRNA binding 
and transport protein. In cultured DA neurons, we found the abundance of FMRP to be 
decreased in the cytoplasm, where it segregates with ER-associated membranes (Figure 23). 
Our data thus demonstrate a decrease of FMRP in the cytoplasm of α-Syn transduced neurons. 
FMRP related protein translation activity is regulated by phosphoinositide 3-kinase (PI3K) 
and mTORC1 that phosphorylate 4E-BPs and thus lead to a de-repression of protein translation. 
The mTOR also phosphorylates and activates p70 S6K1, which phosphorylates ribosomal 
protein S6 to promote cap‐dependent translation. Loss of FMRP in FXS and FMR1 KO mice 
leads to elevated phosphorylation of ERK, eIF4E, S6 and protein level of MMP9 (Figure 59). In 
accordance with previous researches, α-Syn overexpressed LUHMES cells display the same 
core phenotypes (Figure 38). Thus, our study provides an additional perspective with respect to 
α-Syn-mediated PD pathology. 
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Figure 59 Schematic illustrate the affected translation pathway involved in FXS. The 
expressions of MMP9 are increased and the phosphorylation of other blue labelled proteins are 
elevated in FXS. 
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4.2 α-Syn regulates neuronal proteins through modulating FMRP 
Most neuronal cell types vulnerable to PD-associated cell death including DA neurons in 
the SNc have long and highly branched axons, requiring a high amount of energy supply and 
oxidative phosphorylation (Dijkstra et al., 2014). For instance, neurons in the ventral tegmental 
area (VTA), which are considerably less vulnerable than SNc DA neurons, have less L-type-
mediated calcium currents (Brager, Akhavan, & Johnston, 2012; M. C. Chartier-Harlin et al., 
2011; Cilia et al., 2009) and increased hyperpolarization-activated and cyclic nucleotide-gated 
(HCN) currents upon treatment with the complex I inhibitor MPTP, ultimately leading to 
attenuated somatic calcium currents (Braak, Ghebremedhin, Rub, Bratzke, & Del Tredici, 2004). 
Another example is the selective activation of Kir6.2-containing ATP-sensitive potassium 
channels (K-ATP) and tonic hyperpolarization in SNc DA neurons in response to mitochondrial 
stress (De Pablo-Fernandez et al., 2015). These DA neurons have broad APs, large oscillations 
in intracellular Ca2+ and are autonomous pacemakers (Guzman et al., 2009; Nedergaard et al., 
1993) further increasing their vulnerability to age or cellular stress factors. These physiological 
traits distinguish SNc DA cells from neurons that are less vulnerable in PD (Braak et al., 2004). 
The differential expression or function of particular neuronal genes may be the basis for the 
selective vulnerability in PD. 
FMRP is predominantly expressed in neurons in the brain including DA cells of the SNc. In 
accord with previous reports, we found a strong FMRP expression in mouse SNc DA cells 
(Figure 45). As FMRP regulates a number of DA associated neuronal genes, α-Syn-mediated 
FMRP regulation in these cells may thus contribute to PD pathology. For instance, big 
potassium (BK) channels modulate AP duration and the afterhyperpolarization. Because a loss 
of FMRP reduces BK channel activity, FMR1 KO mice have an excessive AP broadening 
leading to elevated presynaptic Ca2+ influx during repetitive activity in both hippocampal and 
cortical pyramidal neurons (Deng et al., 2013). Future research needs to deceiver the specific 
effect of α-Syn on these conductances. Another good example of a cell-type and region-specific 
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effect of FMRP are HCN channels. Their expression is increased (and input resistance reduced) 
in dendrites of hippocampal neurons of FMR1 KO mice (Brager et al., 2012), which is opposite 
to what is observed in the dendrites of cortical L5 neurons (Zhang et al., 2014). These findings 
emphasize the non-uniformity of excitability changes caused by FMRP loss, which affects 
intrinsic membrane excitability in a brain region- and cell type-specific manner. 
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4.3 The potential role of FMRP in α-Syn related disease 
FXS is the most common inherited form of human intellectual disability including low IQ, 
learning disabilities, perseverative behaviors, hyperactivity, impulsivity, and disrupted sleep (Del 
Tredici & Braak, 2016). The majority of these signs and symptoms may be explained by circuit 
hyper-excitability (Brichta & Greengard, 2014) further reflected by hypersensitivity to sensory 
stimuli and hyper-arousal to seizures. In FXS, the dysregulated protein translation is proposed 
to perturb neuronal function by disrupting synaptic maturation and plasticity and eventually 
altering network activity throughout the brain in a cell-type (Bhakar et al., 2012; M. R. Brown et 
al., 2010) and the compartment-specific way (Froula et al., 2018). In our study, FMRP was 
found to be decreased in α-Syn overexpressed cultured dopaminergic neurons (Figure 21), 
which leads to an increased membrane abundance of N-type calcium channel and subsequent 
increased N-type-mediated calcium current (Figure 14 and Figure 31). The consequence of 
calcium overloading through N-type calcium channel and loss of FMRP in SNc DA neurons 
(Figure 60) are confounding factors inducing cell hyperexcitability (Surmeier, Obeso, & Halliday, 
2017). Further research should be undertaken to investigate these channels in helping us to 
better understand the pathology of PD. 
 
Figure 60 Human neuromelanin-positive SNc neurons contain N-type calcium channel. 
Immunofluorescent staining demonstrating the existence of N-type calcium channel subunits  
(CaV2.2) (green) in SNc neurons of post-mortem human brain tissue. 
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According to the metabotropic glutamate receptor (mGluR) theory, the loss of FMRP in 
FXS induces an exaggerated translation of synaptic plasticity-related mRNAs downstream 
group I mGluRs (Boivin et al., 2018). Besides, FMRP can also regulate some proteins through 
direct binding. For example, the carboxyl-terminal domain of FMRP has been recently shown to 
interact with the N-type calcium channel α1 subunit CaV2.2 to promote its proteasome-mediated 
destruction. Decreasing FMRP levels, therefore, reduced CaV2.2 degradation and led to an 
increased CaV2.2 membrane abundance and increased N-type-mediated calcium currents in 
dorsal root neurons. Other examples include the K+ channels BK and Slack (Braak et al., 2003; 
Bruch et al., 2014; Ferron et al., 2014) that are regulated by FMRP independent from protein 
translation. 
Different from FXS, FMR1 did not exhibit hyper-methylation-induced transcriptional 
silencing in cultured neurons overexpressing α-Syn but appeared to be regulated through a 
mechanism involving PKC and CREB-driven transcription (Figure 42-44). FMR1 KO mice were 
protected from reduced striatal DA release when injected with an α-Syn-overexpressing adeno-
associated virus into the SNc (Figure 49), suggesting a protective effect of FMRP loss.  
In addition to DA cell death in the SNc, an α-Syn associated neuronal malfunction has 
been also demonstrated in extra-striatal neuronal circuits, where it may contribute to the 
cognitive demise in PD or DLB (Ferreira et al., 2017; Froula et al., 2018; Nguyen & Krainc, 
2018). Thus investigating FMRP in these circuits will also contribute to the understanding of the 
molecular events that account for neuronal dysfunction outside the basal ganglia in PD. 
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4.4 FMRP as an early biomarker for PD and a potential target for PD therapy 
Based upon the neuropathological examination of iLBD and PD cases, Braak et al. 
proposed that in preclinical stages of PD, LBs appear first in either the olfactory bulb (OB) or the 
dorsal motor nucleus of the vagus (DMV) in the caudal medulla - two brain regions that have 
axons extending to the body surface. It is assumed that axons at these sites were exposed to a 
pathogens or infectious agents to cause LP and that this pathology then retrogradely spreads to 
neighboring neurons by passing from the infected cell to the next cell through synaptic 
connections, ultimately reaching the SNc where it is assumed to initiate the loss of neurons and 
thus symptom onset, before ultimately spreading to the forebrain by the end-stage (Bolam & 
Pissadaki, 2012; Ceravolo et al., 2005). The Braak staging is divided into 6 different stages that 
reflect a progression of LP from the DMV (Braak stage 1) and LC (Braak stage 2) to the SNc 
and amygdala (Braak stage 3) and ultimately reaching cortical areas (Braak stage 4-6) (Braak et 
al., 2003; Del Tredici & Braak, 2016). The Braak stages are correlated with the type and degree 
of clinical symptoms with disease progression. Whereas early stages are characterized by non-
motor symptoms, the typical PD motor signs appear once the SNc is affected at Braak stages 4, 
and cognitive symptoms arise only as LP affects the cortex in Braak stages 5 and 6 (Jellinger, 
2009). 
In line with a prion-like spreading of LP, transplanted fetal DA neurons exhibited 
proteinaceous inclusions after years that strongly resembled LP (Costa et al., 2011; Darnell et 
al., 2011), which were interpreted as spread of LP from the host to the graft. In mice, synthetic, 
preformed α-Syn fibrils propagate from the site of stereotaxic injection to synaptically connected, 
neighboring structures, creating Lewy-like pathology (DelleDonne et al., 2008; Dragicevic, 
Schiemann, & Liss, 2015; Feng et al., 1997). Similarly, proteins extracted from human brains 
with LP and injected into the striatum of monkeys can retrograde propagate (Dury et al., 2013). 
In accord with a spread through anatomical defined connections, LP appears gradually in 
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defined anatomical structures during PD disease progression (Bloch et al., 2006; Bruch et al., 
2017). 
On the other hand, previous studies demonstrated that cell death and LP do not entirely 
correlate. For instance, there is neuronal death in the supraoptic nucleus, even though LP is not 
present there. By contrast, there is no discernible neuron loss in the neighboring, LP-laden 
tuberomammillary nucleus of the hypothalamus (Alisch et al., 2013). In patients who do not 
manifest dementia, the only cortical region that shows substantial neuronal death is the pre-
supplementary motor cortex, where small intra-telencephalic pyramidal neurons degenerate in 
the absence of LP (Deng et al., 2013; Dolen et al., 2007). Furthermore, only about 50% of all 
PD patients have a distribution of LP in the brain that is consistent with the Braak staging model 
(M.-C. Chartier-Harlin et al., 2004). In conclusion, it is apparent that the cellular context is 
important for DA cell death and that the spreading of LP does not necessarily overlap with PD-
associated pathology or disease progression.  
Moreover, in patients with PD with genetic mutation-associated disease risk, the pattern of 
LP can be quite distinct from that of idiopathic PD. For instance, only a part of PD patients with 
a G2019S mutation in the LRRK2 gene manifest LP and most patients with other LRRK2 
mutations even do not have LP (Chen, Wu, Mesri, & Chen, 2016). Another example are PD 
patients harbouring PARK2 mutations that have only sparsely distributed LP in older patients 
with a pattern that is distinct from that found in non‐genetic PD cases (Budimirovic & Kaufmann, 
2011). 
The known disease phenotypes associated with FMR1 are related to the expansion of 
CGG repeats and hypermethylation of FMR1. Conversely, FMR1 is not subjected to epigenetic 
modifications in response to α-Syn because the methylation status of the FMR1 promoter region 
remained unaffected by α-Syn overexpression in cultured neurons (Figure 41). In accordance 
with these results, FMRP was also lost in most neuromelanin-positive neurons of the SNc in 
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human post-mortem brain tissue from PD patients (Figure 55). Surprisingly, we found a similar 
reduction of FMRP in cases that had no history of clinical PD and that had LBP restricted to the 
brain stem. 
FMRP loss precedes LP and DA cell death, thus demonstrating a specific molecular event 
preceding LP in PD. In summary, these results suggest a new role for FMRP in the disease 
progression of LP-associated pathological conditions. A screening study in 56 FXTAS patients, 
in fact, revealed PD was the most frequent initial diagnosis (D. A. Hall et al., 2005). Based on 
our findings, future studies need to examine the usefulness of FMRP as a molecular biomarker 
for disease progression in PD. This is particularly important as only the characterization of early 
molecular changes will permit the development of disease-modifying therapies, that otherwise 
come too late, once the diseases progressed towards DA cell death. 
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5 Summary 
Returning to the aims posed at the beginning of this dissertation, we investigated the role 
of FMRP, which has a pivotal role in regulating neuronal gene expression through mRNA 
binding in FXS, in different models of PD including PD patients’ brain tissue. The most 
significant finding to emerge from this study is that the expression of FMRP is decreased in 
response to α-Syn overexpression in vitro and in mouse model. The loss of FMRP also present 
in all Braak stages of PD cases. As the consequence of FMRP loss, dopaminergic LUHMES 
cells show hyper-activation of mTOR and ERK pathway which reminiscent of FXS (Figure 61). 
Meanwhile, FMRP also activate N-type calcium channel, suggesting a disrupted ion 
homeostasis in DA neurons in the early stage of PD. In summary, our work highlights the 
important role of FMRP in the development of PD pathology and other α-Syn associated 
diseases. 
 
 
Figure 61 Schematic depict how α-Syn regulate indicated proteins through modulating FRMP. 
α-Syn overexpression decreases the expression of FMRP through inhibiting PKC-CREB 
pathway. Reduced FMRP results in an increased calcium influx through modulating N-type 
calcium channel, an activated eIF4E and ERK pathway, increased overall protein synthesis, and 
an increased MMP9 expression. 
 120 
6 Bibliography 
Adamczyk, A., & Strosznajder, J. B. (2006). Alpha-synuclein potentiates Ca2+ influx through 
voltage-dependent Ca2+ channels. Neuroreport, 17(18), 1883-1886. doi: 
10.1097/WNR.0b013e3280115185 
Adamowicz, D. H., Roy, S., Salmon, D. P., Galasko, D. R., Hansen, L. A., Masliah, E., & Gage, 
F. H. (2017). Hippocampal alpha-Synuclein in Dementia with Lewy Bodies Contributes to 
Memory Impairment and Is Consistent with Spread of Pathology. J Neurosci, 37(7), 
1675-1684. doi: 10.1523/JNEUROSCI.3047-16.2016 
Alegre-Abarrategui, J., Brimblecombe, K. R., Roberts, R. F., Velentza-Almpani, E., Tilley, B. S., 
Bengoa-Vergniory, N., & Proukakis, C. (2019). Selective vulnerability in alpha-
synucleinopathies. Acta Neuropathol. doi: 10.1007/s00401-019-02010-2 
Alisch, R. S., Wang, T., Chopra, P., Visootsak, J., Conneely, K. N., & Warren, S. T. (2013). 
Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to 
the FMR1 locus. BMC Med Genet, 14, 18. doi: 10.1186/1471-2350-14-18 
Arawaka, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C. H., . . . Kato, T. (2006). 
The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's 
disease. J Neurosci, 26(36), 9227-9238. doi: 10.1523/JNEUROSCI.0341-06.2006 
Arsenault, J., Gholizadeh, S., Niibori, Y., Pacey, L. K., Halder, S. K., Koxhioni, E., . . . Hampson, 
D. R. (2016). FMRP Expression Levels in Mouse Central Nervous System Neurons 
Determine Behavioral Phenotype. Hum Gene Ther, 27(12), 982-996. doi: 
10.1089/hum.2016.090 
Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., & 
Irizarry, R. A. (2014). Minfi: a flexible and comprehensive Bioconductor package for the 
analysis of Infinium DNA methylation microarrays. Bioinformatics, 30(10), 1363-1369. 
doi: 10.1093/bioinformatics/btu049 
Ashley, C. T., Jr., Wilkinson, K. D., Reines, D., & Warren, S. T. (1993). FMR1 protein: 
conserved RNP family domains and selective RNA binding. Science, 262(5133), 563-
566.  
Auluck, P. K., Caraveo, G., & Lindquist, S. (2010). alpha-Synuclein: membrane interactions and 
toxicity in Parkinson's disease. Annu Rev Cell Dev Biol, 26, 211-233. doi: 
10.1146/annurev.cellbio.042308.113313 
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012). Fragile X syndrome: causes, 
diagnosis, mechanisms, and therapeutics. J Clin Invest, 122(12), 4314-4322. doi: 
10.1172/JCI63141 
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011). alpha-Synuclein occurs physiologically as a 
helically folded tetramer that resists aggregation. Nature, 477(7362), 107-110. doi: 
10.1038/nature10324 
Berg, D., Postuma, R. B., Bloem, B., Chan, P., Dubois, B., Gasser, T., . . . Deuschl, G. (2014). 
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of 
Parkinson's disease. Mov Disord, 29(4), 454-462. doi: 10.1002/mds.25844 
Beyer, K., Domingo-Sabat, M., & Ariza, A. (2009). Molecular pathology of Lewy body diseases. 
Int J Mol Sci, 10(3), 724-745. doi: 10.3390/ijms10030724 
 121 
Bhakar, A. L., Dolen, G., & Bear, M. F. (2012). The pathophysiology of fragile X (and what it 
teaches us about synapses). Annu Rev Neurosci, 35, 417-443. doi: 10.1146/annurev-
neuro-060909-153138 
Bhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., & Klann, E. 
(2012). Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral 
phenotypes in fragile X syndrome mice. Neuron, 76(2), 325-337. doi: 
10.1016/j.neuron.2012.07.022 
Bloch, A., Probst, A., Bissig, H., Adams, H., & Tolnay, M. (2006). Alpha-synuclein pathology of 
the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly 
subjects. Neuropathol Appl Neurobiol, 32(3), 284-295. doi: 10.1111/j.1365-
2990.2006.00727.x 
Bohnen, N. I., & Albin, R. L. (2011). The cholinergic system and Parkinson disease. Behav 
Brain Res, 221(2), 564-573. doi: 10.1016/j.bbr.2009.12.048 
Boivin, M., Willemsen, R., Hukema, R. K., & Sellier, C. (2018). Potential pathogenic 
mechanisms underlying Fragile X Tremor Ataxia Syndrome: RAN translation and/or RNA 
gain-of-function? Eur J Med Genet, 61(11), 674-679. doi: 10.1016/j.ejmg.2017.11.001 
Bolam, J. P., & Pissadaki, E. K. (2012). Living on the edge with too many mouths to feed: why 
dopamine neurons die. Mov Disord, 27(12), 1478-1483. doi: 10.1002/mds.25135 
Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). 
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 
24(2), 197-211.  
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., & Del Tredici, K. (2004). Stages in the 
development of Parkinson's disease-related pathology. Cell Tissue Res, 318(1), 121-
134. doi: 10.1007/s00441-004-0956-9 
Brager, D. H., Akhavan, A. R., & Johnston, D. (2012). Impaired dendritic expression and 
plasticity of h-channels in the fmr1(-/y) mouse model of fragile X syndrome. Cell Rep, 
1(3), 225-233. doi: 10.1016/j.celrep.2012.02.002 
Brichta, L., & Greengard, P. (2014). Molecular determinants of selective dopaminergic 
vulnerability in Parkinson's disease: an update. Front Neuroanat, 8, 152. doi: 
10.3389/fnana.2014.00152 
Brown, M. R., Kronengold, J., Gazula, V. R., Chen, Y., Strumbos, J. G., Sigworth, F. J., . . . 
Kaczmarek, L. K. (2010). Fragile X mental retardation protein controls gating of the 
sodium-activated potassium channel Slack. Nat Neurosci, 13(7), 819-821. doi: 
10.1038/nn.2563 
Brown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., . . . Warren, 
S. T. (2001). Microarray identification of FMRP-associated brain mRNAs and altered 
mRNA translational profiles in fragile X syndrome. Cell, 107(4), 477-487.  
Bruch, J., Xu, H., De Andrade, A., & Hoglinger, G. (2014). Mitochondrial complex 1 inhibition 
increases 4-repeat isoform tau by SRSF2 upregulation. PLoS One, 9(11), e113070. doi: 
10.1371/journal.pone.0113070 
Bruch, J., Xu, H., Rosler, T. W., De Andrade, A., Kuhn, P. H., Lichtenthaler, S. F., . . . Hoglinger, 
G. U. (2017). PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol 
Med. doi: 10.15252/emmm.201606664 
 122 
Brys, I., Nunes, J., & Fuentes, R. (2017). Motor deficits and beta oscillations are dissociable in 
an alpha-synuclein model of Parkinson's disease. Eur J Neurosci. doi: 
10.1111/ejn.13568 
Budimirovic, D. B., & Kaufmann, W. E. (2011). What can we learn about autism from studying 
fragile X syndrome? Dev Neurosci, 33(5), 379-394. doi: 10.1159/000330213 
Buraei, Z., & Yang, J. (2013). Structure and function of the beta subunit of voltage-gated 
Ca(2)(+) channels. Biochim Biophys Acta, 1828(7), 1530-1540. doi: 
10.1016/j.bbamem.2012.08.028 
Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Sudhof, T. C. (2010). 
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 
329(5999), 1663-1667. doi: 10.1126/science.1195227 
Caku, A., Pellerin, D., Bouvier, P., Riou, E., & Corbin, F. (2014). Effect of lovastatin on behavior 
in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A, 
164A(11), 2834-2842. doi: 10.1002/ajmg.a.36750 
Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., & Di Filippo, M. (2014). Direct and indirect 
pathways of basal ganglia: a critical reappraisal. Nat Neurosci, 17(8), 1022-1030. doi: 
10.1038/nn.3743 
Campelo, C., & Silva, R. H. (2017). Genetic Variants in SNCA and the Risk of Sporadic 
Parkinson's Disease and Clinical Outcomes: A Review. Parkinsons Dis, 2017, 4318416. 
doi: 10.1155/2017/4318416 
Candelise, N., Schmitz, M., Llorens, F., Villar-Pique, A., Cramm, M., Thom, T., . . . Zerr, I. 
(2019). Seeding variability of different alpha synuclein strains in synucleinopathies. Ann 
Neurol, 85(5), 691-703. doi: 10.1002/ana.25446 
Carbone, C., Costa, A., Provensi, G., Mannaioni, G., & Masi, A. (2017). The Hyperpolarization-
Activated Current Determines Synaptic Excitability, Calcium Activity and Specific 
Viability of Substantia Nigra Dopaminergic Neurons. Front Cell Neurosci, 11, 187. doi: 
10.3389/fncel.2017.00187 
Castagnola, S., Delhaye, S., Folci, A., Paquet, A., Brau, F., Duprat, F., . . . Maurin, T. (2018). 
New Insights Into the Role of Cav2 Protein Family in Calcium Flux Deregulation in Fmr1-
KO Neurons. Front Mol Neurosci, 11, 342. doi: 10.3389/fnmol.2018.00342 
Castellani, R., Smith, M. A., Richey, P. L., & Perry, G. (1996). Glycoxidation and oxidative stress 
in Parkinson disease and diffuse Lewy body disease. Brain Res, 737(1-2), 195-200.  
Ceman, S., O'Donnell, W. T., Reed, M., Patton, S., Pohl, J., & Warren, S. T. (2003). 
Phosphorylation influences the translation state of FMRP-associated polyribosomes. 
Hum Mol Genet, 12(24), 3295-3305. doi: 10.1093/hmg/ddg350 
Ceravolo, R., Antonini, A., Volterrani, D., Rossi, C., Goldwurm, S., Di Maria, E., . . . Murri, L. 
(2005). Dopamine transporter imaging study in parkinsonism occurring in fragile X 
premutation carriers. Neurology, 65(12), 1971-1973. doi: 
10.1212/01.wnl.0000188821.51055.52 
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., . . . Surmeier, D. J. 
(2007). 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. 
Nature, 447(7148), 1081-1086. doi: 10.1038/nature05865 
 123 
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., . . . 
Destée, A. (2004). α-Synuclein locus duplication as a cause of familial Parkinson's 
disease. The Lancet, 364(9440), 1167-1169. doi: 10.1016/s0140-6736(04)17103-1 
Chartier-Harlin, M. C., Dachsel, J. C., Vilarino-Guell, C., Lincoln, S. J., Lepretre, F., Hulihan, M. 
M., . . . Farrer, M. J. (2011). Translation initiator EIF4G1 mutations in familial Parkinson 
disease. Am J Hum Genet, 89(3), 398-406. doi: 10.1016/j.ajhg.2011.08.009 
Chen, Y. C., Wu, Y. R., Mesri, M., & Chen, C. M. (2016). Associations of Matrix 
Metalloproteinase-9 and Tissue Inhibitory Factor-1 Polymorphisms With Parkinson 
Disease in Taiwan. Medicine (Baltimore), 95(5), e2672. doi: 
10.1097/MD.0000000000002672 
Cilia, R., Kraff, J., Canesi, M., Pezzoli, G., Goldwurm, S., Amiri, K., . . . Tassone, F. (2009). 
Screening for the presence of FMR1 premutation alleles in women with parkinsonism. 
Arch Neurol, 66(2), 244-249. doi: 10.1001/archneurol.2008.548 
Contractor, A., Klyachko, V. A., & Portera-Cailliau, C. (2015). Altered Neuronal and Circuit 
Excitability in Fragile X Syndrome. Neuron, 87(4), 699-715. doi: 
10.1016/j.neuron.2015.06.017 
Costa, A., Gao, L., Carrillo, F., Caceres-Redondo, M. T., Carballo, M., Diaz-Martin, J., . . . 
Pintado, E. (2011). Intermediate alleles at the FRAXA and FRAXE loci in Parkinson's 
disease. Parkinsonism Relat Disord, 17(4), 281-284. doi: 
10.1016/j.parkreldis.2010.12.013 
Covell, D. J., Robinson, J. L., Akhtar, R. S., Grossman, M., Weintraub, D., Bucklin, H. M., . . . 
Lee, V. M. (2017). Novel conformation-selective alpha-synuclein antibodies raised 
against different in vitro fibril forms show distinct patterns of Lewy pathology in 
Parkinson's disease. Neuropathol Appl Neurobiol. doi: 10.1111/nan.12402 
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004). Impaired 
degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science, 
305(5688), 1292-1295. doi: 10.1126/science.1101738 
Dai, S., Hall, D. D., & Hell, J. W. (2009). Supramolecular assemblies and localized regulation of 
voltage-gated ion channels. Physiol Rev, 89(2), 411-452. doi: 
10.1152/physrev.00029.2007 
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999). The substantia nigra of the human 
brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 
122 ( Pt 8), 1437-1448. doi: 10.1093/brain/122.8.1437 
Danesi, C., Achuta, V. S., Corcoran, P., Peteri, U. K., Turconi, G., Matsui, N., . . . Castren, M. L. 
(2018). Increased Calcium Influx through L-type Calcium Channels in Human and 
Mouse Neural Progenitors Lacking Fragile X Mental Retardation Protein. Stem Cell 
Reports. doi: 10.1016/j.stemcr.2018.11.003 
Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., . . . Kostka, M. 
(2007). Different species of alpha-synuclein oligomers induce calcium influx and 
seeding. J Neurosci, 27(34), 9220-9232. doi: 10.1523/JNEUROSCI.2617-07.2007 
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y., Mele, A., Fraser, C. E., . . . Darnell, 
R. B. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function 
and autism. Cell, 146(2), 247-261. doi: 10.1016/j.cell.2011.06.013 
 124 
Dauer, W., & Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron, 
39(6), 889-909.  
Davis, J. K., & Broadie, K. (2017). Multifarious Functions of the Fragile X Mental Retardation 
Protein. Trends Genet, 33(10), 703-714. doi: 10.1016/j.tig.2017.07.008 
De Pablo-Fernandez, E., Doherty, K. M., Holton, J. L., Revesz, T., Djamshidian, A., Limousin, 
P., . . . Ling, H. (2015). Concomitant fragile X-associated tremor ataxia syndrome and 
Parkinson's disease: a clinicopathological report of two cases. J Neurol Neurosurg 
Psychiatry, 86(8), 934-936. doi: 10.1136/jnnp-2014-309460 
De Pablo-Fernandez, E., Lees, A. J., Holton, J. L., & Warner, T. T. (2019). Prognosis and 
Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurol. 
doi: 10.1001/jamaneurol.2018.4377 
De Rubeis, S., & Bagni, C. (2011). Regulation of molecular pathways in the Fragile X 
Syndrome: insights into Autism Spectrum Disorders. J Neurodev Disord, 3(3), 257-269. 
doi: 10.1007/s11689-011-9087-2 
Del Rey, N. L., Quiroga-Varela, A., Garbayo, E., Carballo-Carbajal, I., Fernandez-Santiago, R., 
Monje, M. H. G., . . . Blesa, J. (2018). Advances in Parkinson's Disease: 200 Years 
Later. Front Neuroanat, 12, 113. doi: 10.3389/fnana.2018.00113 
Del Tredici, K., & Braak, H. (2016). Review: Sporadic Parkinson's disease: development and 
distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol, 42(1), 33-50. doi: 
10.1111/nan.12298 
Delic, V., Chandra, S., Abdelmotilib, H., Maltbie, T., Wang, S., Kem, D., . . . West, A. B. (2018). 
Sensitivity and specificity of phospho-Ser129 alpha-synuclein monoclonal antibodies. J 
Comp Neurol, 526(12), 1978-1990. doi: 10.1002/cne.24468 
DelleDonne, A., Klos, K. J., Fujishiro, H., Ahmed, Z., Parisi, J. E., Josephs, K. A., . . . Dickson, 
D. W. (2008). Incidental Lewy body disease and preclinical Parkinson disease. Arch 
Neurol, 65(8), 1074-1080. doi: 10.1001/archneur.65.8.1074 
Deng, P. Y., Rotman, Z., Blundon, J. A., Cho, Y., Cui, J., Cavalli, V., . . . Klyachko, V. A. (2013). 
FMRP regulates neurotransmitter release and synaptic information transmission by 
modulating action potential duration via BK channels. Neuron, 77(4), 696-711. doi: 
10.1016/j.neuron.2012.12.018 
Dictenberg, J. B., Swanger, S. A., Antar, L. N., Singer, R. H., & Bassell, G. J. (2008). A direct 
role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine 
morphogenesis to fragile X syndrome. Dev Cell, 14(6), 926-939. doi: 
10.1016/j.devcel.2008.04.003 
Dijkstra, A. A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Netherlands Brain, B., 
Rozemuller, A. J., & van de Berg, W. D. (2014). Stage-dependent nigral neuronal loss in 
incidental Lewy body and Parkinson's disease. Mov Disord, 29(10), 1244-1251. doi: 
10.1002/mds.25952 
Dolen, G., Osterweil, E., Rao, B. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. 
(2007). Correction of fragile X syndrome in mice. Neuron, 56(6), 955-962. doi: 
10.1016/j.neuron.2007.12.001 
Dolphin, A. C. (2009). Calcium channel diversity: multiple roles of calcium channel subunits. 
Curr Opin Neurobiol, 19(3), 237-244. doi: 10.1016/j.conb.2009.06.006 
 125 
Doria, M., Maugest, L., Moreau, T., Lizard, G., & Vejux, A. (2016). Contribution of cholesterol 
and oxysterols to the pathophysiology of Parkinson's disease. Free Radic Biol Med, 101, 
393-400. doi: 10.1016/j.freeradbiomed.2016.10.008 
Doty, R. L. (2012). Olfactory dysfunction in Parkinson disease. Nat Rev Neurol, 8(6), 329-339. 
doi: 10.1038/nrneurol.2012.80 
Dragicevic, E., Schiemann, J., & Liss, B. (2015). Dopamine midbrain neurons in health and 
Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-
sensitive potassium channels. Neuroscience, 284, 798-814. doi: 
10.1016/j.neuroscience.2014.10.037 
Duda, J., Potschke, C., & Liss, B. (2016). Converging roles of ion channels, calcium, metabolic 
stress, and activity pattern of Substantia nigra dopaminergic neurons in health and 
Parkinson's disease. J Neurochem, 139 Suppl 1, 156-178. doi: 10.1111/jnc.13572 
Dury, A. Y., El Fatimy, R., Tremblay, S., Rose, T. M., Cote, J., De Koninck, P., & Khandjian, E. 
W. (2013). Nuclear Fragile X Mental Retardation Protein is localized to Cajal bodies. 
PLoS Genet, 9(10), e1003890. doi: 10.1371/journal.pgen.1003890 
Ebrahimi, S. S., Oryan, S., Izadpanah, E., & Hassanzadeh, K. (2017). Thymoquinone exerts 
neuroprotective effect in animal model of Parkinson's disease. Toxicol Lett, 276, 108-
114. doi: 10.1016/j.toxlet.2017.05.018 
El-Agnaf, O., Overk, C., Rockenstein, E., Mante, M., Florio, J., Adame, A., . . . Rissman, R. A. 
(2017). Differential effects of immunotherapy with antibodies targeting alpha-synuclein 
oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis, 104, 85-
96. doi: 10.1016/j.nbd.2017.05.002 
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019). Emerging therapies in 
Parkinson disease - repurposed drugs and new approaches. Nat Rev Neurol, 15(4), 
204-223. doi: 10.1038/s41582-019-0155-7 
Fay-Karmon, T., & Hassin-Baer, S. (2019). The spectrum of tremor among carriers of the FMR1 
premutation with or without the fragile X-associated tremor/ataxia syndrome (FXTAS). 
Parkinsonism Relat Disord. doi: 10.1016/j.parkreldis.2019.05.010 
Feng, Y., Gutekunst, C. A., Eberhart, D. E., Yi, H., Warren, S. T., & Hersch, S. M. (1997). 
Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with 
somatodendritic ribosomes. J Neurosci, 17(5), 1539-1547.  
Ferder, I., Parborell, F., Sundblad, V., Chiauzzi, V., Gomez, K., Charreau, E. H., . . . Dain, L. 
(2013). Expression of fragile X mental retardation protein and Fmr1 mRNA during 
folliculogenesis in the rat. Reproduction, 145(4), 335-343. doi: 10.1530/REP-12-0305 
Ferreira, D. G., Temido-Ferreira, M., Vicente Miranda, H., Batalha, V. L., Coelho, J. E., Szego, 
E. M., . . . Outeiro, T. F. (2017). alpha-synuclein interacts with PrP(C) to induce cognitive 
impairment through mGluR5 and NMDAR2B. Nat Neurosci, 20(11), 1569-1579. doi: 
10.1038/nn.4648 
Ferron, L. (2016). Fragile X mental retardation protein controls ion channel expression and 
activity. J Physiol. doi: 10.1113/JP270675 
Ferron, L., Nieto-Rostro, M., Cassidy, J. S., & Dolphin, A. C. (2014). Fragile X mental 
retardation protein controls synaptic vesicle exocytosis by modulating N-type calcium 
channel density. Nat Commun, 5, 3628. doi: 10.1038/ncomms4628 
 126 
Follett, J., Darlow, B., Wong, M. B., Goodwin, J., & Pountney, D. L. (2013). Potassium 
depolarization and raised calcium induces alpha-synuclein aggregates. Neurotox Res, 
23(4), 378-392. doi: 10.1007/s12640-012-9366-z 
Froula, J. M., Henderson, B. W., Gonzalez, J. C., Vaden, J. H., McLean, J. W., Wu, Y., . . . 
Volpicelli-Daley, L. A. (2018). alpha-Synuclein fibril-induced paradoxical structural and 
functional defects in hippocampal neurons. Acta Neuropathol Commun, 6(1), 35. doi: 
10.1186/s40478-018-0537-x 
Fussi, N., Hollerhage, M., Chakroun, T., Nykanen, N. P., Rosler, T. W., Koeglsperger, T., . . . 
Hoglinger, G. U. (2018). Exosomal secretion of alpha-synuclein as protective 
mechanism after upstream blockage of macroautophagy. Cell Death Dis, 9(7), 757. doi: 
10.1038/s41419-018-0816-2 
Fyfe, I. (2017). Movement disorders: Comparison of cognitive impairment in Parkinson disease 
and essential tremor. Nat Rev Neurol. doi: 10.1038/nrneurol.2017.40 
Gantois, I., Khoutorsky, A., Popic, J., Aguilar-Valles, A., Freemantle, E., Cao, R., . . . 
Sonenberg, N. (2017). Metformin ameliorates core deficits in a mouse model of fragile X 
syndrome. Nat Med. doi: 10.1038/nm.4335 
Garber, K., Smith, K. T., Reines, D., & Warren, S. T. (2006). Transcription, translation and 
fragile X syndrome. Curr Opin Genet Dev, 16(3), 270-275. doi: 
10.1016/j.gde.2006.04.010 
Giasson, B. I., Murray, I. V., Trojanowski, J. Q., & Lee, V. M. (2001). A hydrophobic stretch of 12 
amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J 
Biol Chem, 276(4), 2380-2386. doi: 10.1074/jbc.M008919200 
Gibb, W. R., & Lees, A. J. (1988). The relevance of the Lewy body to the pathogenesis of 
idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 51(6), 745-752. doi: 
10.1136/jnnp.51.6.745 
Giguere, N., Burke Nanni, S., & Trudeau, L. E. (2018). On Cell Loss and Selective Vulnerability 
of Neuronal Populations in Parkinson's Disease. Front Neurol, 9, 455. doi: 
10.3389/fneur.2018.00455 
Giri, A., Mok, K. Y., Jansen, I., Sharma, M., Tesson, C., Mangone, G., . . . Simon-Sanchez, J. 
(2017). Lack of evidence for a role of genetic variation in TMEM230 in the risk for 
Parkinson's disease in the Caucasian population. Neurobiol Aging, 50, 167 e111-167 
e113. doi: 10.1016/j.neurobiolaging.2016.10.004 
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013). 100 years of Lewy pathology. 
Nat Rev Neurol, 9(1), 13-24. doi: 10.1038/nrneurol.2012.242 
Grassi, D., Howard, S., Zhou, M., Diaz-Perez, N., Urban, N. T., Guerrero-Given, D., . . . 
Lasmezas, C. I. (2018). Identification of a highly neurotoxic alpha-synuclein species 
inducing mitochondrial damage and mitophagy in Parkinson's disease. Proc Natl Acad 
Sci U S A, 115(11), E2634-E2643. doi: 10.1073/pnas.1713849115 
Greco, C. M., Hagerman, R. J., Tassone, F., Chudley, A. E., Del Bigio, M. R., Jacquemont, S., . 
. . Hagerman, P. J. (2002). Neuronal intranuclear inclusions in a new cerebellar 
tremor/ataxia syndrome among fragile X carriers. Brain, 125(Pt 8), 1760-1771.  
Gross, C., Banerjee, A., Tiwari, D., Longo, F., White, A. R., Allen, A. G., . . . Bassell, G. J. 
(2018). Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range 
 127 
of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacology. 
doi: 10.1038/s41386-018-0150-5 
Guzman, J. N., Ilijic, E., Yang, B., Sanchez-Padilla, J., Wokosin, D., Galtieri, D., . . . Surmeier, 
D. J. (2018). Systemic isradipine treatment diminishes calcium-dependent mitochondrial 
oxidant stress. J Clin Invest, 128(6), 2266-2280. doi: 10.1172/JCI95898 
Hafner, A. S., Donlin-Asp, P. G., Leitch, B., Herzog, E., & Schuman, E. M. (2019). Local protein 
synthesis is a ubiquitous feature of neuronal pre- and postsynaptic compartments. 
Science, 364(6441). doi: 10.1126/science.aau3644 
Hagerman, P. J., & Hagerman, R. J. (2015). Fragile X-associated tremor/ataxia syndrome. Ann 
N Y Acad Sci, 1338, 58-70. doi: 10.1111/nyas.12693 
Hagerman, R. J., & Hagerman, P. (2016). Fragile X-associated tremor/ataxia syndrome - 
features, mechanisms and management. Nat Rev Neurol, 12(7), 403-412. doi: 
10.1038/nrneurol.2016.82 
Hall, D., Pickler, L., Riley, K., Tassone, F., & Hagerman, R. (2010). Parkinsonism and cognitive 
decline in a fragile X mosaic male. Mov Disord, 25(10), 1523-1524. doi: 
10.1002/mds.23150 
Hall, D. A., Berry-Kravis, E., Jacquemont, S., Rice, C. D., Cogswell, J., Zhang, L., . . . Leehey, 
M. A. (2005). Initial diagnoses given to persons with the fragile X associated 
tremor/ataxia syndrome (FXTAS). Neurology, 65(2), 299-301. doi: 
10.1212/01.wnl.0000168900.86323.9c 
Hall, D. A., Howard, K., Hagerman, R., & Leehey, M. A. (2009). Parkinsonism in FMR1 
premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism 
Relat Disord, 15(2), 156-159. doi: 10.1016/j.parkreldis.2008.04.037 
Hall, D. A., Jennings, D., Seibyl, J., Tassone, F., & Marek, K. (2010). FMR1 gene expansion 
and scans without evidence of dopaminergic deficits in parkinsonism patients. 
Parkinsonism Relat Disord, 16(9), 608-611. doi: 10.1016/j.parkreldis.2010.07.006 
Halliday, G., Herrero, M. T., Murphy, K., McCann, H., Ros-Bernal, F., Barcia, C., . . . Obeso, J. 
A. (2009). No Lewy pathology in monkeys with over 10 years of severe MPTP 
Parkinsonism. Mov Disord, 24(10), 1519-1523. doi: 10.1002/mds.22481 
Halliday, G. M., Blumbergs, P. C., Cotton, R. G., Blessing, W. W., & Geffen, L. B. (1990). Loss 
of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. 
Brain Res, 510(1), 104-107. doi: 10.1016/0006-8993(90)90733-r 
Halliday, G. M., McRitchie, D. A., Cartwright, H., Pamphlett, R., Hely, M. A., & Morris, J. G. 
(1996). Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy 
body disease. J Clin Neurosci, 3(1), 52-60.  
Hasegawa, M., Nonaka, T., & Masuda-Suzukake, M. (2016). Prion-like mechanisms and 
potential therapeutic targets in neurodegenerative disorders. Pharmacol Ther. doi: 
10.1016/j.pharmthera.2016.11.010 
Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., & Masliah, E. (1999). 
Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in 
vitro. Neuroreport, 10(4), 717-721.  
 128 
Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T., & Masliah, E. (1999). Role of 
cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J 
Biol Chem, 274(41), 28849-28852. doi: 10.1074/jbc.274.41.28849 
Hawkes, C. H., Del Tredici, K., & Braak, H. (2010). A timeline for Parkinson's disease. 
Parkinsonism Relat Disord, 16(2), 79-84. doi: 10.1016/j.parkreldis.2009.08.007 
Hein, M. Y., Hubner, N. C., Poser, I., Cox, J., Nagaraj, N., Toyoda, Y., . . . Mann, M. (2015). A 
human interactome in three quantitative dimensions organized by stoichiometries and 
abundances. Cell, 163(3), 712-723. doi: 10.1016/j.cell.2015.09.053 
Higashimori, H., Morel, L., Huth, J., Lindemann, L., Dulla, C., Taylor, A., . . . Yang, Y. (2013). 
Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies 
glutamate transporter GLT1 dysregulation in the fragile X mouse. Hum Mol Genet, 
22(10), 2041-2054. doi: 10.1093/hmg/ddt055 
Hollerhage, M., Goebel, J. N., de Andrade, A., Hildebrandt, T., Dolga, A., Culmsee, C., . . . 
Hoglinger, G. U. (2014). Trifluoperazine rescues human dopaminergic cells from wild-
type alpha-synuclein-induced toxicity. Neurobiol Aging, 35(7), 1700-1711. doi: 
10.1016/j.neurobiolaging.2014.01.027 
Hurley, M. J., & Dexter, D. T. (2012). Voltage-gated calcium channels and Parkinson's disease. 
Pharmacol Ther, 133(3), 324-333. doi: 10.1016/j.pharmthera.2011.11.006 
Jalnapurkar, I., Cochran, D. M., & Frazier, J. A. (2019). New Therapeutic Options for Fragile X 
Syndrome. Curr Treat Options Neurol, 21(3), 12. doi: 10.1007/s11940-019-0551-8 
Jellinger, K. A. (2009). A critical evaluation of current staging of alpha-synuclein pathology in 
Lewy body disorders. Biochim Biophys Acta, 1792(7), 730-740. doi: 
10.1016/j.bbadis.2008.07.006 
Jellinger, K. A., & Lantos, P. L. (2010). Papp-Lantos inclusions and the pathogenesis of multiple 
system atrophy: an update. Acta Neuropathol, 119(6), 657-667. doi: 10.1007/s00401-
010-0672-3 
Jeon, S. J., Han, S. H., Yang, S. I., Choi, J. W., Kwon, K. J., Park, S. H., . . . Shin, C. Y. (2012). 
Positive feedback regulation of Akt-FMRP pathway protects neurons from cell death. J 
Neurochem, 123(2), 226-238. doi: 10.1111/j.1471-4159.2012.07886.x 
Jiang, P., & Dickson, D. W. (2018). Parkinson's disease: experimental models and reality. Acta 
Neuropathol, 135(1), 13-32. doi: 10.1007/s00401-017-1788-5 
Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896-912. doi: 
10.1016/s0140-6736(14)61393-3 
Karampetsou, M., Ardah, M. T., Semitekolou, M., Polissidis, A., Samiotaki, M., Kalomoiri, M., . . 
. Vekrellis, K. (2017). Phosphorylated exogenous alpha-synuclein fibrils exacerbate 
pathology and induce neuronal dysfunction in mice. Sci Rep, 7(1), 16533. doi: 
10.1038/s41598-017-15813-8 
Kazdoba, T. M., Leach, P. T., Silverman, J. L., & Crawley, J. N. (2014). Modeling fragile X 
syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res, 3(4), 118-133. doi: 
10.5582/irdr.2014.01024 
Kim, M., Bellini, M., & Ceman, S. (2009). Fragile X mental retardation protein FMRP binds 
mRNAs in the nucleus. Mol Cell Biol, 29(1), 214-228. doi: 10.1128/MCB.01377-08 
 129 
Kones, R. (2010). Parkinson's disease: mitochondrial molecular pathology, inflammation, 
statins, and therapeutic neuroprotective nutrition. Nutr Clin Pract, 25(4), 371-389. doi: 
10.1177/0884533610373932 
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008). Lewy body-
like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med, 
14(5), 504-506. doi: 10.1038/nm1747 
Kurtis, M. M., Rajah, T., Delgado, L. F., & Dafsari, H. S. (2017). The effect of deep brain 
stimulation on the non-motor symptoms of Parkinson's disease: a critical review of the 
current evidence. NPJ Parkinsons Dis, 3, 16024. doi: 10.1038/npjparkd.2016.24 
Kuusisto, E., Parkkinen, L., & Alafuzoff, I. (2003). Morphogenesis of Lewy bodies: dissimilar 
incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol, 62(12), 
1241-1253. doi: 10.1093/jnen/62.12.1241 
Lai, D., Sakkas, D., & Huang, Y. (2006). The fragile X mental retardation protein interacts with a 
distinct mRNA nuclear export factor NXF2. RNA, 12(8), 1446-1449. doi: 
10.1261/rna.94306 
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013). The many faces of alpha-
synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci, 14(1), 38-
48. doi: 10.1038/nrn3406 
Lazaro, D. F., Dias, M. C., Carija, A., Navarro, S., Madaleno, C. S., Tenreiro, S., . . . Outeiro, T. 
F. (2016). The effects of the novel A53E alpha-synuclein mutation on its oligomerization 
and aggregation. Acta Neuropathol Commun, 4(1), 128. doi: 10.1186/s40478-016-0402-
8 
Lee, B., Lee, K., Panda, S., Gonzales-Rojas, R., Chong, A., Bugay, V., . . . Lee, H. Y. (2018). 
Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X 
syndrome from exaggerated repetitive behaviours. Nat Biomed Eng, 2(7), 497-507. doi: 
10.1038/s41551-018-0252-8 
Lee, H. Y., Ge, W. P., Huang, W., He, Y., Wang, G. X., Rowson-Baldwin, A., . . . Jan, L. Y. 
(2011). Bidirectional regulation of dendritic voltage-gated potassium channels by the 
fragile X mental retardation protein. Neuron, 72(4), 630-642. doi: 
10.1016/j.neuron.2011.09.033 
Lemkau, L. R., Comellas, G., Kloepper, K. D., Woods, W. S., George, J. M., & Rienstra, C. M. 
(2012). Mutant protein A30P alpha-synuclein adopts wild-type fibril structure, despite 
slower fibrillation kinetics. J Biol Chem, 287(14), 11526-11532. doi: 
10.1074/jbc.M111.306902 
Li, J., Uversky, V. N., & Fink, A. L. (2001). Effect of familial Parkinson's disease point mutations 
A30P and A53T on the structural properties, aggregation, and fibrillation of human 
alpha-synuclein. Biochemistry, 40(38), 11604-11613. doi: 10.1021/bi010616g 
Li, J. Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., . . . Brundin, P. (2008). 
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-
graft disease propagation. Nat Med, 14(5), 501-503. doi: 10.1038/nm1746 
Li, Y., Xu, M., Ding, X., Yan, C., Song, Z., Chen, L., . . . Yang, C. (2016). Protein kinase C 
controls lysosome biogenesis independently of mTORC1. Nat Cell Biol, 18(10), 1065-
1077. doi: 10.1038/ncb3407 
 130 
Lill, C. M. (2016). Genetics of Parkinson's disease. Mol Cell Probes, 30(6), 386-396. doi: 
10.1016/j.mcp.2016.11.001 
Liss, B., & Striessnig, J. (2019). The Potential of L-Type Calcium Channels as a Drug Target for 
Neuroprotective Therapy in Parkinson's Disease. Annu Rev Pharmacol Toxicol, 59, 263-
289. doi: 10.1146/annurev-pharmtox-010818-021214 
Liu, B., Li, Y., Stackpole, E. E., Novak, A., Gao, Y., Zhao, Y., . . . Richter, J. D. (2018). 
Regulatory discrimination of mRNAs by FMRP controls mouse adult neural stem cell 
differentiation. Proc Natl Acad Sci U S A, 115(48), E11397-E11405. doi: 
10.1073/pnas.1809588115 
Lubs, H. A. (1969). A marker X chromosome. Am J Hum Genet, 21(3), 231-244.  
Mao, L. M., Tang, Q., & Wang, J. Q. (2007). Protein kinase C-regulated cAMP response 
element-binding protein phosphorylation in cultured rat striatal neurons. Brain Res Bull, 
72(4-6), 302-308. doi: 10.1016/j.brainresbull.2007.01.009 
Marat, A. L., Wallroth, A., Lo, W. T., Muller, R., Norata, G. D., Falasca, M., . . . Haucke, V. 
(2017). mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-
bisphosphate. Science, 356(6341), 968-972. doi: 10.1126/science.aaf8310 
Marin, R., Fabelo, N., Martin, V., Garcia-Esparcia, P., Ferrer, I., Quinto-Alemany, D., & Diaz, M. 
(2017). Anomalies occurring in lipid profiles and protein distribution in frontal cortex lipid 
rafts in dementia with Lewy bodies disclose neurochemical traits partially shared by 
Alzheimer's and Parkinson's diseases. Neurobiol Aging, 49, 52-59. doi: 
10.1016/j.neurobiolaging.2016.08.027 
Maroteaux, L., Campanelli, J. T., & Scheller, R. H. (1988). Synuclein: a neuron-specific protein 
localized to the nucleus and presynaptic nerve terminal. J Neurosci, 8(8), 2804-2815.  
Melo, T. Q., Copray, S., & Ferrari, M. F. R. (2018). Alpha-Synuclein Toxicity on Protein Quality 
Control, Mitochondria and Endoplasmic Reticulum. Neurochem Res, 43(12), 2212-2223. 
doi: 10.1007/s11064-018-2673-x 
Miyashiro, K. Y., Beckel-Mitchener, A., Purk, T. P., Becker, K. G., Barret, T., Liu, L., . . . 
Eberwine, J. (2003). RNA cargoes associating with FMRP reveal deficits in cellular 
functioning in Fmr1 null mice. Neuron, 37(3), 417-431.  
Moors, T. E., Hoozemans, J. J., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M. C., & 
van de Berg, W. D. (2017). Therapeutic potential of autophagy-enhancing agents in 
Parkinson's disease. Mol Neurodegener, 12(1), 11. doi: 10.1186/s13024-017-0154-3 
Morris, T. J., Butcher, L. M., Feber, A., Teschendorff, A. E., Chakravarthy, A. R., Wojdacz, T. K., 
& Beck, S. (2014). ChAMP: 450k Chip Analysis Methylation Pipeline. Bioinformatics, 
30(3), 428-430. doi: 10.1093/bioinformatics/btt684 
Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., . . . Bagni, C. (2008). 
The fragile X syndrome protein represses activity-dependent translation through 
CYFIP1, a new 4E-BP. Cell, 134(6), 1042-1054. doi: 10.1016/j.cell.2008.07.031 
Narkiewicz, J., Giachin, G., & Legname, G. (2014). In vitro aggregation assays for the 
characterization of alpha-synuclein prion-like properties. Prion, 8(1), 19-32. doi: 
10.4161/pri.28125 
 131 
Nath, S., Goodwin, J., Engelborghs, Y., & Pountney, D. L. (2011). Raised calcium promotes 
alpha-synuclein aggregate formation. Mol Cell Neurosci, 46(2), 516-526. doi: 
10.1016/j.mcn.2010.12.004 
Nguyen, M., & Krainc, D. (2018). LRRK2 phosphorylation of auxilin mediates synaptic defects in 
dopaminergic neurons from patients with Parkinson's disease. Proc Natl Acad Sci U S A, 
115(21), 5576-5581. doi: 10.1073/pnas.1717590115 
Niere, F., & Raab-Graham, K. F. (2017). mTORC1 Is a Local, Postsynaptic Voltage Sensor 
Regulated by Positive and Negative Feedback Pathways. Front Cell Neurosci, 11, 152. 
doi: 10.3389/fncel.2017.00152 
Niu, Y. Q., Yang, J. C., Hall, D. A., Leehey, M. A., Tassone, F., Olichney, J. M., . . . Zhang, L. 
(2014). Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited. 
Parkinsonism Relat Disord, 20(4), 456-459. doi: 10.1016/j.parkreldis.2014.01.006 
Nordlund, J., Backlin, C. L., Wahlberg, P., Busche, S., Berglund, E. C., Eloranta, M. L., . . . 
Syvanen, A. C. (2013). Genome-wide signatures of differential DNA methylation in 
pediatric acute lymphoblastic leukemia. Genome Biol, 14(9), r105. doi: 10.1186/gb-2013-
14-9-r105 
Nuber, S., Rajsombath, M., Minakaki, G., Winkler, J., Muller, C. P., Ericsson, M., . . . Selkoe, D. 
J. (2018). Abrogating Native alpha-Synuclein Tetramers in Mice Causes a L-DOPA-
Responsive Motor Syndrome Closely Resembling Parkinson's Disease. Neuron, 100(1), 
75-90 e75. doi: 10.1016/j.neuron.2018.09.014 
Oliveira, L. M., Falomir-Lockhart, L. J., Botelho, M. G., Lin, K. H., Wales, P., Koch, J. C., . . . 
Jovin, T. M. (2015). Elevated alpha-synuclein caused by SNCA gene triplication impairs 
neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent 
stem cells. Cell Death Dis, 6, e1994. doi: 10.1038/cddis.2015.318 
Oliveras-Salva, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D'Hooge, R., . . . 
Baekelandt, V. (2013). rAAV2/7 vector-mediated overexpression of alpha-synuclein in 
mouse substantia nigra induces protein aggregation and progressive dose-dependent 
neurodegeneration. Mol Neurodegener, 8, 44. doi: 10.1186/1750-1326-8-44 
Oostra, B. A., & Willemsen, R. (2003). A fragile balance: FMR1 expression levels. Hum Mol 
Genet, 12 Spec No 2, R249-257. doi: 10.1093/hmg/ddg298 
Orr, A. A., Wordehoff, M. M., Hoyer, W., & Tamamis, P. (2016). Uncovering the Binding and 
Specificity of beta-Wrapins for Amyloid-beta and alpha-Synuclein. J Phys Chem B, 
120(50), 12781-12794. doi: 10.1021/acs.jpcb.6b08485 
Osterweil, E. K., Chuang, S. C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K., & Bear, 
M. F. (2013). Lovastatin corrects excess protein synthesis and prevents epileptogenesis 
in a mouse model of fragile X syndrome. Neuron, 77(2), 243-250. doi: 
10.1016/j.neuron.2012.01.034 
Osterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010). Hypersensitivity to mGluR5 
and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model 
of fragile X syndrome. J Neurosci, 30(46), 15616-15627. doi: 
10.1523/JNEUROSCI.3888-10.2010 
 132 
Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., & Wolozin, B. (1999). 
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J 
Neurosci, 19(14), 5782-5791.  
Pacelli, C., Giguere, N., Bourque, M. J., Levesque, M., Slack, R. S., & Trudeau, L. E. (2015). 
Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors 
to the Vulnerability of Dopamine Neurons. Curr Biol, 25(18), 2349-2360. doi: 
10.1016/j.cub.2015.07.050 
Pan-Montojo, F., Schwarz, M., Winkler, C., Arnhold, M., O'Sullivan, G. A., Pal, A., . . . 
Reichmann, H. (2012). Environmental toxins trigger PD-like progression via increased 
alpha-synuclein release from enteric neurons in mice. Sci Rep, 2, 898. doi: 
10.1038/srep00898 
Parkinson, J. (1817). An essay on the shaking palsy. 
Patil, S. P., Jain, P. D., Ghumatkar, P. J., Tambe, R., & Sathaye, S. (2014). Neuroprotective 
effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience, 277, 
747-754. doi: 10.1016/j.neuroscience.2014.07.046 
Peelaerts, W., Bousset, L., Baekelandt, V., & Melki, R. (2018). a-Synuclein strains and seeding 
in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and 
multiple system atrophy: similarities and differences. Cell Tissue Res, 373(1), 195-212. 
doi: 10.1007/s00441-018-2839-5 
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., . . . 
Baekelandt, V. (2015). alpha-Synuclein strains cause distinct synucleinopathies after 
local and systemic administration. Nature, 522(7556), 340-344. doi: 
10.1038/nature14547 
Peng, C., Gathagan, R. J., Covell, D. J., Medellin, C., Stieber, A., Robinson, J. L., . . . Lee, V. M. 
(2018). Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-
synucleinopathies. Nature, 557(7706), 558-563. doi: 10.1038/s41586-018-0104-4 
Perez-Villalba, A., Sirerol-Piquer, M. S., Belenguer, G., Soriano-Canton, R., Munoz-Manchado, 
A. B., Villadiego, J., . . . Farinas, I. (2018). Synaptic Regulator alpha-Synuclein in 
Dopaminergic Fibers Is Essentially Required for the Maintenance of Subependymal 
Neural Stem Cells. J Neurosci, 38(4), 814-825. doi: 10.1523/JNEUROSCI.2276-17.2017 
Phillipson, O. T. (2017). Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, 
& circadian dysfunction in Parkinson's disease. An integrated strategy for management. 
Ageing Res Rev, 40, 149-167. doi: 10.1016/j.arr.2017.09.006 
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., . . . Lang, A. E. 
(2017). Parkinson disease. Nat Rev Dis Primers, 3, 17013. doi: 10.1038/nrdp.2017.13 
Ponzini, E., De Palma, A., Cerboni, L., Natalello, A., Rossi, R., Moons, R., . . . Grandori, R. 
(2019). Methionine oxidation in alpha-synuclein inhibits its propensity for ordered 
secondary structure. J Biol Chem, 294(14), 5657-5665. doi: 10.1074/jbc.RA118.001907 
Postuma, R. B., & Berg, D. (2016). Advances in markers of prodromal Parkinson disease. Nat 
Rev Neurol, 12(11), 622-634. doi: 10.1038/nrneurol.2016.152 
Prymaczok, N. C., Riek, R., & Gerez, J. (2016). More than a Rumor Spreads in Parkinson's 
Disease. Front Hum Neurosci, 10, 608. doi: 10.3389/fnhum.2016.00608 
 133 
Puschmann, A., Ross, O. A., Vilarino-Guell, C., Lincoln, S. J., Kachergus, J. M., Cobb, S. A., . . . 
Nilsson, C. (2009). A Swedish family with de novo alpha-synuclein A53T mutation: 
evidence for early cortical dysfunction. Parkinsonism Relat Disord, 15(9), 627-632. doi: 
10.1016/j.parkreldis.2009.06.007 
Ray Chaudhuri, K., Qamar, M. A., Rajah, T., Loehrer, P., Sauerbier, A., Odin, P., & Jenner, P. 
(2016). Non-oral dopaminergic therapies for Parkinson's disease: current treatments and 
the future. NPJ Parkinsons Dis, 2, 16023. doi: 10.1038/npjparkd.2016.23 
Rcom-H'cheo-Gauthier, A., Goodwin, J., & Pountney, D. L. (2014). Interactions between calcium 
and alpha-synuclein in neurodegeneration. Biomolecules, 4(3), 795-811. doi: 
10.3390/biom4030795 
Richter, J. D., Bassell, G. J., & Klann, E. (2015). Dysregulation and restoration of translational 
homeostasis in fragile X syndrome. Nat Rev Neurosci, 16(10), 595-605. doi: 
10.1038/nrn4001 
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J., & Kraneveld, A. D. (2017). 
Exploring Braak's Hypothesis of Parkinson's Disease. Front Neurol, 8, 37. doi: 
10.3389/fneur.2017.00037 
Rodriguez-Sabate, C., Sabate, M., Llanos, C., Morales, I., Sanchez, A., & Rodriguez, M. (2017). 
The functional connectivity in the motor loop of human basal ganglia. Brain Imaging 
Behav, 11(2), 417-429. doi: 10.1007/s11682-016-9512-y 
Rodriguez, J. A., Ivanova, M. I., Sawaya, M. R., Cascio, D., Reyes, F. E., Shi, D., . . . Eisenberg, 
D. S. (2015). Structure of the toxic core of alpha-synuclein from invisible crystals. 
Nature, 525(7570), 486-490. doi: 10.1038/nature15368 
Salat, U., Bardoni, B., Wohrle, D., & Steinbach, P. (2000). Increase of FMRP expression, raised 
levels of FMR1 mRNA, and clonal selection in proliferating cells with unmethylated 
fragile X repeat expansions: a clue to the sex bias in the transmission of full mutations? 
J Med Genet, 37(11), 842-850.  
Schmidt, E. K., Clavarino, G., Ceppi, M., & Pierre, P. (2009). SUnSET, a nonradioactive method 
to monitor protein synthesis. Nat Methods, 6(4), 275-277. doi: 10.1038/nmeth.1314 
Scholz, D., Poltl, D., Genewsky, A., Weng, M., Waldmann, T., Schildknecht, S., & Leist, M. 
(2011). Rapid, complete and large-scale generation of post-mitotic neurons from the 
human LUHMES cell line. J Neurochem, 119(5), 957-971. doi: 10.1111/j.1471-
4159.2011.07255.x 
Schrag, A., Sheikh, S., Quinn, N. P., Lees, A. J., Selai, C., Mathias, C., . . . Jahanshahi, M. 
(2010). A comparison of depression, anxiety, and health status in patients with 
progressive supranuclear palsy and multiple system atrophy. Mov Disord, 25(8), 1077-
1081. doi: 10.1002/mds.22794 
Schulz, J., Pagano, G., Fernandez Bonfante, J. A., Wilson, H., & Politis, M. (2018). Nucleus 
basalis of Meynert degeneration precedes and predicts cognitive impairment in 
Parkinson's disease. Brain, 141(5), 1501-1516. doi: 10.1093/brain/awy072 
Sellier, C., Buijsen, R. A. M., He, F., Natla, S., Jung, L., Tropel, P., . . . Charlet-Berguerand, N. 
(2017). Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May 
Contribute to Fragile X Tremor Ataxia Syndrome. Neuron, 93(2), 331-347. doi: 
10.1016/j.neuron.2016.12.016 
 134 
Sgobio, C., Kupferschmidt, D. A., Cui, G., Sun, L., Li, Z., Cai, H., & Lovinger, D. M. (2014). 
Optogenetic measurement of presynaptic calcium transients using conditional 
genetically encoded calcium indicator expression in dopaminergic neurons. PLoS One, 
9(10), e111749. doi: 10.1371/journal.pone.0111749 
Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., & Zukin, R. 
S. (2010). Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci, 30(2), 
694-702. doi: 10.1523/JNEUROSCI.3696-09.2010 
Shen, M., Wang, F., Li, M., Sah, N., Stockton, M. E., Tidei, J. J., . . . Zhao, X. (2019). Reduced 
mitochondrial fusion and Huntingtin levels contribute to impaired dendritic maturation 
and behavioral deficits in Fmr1-mutant mice. Nat Neurosci, 22(3), 386-400. doi: 
10.1038/s41593-019-0338-y 
Sidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., & Ethell, I. M. (2014). Genetic removal 
of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse 
model. J Neurosci, 34(30), 9867-9879. doi: 10.1523/JNEUROSCI.1162-14.2014 
Smyth, G. K. (2004). Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments. Stat Appl Genet Mol Biol, 3, Article3. doi: 
10.2202/1544-6115.1027 
Soldner, F., Stelzer, Y., Shivalila, C. S., Abraham, B. J., Latourelle, J. C., Barrasa, M. I., . . . 
Jaenisch, R. (2016). Parkinson-associated risk variant in distal enhancer of alpha-
synuclein modulates target gene expression. Nature, 533(7601), 95-99. doi: 
10.1038/nature17939 
Sorrentino, Z. A., Brooks, M. M. T., Hudson, V., 3rd, Rutherford, N. J., Golde, T. E., Giasson, B. 
I., & Chakrabarty, P. (2017). Intrastriatal injection of alpha-synuclein can lead to 
widespread synucleinopathy independent of neuroanatomic connectivity. Mol 
Neurodegener, 12(1), 40. doi: 10.1186/s13024-017-0182-z 
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. 
(1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839-840. doi: 
10.1038/42166 
Stacy, M. (2011). Nonmotor symptoms in Parkinson's disease. Int J Neurosci, 121 Suppl 2, 9-
17. doi: 10.3109/00207454.2011.620196 
Stefani, G., Fraser, C. E., Darnell, J. C., & Darnell, R. B. (2004). Fragile X mental retardation 
protein is associated with translating polyribosomes in neuronal cells. J Neurosci, 
24(33), 7272-7276. doi: 10.1523/JNEUROSCI.2306-04.2004 
Sunamura, N., Iwashita, S., Enomoto, K., Kadoshima, T., & Isono, F. (2018). Loss of the fragile 
X mental retardation protein causes aberrant differentiation in human neural progenitor 
cells. Sci Rep, 8(1), 11585. doi: 10.1038/s41598-018-30025-4 
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017). Selective neuronal vulnerability in 
Parkinson disease. Nat Rev Neurosci, 18(2), 101-113. doi: 10.1038/nrn.2016.178 
Tan, Y., Sgobio, C., Arzberger, T., Machleid, F., Tang, Q., Findeis, E., . . . Koeglsperger, T. 
(2019). Loss of fragile X mental retardation protein precedes Lewy pathology in 
Parkinson's disease. Acta Neuropathol. doi: 10.1007/s00401-019-02099-5 
Teschendorff, A. E., Marabita, F., Lechner, M., Bartlett, T., Tegner, J., Gomez-Cabrero, D., & 
Beck, S. (2013). A beta-mixture quantile normalization method for correcting probe 
 135 
design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics, 29(2), 189-
196. doi: 10.1093/bioinformatics/bts680 
Tian, Y., Morris, T. J., Webster, A. P., Yang, Z., Beck, S., Feber, A., & Teschendorff, A. E. 
(2017). ChAMP: updated methylation analysis pipeline for Illumina BeadChips. 
Bioinformatics, 33(24), 3982-3984. doi: 10.1093/bioinformatics/btx513 
Tibar, H., El Bayad, K., Bouhouche, A., Ait Ben Haddou, E. H., Benomar, A., Yahyaoui, M., . . . 
Regragui, W. (2018). Non-Motor Symptoms of Parkinson's Disease and Their Impact on 
Quality of Life in a Cohort of Moroccan Patients. Front Neurol, 9, 170. doi: 
10.3389/fneur.2018.00170 
Tonges, L., Szego, E. M., Hause, P., Saal, K. A., Tatenhorst, L., Koch, J. C., . . . Lingor, P. 
(2014). Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's 
disease. Front Aging Neurosci, 6, 239. doi: 10.3389/fnagi.2014.00239 
Tranfaglia, M. R. (2011). The psychiatric presentation of fragile x: evolution of the diagnosis and 
treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci, 33(5), 
337-348. doi: 10.1159/000329421 
Tsang, B., Arsenault, J., Vernon, R. M., Lin, H., Sonenberg, N., Wang, L. Y., . . . Forman-Kay, J. 
D. (2019). Phosphoregulated FMRP phase separation models activity-dependent 
translation through bidirectional control of mRNA granule formation. Proc Natl Acad Sci 
U S A. doi: 10.1073/pnas.1814385116 
Ulusoy, A., Phillips, R. J., Helwig, M., Klinkenberg, M., Powley, T. L., & Di Monte, D. A. (2016). 
Brain-to-stomach transfer of alpha-synuclein via vagal preganglionic projections. Acta 
Neuropathol. doi: 10.1007/s00401-016-1661-y 
Veys, L., Vandenabeele, M., Ortuno-Lizaran, I., Baekelandt, V., Cuenca, N., Moons, L., & De 
Groef, L. (2019). Retinal alpha-synuclein deposits in Parkinson's disease patients and 
animal models. Acta Neuropathol, 137(3), 379-395. doi: 10.1007/s00401-018-01956-z 
Visanji, N. P., Brotchie, J. M., Kalia, L. V., Koprich, J. B., Tandon, A., Watts, J. C., & Lang, A. E. 
(2016). alpha-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and 
Opportunities in a New Era. Trends Neurosci, 39(11), 750-762. doi: 
10.1016/j.tins.2016.09.003 
Volpicelli-Daley, L. A., Kirik, D., Stoyka, L. E., Standaert, D. G., & Harms, A. S. (2016). How can 
rAAV-alpha-synuclein and the fibril alpha-synuclein models advance our understanding 
of Parkinson's disease? J Neurochem, 139 Suppl 1, 131-155. doi: 10.1111/jnc.13627 
Volpicelli-Daley, L. A., Luk, K. C., & Lee, V. M. (2014). Addition of exogenous alpha-synuclein 
preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-
synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc, 9(9), 2135-2146. 
doi: 10.1038/nprot.2014.143 
Wang, C. Y., Lai, M. D., Phan, N. N., Sun, Z., & Lin, Y. C. (2015). Meta-Analysis of Public 
Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical 
Cancer Patients. PLoS One, 10(7), e0125766. doi: 10.1371/journal.pone.0125766 
Wang, G., Achim, C. L., Hamilton, R. L., Wiley, C. A., & Soontornniyomkij, V. (1999). Tyramide 
signal amplification method in multiple-label immunofluorescence confocal microscopy. 
Methods, 18(4), 459-464. doi: 10.1006/meth.1999.0813 
 136 
Wang, H., Morishita, Y., Miura, D., Naranjo, J. R., Kida, S., & Zhuo, M. (2012). Roles of CREB 
in the regulation of FMRP by group I metabotropic glutamate receptors in cingulate 
cortex. Mol Brain, 5, 27. doi: 10.1186/1756-6606-5-27 
Wang, H., Pati, S., Pozzo-Miller, L., & Doering, L. C. (2015). Targeted pharmacological 
treatment of autism spectrum disorders: fragile X and Rett syndromes. Front Cell 
Neurosci, 9, 55. doi: 10.3389/fncel.2015.00055 
Wang, H., Wu, L. J., Kim, S. S., Lee, F. J., Gong, B., Toyoda, H., . . . Zhuo, M. (2008). FMRP 
acts as a key messenger for dopamine modulation in the forebrain. Neuron, 59(4), 634-
647. doi: 10.1016/j.neuron.2008.06.027 
Wang, W., Nguyen, L. T., Burlak, C., Chegini, F., Guo, F., Chataway, T., . . . Hoang, Q. Q. 
(2016). Caspase-1 causes truncation and aggregation of the Parkinson's disease-
associated protein alpha-synuclein. Proc Natl Acad Sci U S A. doi: 
10.1073/pnas.1610099113 
Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L. T., Liao, J., . . . Hoang, Q. Q. 
(2011). A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad 
Sci U S A, 108(43), 17797-17802. doi: 10.1073/pnas.1113260108 
Waskiewicz, A. J., Flynn, A., Proud, C. G., & Cooper, J. A. (1997). Mitogen-activated protein 
kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J, 16(8), 1909-
1920. doi: 10.1093/emboj/16.8.1909 
Waskiewicz, A. J., Johnson, J. C., Penn, B., Mahalingam, M., Kimball, S. R., & Cooper, J. A. 
(1999). Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 
4E by protein kinase Mnk1 in vivo. Mol Cell Biol, 19(3), 1871-1880. doi: 
10.1128/mcb.19.3.1871 
Winslow, A. R., Chen, C. W., Corrochano, S., Acevedo-Arozena, A., Gordon, D. E., Peden, A. 
A., . . . Rubinsztein, D. C. (2010). alpha-Synuclein impairs macroautophagy: implications 
for Parkinson's disease. J Cell Biol, 190(6), 1023-1037. doi: 10.1083/jcb.201003122 
Yorgason, J. T., Espana, R. A., & Jones, S. R. (2011). Demon voltammetry and analysis 
software: analysis of cocaine-induced alterations in dopamine signaling using multiple 
kinetic measures. J Neurosci Methods, 202(2), 158-164. doi: 
10.1016/j.jneumeth.2011.03.001 
Zaichick, S. V., McGrath, K. M., & Caraveo, G. (2017). The role of Ca(2+) signaling in 
Parkinson's disease. Dis Model Mech, 10(5), 519-535. doi: 10.1242/dmm.028738 
Zeng, Y., Adamson, R. H., Curry, F. R., & Tarbell, J. M. (2014). Sphingosine-1-phosphate 
protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart 
Circ Physiol, 306(3), H363-372. doi: 10.1152/ajpheart.00687.2013 
Zhang, K., Li, Y. J., Guo, Y., Zheng, K. Y., Yang, Q., Yang, L., . . . Zhao, M. G. (2017). Elevated 
progranulin contributes to synaptic and learning deficit due to loss of fragile X mental 
retardation protein. Brain, 140(12), 3215-3232. doi: 10.1093/brain/awx265 
Zhang, M., Mu, H., Shang, Z., Kang, K., Lv, H., Duan, L., . . . Zhang, R. (2017). Genome-wide 
pathway-based association analysis identifies risk pathways associated with Parkinson's 
disease. Neuroscience, 340, 398-410. doi: 10.1016/j.neuroscience.2016.11.004 
 137 
Zhang, W., Xu, C., Tu, H., Wang, Y., Sun, Q., Hu, P., . . . Liu, J. (2015). GABAB receptor 
upregulates fragile X mental retardation protein expression in neurons. Sci Rep, 5, 
10468. doi: 10.1038/srep10468 
Zhao, W., Chuang, S. C., Bianchi, R., & Wong, R. K. (2011). Dual regulation of fragile X mental 
retardation protein by group I metabotropic glutamate receptors controls translation-
dependent epileptogenesis in the hippocampus. J Neurosci, 31(2), 725-734. doi: 
10.1523/JNEUROSCI.2915-10.2011 
Zhou, W., Laird, P. W., & Shen, H. (2017). Comprehensive characterization, annotation and 
innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res, 45(4), 
e22. doi: 10.1093/nar/gkw967 
Zhu, P. J., Chen, C. J., Mays, J., Stoica, L., & Costa-Mattioli, M. (2018). mTORC2, but not 
mTORC1, is required for hippocampal mGluR-LTD and associated behaviors. Nat 
Neurosci, 21(6), 799-802. doi: 10.1038/s41593-018-0156-7 
 
  
 138 
7 Publication 
Tan, Y., Sgobio, C., Arzberger, T., Machleid, F., Tang, Q., Findeis, E., . . . Koeglsperger, T. 
(2019). Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's 
disease. Acta Neuropathol. doi: 10.1007/s00401-019-02099-5 
  
 139 
8 Copyright authorization 
 
 Copyright Transfer  12.11.2019  
 
Besuchen Sie uns: springer.com 
 
 
 
 
 
 Copyright Transfer Statement  
  
 
 
 
 
 
Lieber Autor, liebe Autorin,  
 
  
 
Hinweis: Sie haben dem Copyright Transfer Statement (CTS) zugestimmt und erhalten diese 
E-Mail für Ihre persönliche Ablage.   
  
 
1. Publication  
The copyright to this article, (including any supplementary information and graphic elements 
therein (e.g. illustrations, charts, moving images) (the ‘Article'), is hereby assigned for good 
and valuable consideration to Springer-Verlag GmbH Germany, part of Springer Nature (the 
'Assignee'). Headings are for convenience only.  
 
  
 
2. Grant of Rights  
In consideration of the Assignee evaluating the Article for publication, the Author(s) grant the 
Assignee without limitation the exclusive (except as set out in clauses 3, 4 and 5 a) iv), 
assignable and sub-licensable right, unlimited in time and territory, to copy-edit, reproduce, 
publish, distribute, transmit, make available and store the Article, including abstracts thereof, in 
all forms of media of expression now known or developed in the future, including pre- and 
reprints, translations, photographic reproductions and extensions. Furthermore, to enable 
additional publishing services, such as promotion of the Article, the Author(s) grant the 
Assignee the right to use the Article (including the use of any graphic elements on a stand-
alone basis) in whole or in part in electronic form, such as for display in databases or data 
networks (e.g. the Internet), or for print or download to stationary or portable devices. This 
includes interactive and multimedia use as well as posting the Article in full or in part or its 
abstract on social media, and the right to alter the Article to the extent necessary for such use. 
The Assignee may also let third parties share the Article in full or in part or its abstract on 
social media and may in this context sub-license the Article and its abstract to social media 
users. Author(s) grant to Assignee the right to re-license Article metadata without restriction 
(including but not limited to author name, title, abstract, citation, references, keywords and any 
additional information as determined by Assignee).  
 
  
 
3. Self-Archiving  
Author(s) are permitted to self-archive a pre-print and an author's accepted manuscript version 
of their Article.  
a. A pre-print is the author’s version of the Article before peer-review has taken place 
("Pre-Print”). Prior to acceptance for publication, Author(s) retain the right to make a 
Pre-Print of their Article available on any of the following: their own personal, self-
maintained website; a legally compliant, non-commercial pre-print server such as but 
 
 
 140 
not limited to arXiv and bioRxiv. Once the Article has been published, the Author(s) 
should update the acknowledgement and provide a link to the definitive version on the 
publisher’s website: “This is a pre-print of an article published in [insert journal title]. 
The final authenticated version is available online at: https://doi.org/[insert DOI]”.  
b. An Author's Accepted Manuscript (AAM) is the version accepted for publication in a 
journal following peer review but prior to copyediting and typesetting that can be made 
available under the following conditions:  
a. Author(s) retain the right to make an AAM of their Article available on their own 
personal, self-maintained website immediately on acceptance,  
b. Author(s) retain the right to make an AAM of their Article available for public 
release on any of the following 12 months after first publication ("Embargo 
Period"): their employer's internal website; their institutional and/or funder 
repositories. AAMs may also be deposited in such repositories immediately on 
acceptance, provided that they are not made publicly available until after the 
Embargo Period.  
An acknowledgement in the following form should be included, together with a link to the 
published version on the publisher's website: “This is a post-peer-review, pre-copyedit version 
of an article published in [insert journal title]. The final authenticated version is available online 
at: http://dx.doi.org/[insert DOI]”.  
  
 
4. Authors' Retained Rights  
Author(s) retain the following non-exclusive rights for the published version provided that, when 
reproducing the Article or extracts from it, the Author(s) acknowledge and reference first 
publication in the Journal:  
a. to reuse graphic elements created by the Author(s) and contained in the Article, in 
presentations and other works created by them;  
b. they and any academic institution where they work at the time may reproduce the 
Article for the purpose of course teaching (but not for inclusion in course pack material 
for onward sale by libraries and institutions); and  
c. to reproduce, or to allow a third party Assignee to reproduce the Article in whole or in 
part in any printed volume (book or thesis) written by the Author(s).  
 
  
 
5. Warranties  
The Author(s) warrant and represent that:  
a. (i) the Author(s) are the sole copyright owners or have been authorised by any 
additional copyright owner(s) to assign the rights defined in clause 2, (ii) the Article 
does not infringe any intellectual property rights (including without limitation copyright, 
database rights or trade mark rights) or other third party rights and no licence from or 
payments to a third party are required to publish the Article, (iii) the Article has not 
been previously published or licensed, (iv) if the Article contains material from other 
sources (e.g. illustrations, tables, text quotations), Author(s) have obtained written 
permissions to the extent necessary from the copyright holder(s), to license to the 
Assignee the same rights as set out in Clause 2 but on a non-exclusive basis and 
without the right to use any graphic elements on a stand-alone basis and have cited 
any such material correctly;  
b. all of the facts contained in the Article are according to the current body of science true 
and accurate;  
c. nothing in the Article is obscene, defamatory, violates any right of privacy or publicity, 
infringes any other human, personal or other rights of any person or entity or is 
otherwise unlawful and that informed consent to publish has been obtained for all 
research participants;  
d. nothing in the Article infringes any duty of confidentiality which any of the Author(s) 
 
 141 
might owe to anyone else or violates any contract, express or implied, of any of the 
Author(s). All of the institutions in which work recorded in the Article was created or 
carried out have authorised and approved such research and publication; and  
e. the signatory (the Author or the employer) who has signed this agreement has full 
right, power and authority to enter into this agreement on behalf of all of the Author(s).  
  
 
6. Cooperation  
The Author(s) shall cooperate fully with the Assignee in relation to any legal action that might 
arise from the publication of the Article, and the Author(s) shall give the Assignee access at 
reasonable times to any relevant accounts, documents and records within the power or control 
of the Author(s). The Author(s) agree that the distributing entity is intended to have the benefit 
of and shall have the right to enforce the terms of this agreement.  
 
  
 
7. Author List  
After signing, changes of authorship or the order of the authors listed will not be accepted 
unless formally approved in writing by the Assignee.   
  
 
8. Edits & Corrections  
The Author(s) agree(s) that the Assignee may retract the Article or publish a correction or other 
notice in relation to the Article if the Assignee considers in its reasonable opinion that such 
actions are appropriate from a legal, editorial or research integrity perspective.  
 
  
 
Diese E-Mail wurde automatisch gesendet; Bitte antworten Sie nicht auf diese Adresse. Falls 
Sie Fragen haben, besuchen Sie bitte unsere Hilfe-Seiten.   
  
 
Vielen Dank.  
 
  
 
Mit freundlichen Grüßen,  
 
  
 
Springer Autorenservice  
 
 
 
 
  
 Details des Artikels   
   
 
  
 
Zeitschrift 
 
 
 Acta Neuropathologica 
 
 
 
Titel des Artikels 
 
 
 Loss of  Fragile X Mental Retardation 
Protein Precedes Lewy Pathology in 
Parkinson’s Disease. 
 
 
 
 
DOI 
 
 
 10.1007/s00401-019-02099-5 
 
 
 
Korrespondenzautor 
 
 
 Thomas Koeglsperger 
 
 
 
 
Übertragung des Urheberrechts an 
 
 
 Springer-Verlag GmbH Germany, part of 
Springer Nature 
 
 
 
Übertragen am 
 
 
 Tue Nov 12 10:42:40 CET 2019 
 
 
 
 
 
 
 
 142 
 
 
 
 
 Service Contacts  
    
 
 
 
 
 
Springer Nature Customer Service 
Center 
 
 
 Tiergartenstr. 15-17  
69121 Heidelberg  
Germany  
phone: +49 6221 345 0  
fax: +49 6221 345 4229  
customerservice@springernature.com  
 
 Springer New York, LCC 
 
 
 233 Spring Street  
New York, NY 10013  
USA  
phone: +1 212 460 1500 or 800-
SPRINGER  
(Weekdays 8:30am - 5:30pm ET)  
fax: +1 212-460-1700  
customerservice@springernature.com  
 
 
   
  
 
  
 
© Springer Nature 2019, springer.com  
 
   
  
  
 143 
9 Acknowledgment 
First of all, I would like to express my sincere gratitude to all my supervisors, Prof. Dr. 
Günter U. Höglinger, Prof. Dr. Harald Luksch and Dr. Thomas Köglsperger for giving me the 
opportunity to do my Ph.D. at DZNE and TUM. Both are internationally renowned and I am very 
proud that I have had a chance to work in such a nice academic environment. Especially, I 
would like to express my greatest appreciation to Dr. Thomas Köglsperger for all the tireless 
guidance and constant inspiration throughout my Ph.D. process. Whenever we had a 
conversation, he supervised me well and always brought versatile ideas for the project. His 
guidance helped me to broaden my vision of the research field and to think more independently. 
I am equally indebted to my present and previous group members: Felix Machleid, Qilin 
Tang, Pan Gao, Diana Haba-Schneider, Rohit Kumar, Dr. Hong Xu, Dr. Sigrid Schwarz, Dr. 
Thomas Rösler, Dr. Matthias Höllerhage, Dr. Niko-Petteri Nykänen, Sofia Zampagni, Moritz 
Kolling, Natasha Fussi, Tasnim Chakroun, Elisabeth Findeiss, Valentin Evsyukov, Tabea 
Strauß, Amir Tayaranian, Andreas Peukert, Christina Tauber, Charlotte Voigt, Lena 
Jaschkowitz, Sabine Gallagher, Ruth Götz.  Thanks to all of you for providing me a friendly and 
homely lab environment. 
My cordial gratitude goes to my collaborators: Prof. Dr. J. Herms, Dr. Carmelo Sgobio, Dr. 
Thomas Arzberger, Dr. Joerg Tost, and Prof. Dr. med. Kai Bötzel. All your help and contribution 
facilitated our publication and I also learned a lot through fruitful conversation. 
It would be an injustice not to mention my colleagues from the neighboring research 
groups: Dr. Farida Hellal, Dr. Chenchen Pan, Shan Zhao, Dr. Marika Ruiyao Cai. You all gave 
me lots of support and help. 
Undoubtedly, I would like to appreciate my beloved Yiyuan Chen for years of waiting and 
mental support. Likewise, without my parents’ unconditional support and love, I could not have 
fulfilled my academic achievement. 
 144 
Finally, I would like to acknowledge the China Scholarship Council (CSC) for four-year 
financial support in Munich and Dr. Thomas Köglsperger for an additional 15 months of funding 
support. 
Thanks again for all of you. You all are the best! 
 
